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Oliver Dougal Gilliatt Rupar 
An assessment of universal tumour associated antigens in primary liver neoplasms.  
Abstract 
Rates of primary liver cancer are increasing in the Western world, a fact yet to be 
reflected in research with most currently undertaken in Asia. Whilst here in the UK, 
during a diagnostic and therapeutic workup within the NHS, surgically resected tumours 
are routinely kept in storage for up to thirty years. Meaning there is a huge, currently 
unused, resource that could potentially be included in clinical research. 
The regional specialist centre in the Southwest of England has been performing liver 
resections since 2005, no basic-science research has been performed using these 
archived specimens. In this research I have assessed the presence of genetic alterations, 
attempted to quantify the transcriptome, and measured protein expression in patients 
with liver cancer using a digital pathology platform. Telomerase and Survivin, the two 
targets of these endeavours, have previously been shown to be expressed in numerous 
cancer types, earning the title ‘universal tumour associated antigen.’ The techniques 
used in this research project are, mostly, already used in healthcare diagnostics, 
meaning there is potential for vastly increasing the power of these results should the 
study be increased.  
Genetic alterations in the promoter sequences were amplified and sequenced using 
DNA from archived samples. Attempts to quantify the transcribed component which 
have been locked away in tiny exosomes (which lack degradation enzymes) were made 
using a quantitative polymerase chain reaction. Protein expression was detected in 
tumours and background liver tissues using immunohistochemistry and quantified using 
digital pathology techniques on whole-slide images. Haematological protein levels were 
assessed using the enzyme linked immunosorbent assay. All of these characteristics 
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were then compared with clinical measures such as tumour size, grade, stage, vascular 
invasion, overall survival, and diseases associated with liver carcinogenesis.  
Lessons learned from my work, particularly the techniques used on the source material, 
could be used in any NHS department without the need for significant financial 
investment required for a formal research facility. Access to these precious resources 
allows a more accurate representation of these antigens in the local clinical cohort. 
Below I have provided evidence that Telomerase promoter mutations are an HCC-
specific alteration, and are present in tumours with vascular invasion. There is also early 
evidence that these mutations may correlate with a reduced overall survival. The 
Survivin promoter has been found to be a germline characteristic, whilst Survivin 
protein expression has been found to correlate with numerous adverse clinical features 
including tumour stage, grade, vascular invasion, perineural invasion and overall 
survival. These results are very encouraging and could possibly even be used as a risk-
stratification tool during future routine clinical liver tumour workup, as an aid to 
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Primary liver cancers (PLCs) are the sixth most common cancer type and, globally, the 
second most common cause of cancer related deaths (Bray et al., 2018; Pezzuto et al., 
2017). The two most common sub-types of primary liver cancer are Hepatocellular 
Carcinoma (HCC) and Cholangiocellular Carcinoma (CCA) which account for the vast 
majority (more than 99%) of PLCs. HCCs are tumours of the liver cells (hepatocytes) 
and comprise around 80-90% of all PLCs with CCAs, or bile duct malignancies, 
accounting for 10-15% of the remaining tumours.  
In the UK PLCs are the 18th most common cancer type and account for 2% of new 
cancer diagnoses annually (Cancer Research UK, 2017). However, it is predicted that 
age standardised rates (ASR) of British PLCs will increase, by up to 43% for men, 
between 2014 to 2035 from 16 to 23 cases per 100,000 (Smittenaar et al., 2016). The 
predicted rise in cases for women is less marked, from 6.87 to 8.32 cases per 100,000 
patients within in the same timeframe, but is nonetheless a notable increase in disease 
frequency. Therefore, there is a national (and international) need for improved 
understanding of the mechanisms involved in tumourigenesis for both current and future 
patients.  
The most pronounced increases in rates of PLC have generally been observed in 
Holland, the UK and the USA (Liu et al., 2019). The reasons for this are multitudinous 
and centre on the fact that the aetiology of primary liver is evolving from traditional risk 
factors (viral hepatitis & alcohol - discussed more below) to include newer aetiologies 
(obesity, type two diabetes and the metabolic syndrome) that are only now becoming 
clinically apparent. These conditions result in chronic liver damage and cellular 
regeneration and can result in the reversible deposition of fibrous tissues (fibrosis) upon 
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repeated injury-regeneration cycles that can progress to the permanent deposition of 
scar tissue (cirrhosis). The correlation between fibrosis, cirrhosis and carcinogenesis has 
been established in HCC but does not correlate with rates of cholangiocellular 
carcinogenesis, as most of these tumours occur sporadically. 
1.1 Hepatocellular Carcinoma 
The World Health Organisation (WHO) classify seven subtypes of Hepatocellular 
Carcinoma, based on morphological phenotypes (International Classification of 
Diseases for Oncology, 2019). The tumour subtypes are: hepatocarcinoma, 
fibrolamellar, scirrhous (sclerosing), spindle cell variant (sarcomatoid), clear cell, 
pleomorphic and mixed (hepatocholangiocarcinoma/ HCC-CCA) tumours.  
Other classifications are available such as those based on cellular architectural patterns 
or cytological variants and can occur in combination (Hamilton & Aaltonen, 2000; 
Torbenson, 2017). Architectural variants include: trabecular (plate like), 
pseudoglandular/ acinar, compact and scirrhous. Cytological properties include: 
pleomorphic cell, clear cell, sarcomatous change, fatty change, bile production, 
inclusion bodies (Mallory hyaline, globular hyaline, pale or ground glass), fibrolamellar 
and finally undifferentiated HCC (Hamilton & Aaltonen, 2000). Of note, where the 
tumour may display characteristics from more than one morphological subtype, the 
tumour with the worse prognosis is ultimately used for classification and 
prognostication (Torbenson, 2017). Some variants of HCC – such as scirrhous – have 
no prognostic difference when compared to classical HCCs (Jiang et al., 2018). 
However, prognostic differences between HCC subtypes, such as fibrolamellar and 
mixed tumours have a better and worse prognosis respectively (Bergquist et al., 2016; 
Jiang et al., 2018; Torbenson, 2017). Hence, HCC classifications are not exhaustive, or 
mutually exclusive, and cannot possibly reflect the wide variety of genetic mechanisms 
involved in carcinogenesis. There are clearly many ways of sub-classifying HCCs, some 
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of which will not have been recorded in archived clinical samples. For the purposes of 
consistency, the WHO adopted classification will be used in preference to others.  
Overall, there is a significant volume of evidence describing tumour morphology in 
great detail with mixed evidence for patient outcomes, such as overall mortality. In the 
era of personalised medicine, with a multitude of aetiological causes of PLC the genetic 
make-up of tumours may hold the key to further understanding neoplastic initiation and 
development. 
1.1.1 Subtypes  
1.1.1.1 Good prognosis: FL-HCC 
A relatively common subtype of HCC that occurs in younger patients and carriers a 
more favourable prognosis is called fibrolamellar HCC (FL-HCC). Intra-tumoural 
bands of parallel fibrous tissues are characteristic for this disease that is diagnosed 
based on typical histological characteristics. Contrary to traditional HCCs, fibrolamellar 
tumours are only found in patients where there is no background cirrhosis present 
(Torbenson, 2017). There are also no known risk factors for developing FL-HCC 
(Shafizadeh & Kakar, 2013) but a segmental deletion yielding the DNAJB1-PRKACA 
gene fusion has been recognised as a signature event in FL-HCC, (Kastenhuber et al., 
2017). 
1.1.1.2 Intermediate prognostic tumour types 
The so called ‘classical HCCs’ account for the majority of hepatocellular tumours with 
no difference in prognosis between classical and scirrhous subtypes (Jiang et al., 2018). 
The steatohepatitic variant of HCC is, somewhat unsurprisingly, associated with 
metabolic diseases but does not appear to have any correlation with gender, aetiology, 
tumour size, number of lesions or grade of tumour (Jain et al., 2013).  In a small HCV 
cirrhosis associated HCC cohort, 35% of HCCs were of the steatohepatitic subtype, 
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with 64% of this subgroup having at least one risk factor for NAFLD/ NASH (Salomao 
et al., 2010).  
Clear cell HCCs are generally well differentiated tumours arising on a background of 
cirrhosis, and have a male preponderance (2.3:1, M: F ratio) but are more common in 
women than traditional HCC (~7:1 M: F ratio) (Yang et al., 1996). There is mixed 
evidence showing either slightly better, or equivocal, differences in prognosis of clear 
cell HCCs (Jabbour et al., 2019; Yang et al., 1996). Clear cell HCCs carry a higher rate 
of isocitrate dehydrogenase 1 (IDH-1) mutations compared to other HCC subtypes with 
these mutations conferring a poorer prognosis by altering cellular metabolism and 
promoting tumourigenesis (Lee et al., 2017). This molecular sub-classification of 
tumours holds intriguing diagnostic and therapeutic implications as the advent of 
targeted IDH therapies may increase the therapeutic arsenal available to clinicians.  
Scirrhous HCCs highlights the diagnostic difficulties of assessing PLCs, as they can be 
radiologically indistinguishable from CCA, whilst also possessing intra-tumoural 
fibrosis similar to FL-HCC (Jabbour et al., 2019). However, when assessing 
immunohistochemical expression, a combination of Arginase-1 and Glypican-3 (GPC-
3) expression is 100% sensitive for scirrhous HCC when differentiating from CCA 
(Krings et al., 2013). This is further evidence of the power of specific, targeted, analysis 
in PLCs, and that different approaches may yield similar results for tumour assessment 
and stratification. 
1.1.1.3 Poor prognostic tumours 
Mixed HCC-CCA, Sarcomatoid and small cell HCCs are quite rare and hold a poorer 
prognosis compared to classical HCCs. In many respects, sarcomatoid HCCs have 
similar properties to mixed HCC-CCA, with comparable rates of lymph node 
metastases and adjacent organ invasion (Li et al., 2018). In terms of median overall 
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survival, sarcomatoid HCCs have a worse prognosis (8.7 months with a 0% 3-year 
survival) compared to mixed tumours (24.9 months, 36% 3-year survival) (Li et al., 
2018; Liao et al., 2019). If patients undergo liver transplantation, mixed tumours have a 
high rate of recurrence, especially within the first year after surgery, demonstrating their 
aggressive tumour behaviour (Park et al., 2013).  
The rarity of these subtypes of HCC makes estimates of prognostic differentiation 
challenging this is typified by case reports identifying small cell HCCs, a case series of 
three tumours (from 520 HCCs at one centre) described poor survival after diagnosis 
(one month for two patients and 5 months for the third patient) in elderly patients 
(Zanconati et al., 1996). Two of these patients were deemed unfit for invasive treatment 
and the tumours were found at autopsy.  
1.1.2 Aetiology 
Around 90% of HCCs arise in the context of chronically inflamed, scarred, cirrhotic, 
liver tissues (Jindal et al., 2019; Mittal & El-Serag, 2013). The inflammation-
metaplasia-carcinoma sequence that occurs is responsible for the majority of these 
cancers developing as the increased rates of cellular turnover hence allowing more 
opportunities for driver mutations to develop. However, there are certain circumstances 
when tumours occur in the absence of cirrhosis, such as in the context of NAFLD 
without cirrhosis and in fibrolamellar tumours (Kulik & El-Serag, 2019; Torbenson, 
2017).  
Globally, the rates of PLC are changing to reflect chronological variations in causative 
risk factors – with reductions in countries where Hepatitis B Virus (HBV) was 
previously a major driver (SE Asia and Africa) and rising incidence in countries like the 
UK, which have seen a sharp increase in number of individuals with cirrhosis. 
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However, the legacy of chronic viral hepatitis still accounts for the majority of HCC 
cases, when considered at the international scale.  
The global burden of diseases such as hepatitis, cirrhosis and diabetes have increased 
between 1990 - 2010 by 46.4%, 32.5% and 92.7% respectively (Lozano et al., 2012). 
These deeply concerning increases in liver cancer-associated conditions go some way to 
explain the recorded increase in rates of PLC. Western diet and lifestyle will play an 
increasing prominent role in the aetiology of future PLCs in North America and Europe. 
As obesity rates continue to soar in the Western world, future rates of PLC are predicted 
to reflect the already measurable increase in obesity driven cancer development 
(Massoud & Charlton, 2018). 
1.1.2.1 Fibrosis & Cirrhosis 
Scarring of the liver (cirrhosis) is an irreversible change that results from chronic 
inflammation and is found in 80-90% of post mortem autopsies in patients with HCC 
(Fattovich et al., 2004). The majority of the remaining 10 – 20% of HCCs in this study 
had a degree of liver fibrosis with only a very small proportion having absolutely 
normal background liver histology (Fattovich et al., 2004). More recent evidence has 
indicated that the risk of HCC remains low in all patients without cirrhosis, with the 
exception of those with higher fibrotic indices (Kulik & El-Serag, 2019). However, 
there is no simple dose-response relationship for fibrosis/cirrhosis and HCC 
development, indicating the complexity of this highly heterogeneous disease entity. 
Amongst newly diagnosed cases of HCC, in the absence of advanced fibrosis or 
cirrhosis, NAFLD is the largest aetiological factor in an American study cohort (Kulik 
& El-Serag, 2019).  
Fibrosis is the result of increased extra cellular matrix (ECM) deposition secondary to 
chronic inflammation and activation of both the innate and adaptive immune responses 
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(Parola & Pinzani, 2019). The pro-fibrogenic environment resulting from chronic 
inflammation leads to hepatic stellate cell (HSC) recruitment, activation and trans-
differentiation into fibrogenic myofibroblasts (Tsuchida & Friedman, 2017). Inhibiting 
the activation of HSCs is the target of a number of phase II and III clinical trials which 
are exciting potential therapies of the future. As the number of hepatotoxic insults 
increases the risks of developing HCC is also raised. An example of multifactorial 
hepatotoxic insults is highlighted by the increase in incidence of HCCs in non-cirrhotic 
diabetics who drink alcohol, owing to the synergistic effect of multiple hepatotoxins 
(Kulik & El-Serag, 2019).  
Changes in hepatic cellular structure and physiology from ECM deposition, 
proliferating activated stellate cells and neovascularisation of hepatic sinusoids result in 
cirrhosis (Tsochatzis et al., 2014). Cirrhosis was previously considered an advanced 
stage of liver fibrosis with irreversible distortion of the hepatic vasculature (Schuppan 
& Afdhal, 2008). However, there is increasing evidence from the follow up of treated 
viral hepatitis patients, that this might not be the case. Successful treatment of the 
underlying pro-fibrotic disease reduces the pro-inflammatory environment and leads to 
a regression in fibrotic indices as fibrolytic pathways are up-regulated (Jung & Yim, 
2017).  
When the native sinusoidal endothelial cells are disrupted, there is shunting of blood 
from portal and arterial vessels to the hepatic veins results in a decrease in exchange 
between hepatic sinusoids and hepatocytes, further reducing liver function (Schuppan & 
Afdhal, 2008).  The molecular mechanisms behind this are complex, but sinusoidal 
endothelial cells are defenestrated then capillarised, causing a loss of substrate 
exchange (Zhou et al., 2014). As the functionality of liver cells decreases with repeated 
exposure to noxious stimuli, scar tissue deposition increases further reducing the 
functional capacity of the liver (Jung & Yim, 2017).  
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Annual rates of HCC incidence in cirrhosis varies between 4 – 30%, depending on the 
underlying aetiology (PBC and HCV respectively), demonstrating an irrefutable 
increase in cancer-risk, regardless of the underlying disease process causing cirrhosis 
(Fattovich et al., 2004). 
1.1.2.2 Infectious Causes of HCC 
Globally, HBV and HCV are thought to be responsible for 43.3 % and 18.7% of 
primary liver cancers respectively (Liu et al., 2019). The prevalence of these infectious 
diseases, and their legacy (i.e., cirrhosis and liver cancer) varies widely depending on 
geographical location. Liver cancer has traditionally been most prevalent in eastern 
Asian countries and sub-Saharan Africa, and between them account for up to 83% of 
cases globally (GLOBOSCAN 2012 (IARC), 2015). In the most part this is due to 
vertical transmission of HBV during childbirth coupled with historically low rates of 
vaccination against HBV in these host countries. The risk of developing HCC from 
HBV is associated with the length of infection, viral load and the severity of liver 
disease present as HBV is able to integrate into the hosts’ DNA (Forner et al., 2018; 
Schulze et al., 2015).  
The other main hepatotropic infection, HCV is more prevalent in Western populations 
and are associated with iatrogenic infection from blood product transfusion or 
recreational intravenous drug use (El-Serag, 2011; Forner et al., 2012). HCV is now 
curable in over 95% of cases with the direct acting antivirals (DAA) and the widespread 
use of these has already resulted in a fall in number of cases of chronic HCV, and fewer 
cases of HCV-associated HCC.  
However, active viral hepatitis remains the main driving factor behind global HCC 
development (Kulik & El-Serag, 2019). As such the WHO has invested heavily in a 
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global effort to eliminate viral hepatitis transmission in all member states, with an 
ambitious target of a 90% reduction in new cases by 2030 (Cooke et al., 2019). 
In the US, prior to curative treatment for HCV being available, rates of cirrhosis had 
doubled in patients with HCV along with a 10-fold increase in the rates of HCC (Mittal 
& El-Serag, 2013). A demonstration of the dynamic relationship between aetiology and 
carcinogenesis is exemplified by rates of HCV attributable HCC that are decreasing, 
after the advent of direct acting antivirals (DAA), from 46.4% in 2013 (prior to DAA 
use) to 33.7% in 2016, when measured by transplant-indication for HCC treatment 
(Vaziri et al., 2018). Age standardised rates of PLC due to HCV had increased by 7.6% 
from 1990 to 2010, whilst those due to HBV have only risen by 2.6% in the same 
period (Lozano et al., 2012). With synergistic effects of multiple hepatotoxic insults on 
fibrotic and cirrhotic changes reducing the local and global burden of HBV and HCV 
infections will lead to a decrease in future HCC development (Jindal et al., 2019; Mittal 
& El-Serag, 2013).  
We very much find ourselves in unknown territory for monitoring patients who have 
achieved a sustained viral response (SVR) against HCV, as a result of DAA therapies. 
Previously these patients would have required regular surveillance for HCC 
development as they were deemed high risk but the need for large prospective 
multicentre studies are required to clarify this (Peck-Radosavljevic and Singal, 2019). 
In SE Asia and sub-Saharan Africa, a carcinogen produced by Aspergillus species 
(Aflatoxin B1) is able to grow in foodstuffs (grain, corn, cassava) when stored in high 
moisture conditions (Mittal & El-Serag, 2013). The dietary ingestion and hence 
exposure to these toxins promotes mutations in the tumour suppressor gene, p53, 
resulting in a genetic basis of tumourigenesis in as many as 90% of Aflatoxin-related 
HCCs (Gouas et al., 2009). The regions where Aflatoxin-related HCCs and HBV-
related HCCs overlap considerably account for a synergistic effect of dual-exposure 
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leading to an increased chance of developing HCC (Schulze et al., 2015). Fortunately, 
rates of Aflatoxin-related PLCs in the West are vanishingly rare as the climatic 
conditions required for Aspergillus growth simply do not occur. 
1.1.2.3 Diet, Lifestyle & Environmental. 
The link between heavy alcohol consumption (>80g/day) and cirrhosis development is 
well established, however full comprehension of the mechanisms involved remain 
incompletely understood (Mittal & El-Serag, 2013; Morgan et al., 2004). What is clear 
is that even mild alcohol consumption (10g/day, ~ 1unit) is associated with a higher rate 
of carcinogenesis (Ganne-Carrié & Nahon, 2019). The mechanisms whereby alcohol 
induces changes in cellular signalling are complex. Increased production of reactive 
oxygen species, increased gut permeability, changes in folate and lipid metabolism, 
activation of innate immunity and toxic effects on mitochondrial biology are just some 
of the mechanisms proposed to be adversely altered by ethanol (Ganne-Carrié & Nahon, 
2019). The societal effects of chronic alcohol ingestion (addiction, unemployment, 
tobacco smoking etc.) and those in lower socioeconomic groups are associated with 
poorer outcomes. Those addicted to alcohol present at a later stage, have poor 
concordance to screening and follow up owing to the addictive nature of the substance 
(Ganne-Carrié & Nahon, 2019).  
In Italy and the US, alcohol is thought to cause between 32-45% of HCCs, and at higher 
rates when there was HCV was a cofactor in tumour development (Morgan et al., 2004). 
Globally alcohol accounts for 14.7% of primary liver cancers in 2016, but there are 
wide geographical variations with up to 34.5% of PLCs in Western Europe being 
attributed to alcohol excess (Liu et al., 2019).   
As waistlines expand and medical conditions such as dyslipidaemia, diabetes mellitus 
and the metabolic syndrome are increasing due to poor diet and an increasingly 
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sedentary lifestyle. These metabolic diseases are resulting in increased rates of primary 
liver cancer owing to the metabolic burden being placed on the liver as it digests the 
increased dietary fat and macronutrients that result in the inflammatory states: non-
alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis: NASH (Jindal 
et al., 2019).  Diet and lifestyle factors are inextricably linked to type two diabetes, the 
rates of which are increasing globally. Whilst type two diabetes is a risk factor for HCC 
development, there is also the possibility of NAFLD acting as an independent risk 
factor, though the evidence for this is less certain (Kulik & El-Serag, 2019). Rates of 
death from PLC are increased five-fold in those with a high baseline body mass index 
(BMI), further highlighting the link between obesity and hepatocarcinogenesis (Forner 
et al., 2018). Regardless of geographical location, alcohol intake or diabetic status, an 
elevated BMI (>25 kg/m2) is linked to liver cancer generation (Jindal et al., 2019).  
1.1.3 Incidence  
A national study, using data from all hospital discharge records in France from between 
2009 and 2012 found 31927 incident cases of adult HCC giving an annual incidence of 
16.4 cases per 100,000 (Goutté et al., 2017). Eighty percent of these cases were in men, 
73.4% occurred in cirrhotic patients and 44% were as a result of alcohol consumption, 
in the absence of viral infection. Somewhat surprisingly, 36.4% had an unknown 
aetiology.  
Incidence rates have exploded in Western populations recently, with a rise of 62.8% of 
cases in men (41.2% in Women) between 1990 to 2009 in the US (AACR Cancer 
Progress Report Writing Committee et al., 2013). Furthermore, in America, HCC cases 
have increased considerably since the 1970’s. In 1973 the incidence of HCC was 1.51 
cases per 100,000 whilst in 2011 it was 6.20 per 100,000 (Njei et al., 2015). 
Interestingly, there have been large increases in PLC in high socioeconomic index 
countries, with the UK having the third highest increase in estimated annual percentage 
 12 
change, reflecting both the changing landscape of aetiological conditions (amongst 
others: rich diet and alcohol as mentioned above) associated with PLCs, (Liu et al., 
2019). 
Gender is important in HCC development and varies geographically with a 4:1 male: 
female ratio in South Korea, and approaching a 2:1 (male: female) ratio in UK (Mittal 
& El-Serag, 2013). Circulating oestrogen plays a role in HCC tumour development as 
fewer women develop HCC, and in women who are treated for HCC, oestrogen 
replacement (for menopausal symptoms) is protective, giving a reduced risk of HCC-
recurrence and prolonged survival (Fujiwara et al., 2017). The immunomodulatory 
effects of oestrogens (immune-stimulating) is thought to result in less inflammatory 
damage, apoptosis and oxidative stress compared with immune suppressing androgens 
which increases fibrogenesis (Ruggieri et al., 2018). 
However, developing countries may be underestimating the reported rates of HCC 
owing to their poor-quality data provided, and limited abilities to detect or manage 
HCCs, with an estimated 120,772 missed incident cases of HCC in 2012 (Sartorius et 
al., 2015). This incomplete data makes accurate estimates of HCC rates difficult to fully 
describe, but are improving with time. 
1.1.4 Stage 
Numerous disease staging systems used when assessing HCCs. These include the 
tumour- lymph node-metastasis (TMN), Okuda, Cancer of the Liver Italian Program 
(CLIP), Japanese Integrated Staging (JIS), Chinese University Prognostic Index (CUPI), 
Hong Kong Liver Cancer (HKLC) and most commonly used in the West, the Barcelona 
Clinic Liver Cancer (BCLC) staging system (Forner et al., 2018). HCC is stage-
orientated for cancer therapies, with various treatment options offered to patients 
depending on the stage hierarchy of their disease (Vitale et al., 2020). These stage-
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boundaries are not fixed, as roughly half of patients benefit from down-staging therapies 
able to reduce tumour burden, meaning carefully selected patients can be considered for 
curative treatment such as liver transplantation (Bryce & Tsochatzis, 2017). Staging 
disease is currently based on radiological and liver dysfunction parameters, with 
minimal emphasis being placed on individual tumour biology in this era of personalised 
medicine. The one exception being serially measured alpha-foetoprotein (AFP) 
>100ng/ml was found to be the only independent risk factor of HCC recurrence post 
liver transplant (Mehta et al., 2020). 
Generally, in earlier stage disease more treatment options are available to patients. The 
five BCLC stages of HCC (stage 0, A, B, C and D) and their respective survival 
statistics are outlined in figure 1, which takes into account not only the stage of disease, 
but also other disease characteristics (such as the size and number of tumours, portal 
pressures, liver function and other associated diseases) as well as the patients 
performance status (Forner et al., 2018). 
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Figure 1. Stages of HCC disease, management and expected survival. 
Therefore, patients that undergo surgical resection, or transplantation, have relatively 
confined tumour disease, which has the potential to be a selection bias to any studies 
solely analysing these tissues. 
1.1.5 Grade 
Since 1954 the Edmondson-Steiner (ES) classification of HCCs has been in use with 
grades I-IV correlating with adverse features of cellular differentiation (Edmondson & 
Steiner, 1954). From the most differentiated (grade I, well differentiated), to increased 
cytoplasmic & nuclear volumes (grade II, mild differentiation), increased 
hyperchromatic features with an increase in relative nuclear proportion in the cell (grade 
III, moderately differentiated) to variable, often scanty, cytoplasmic volumes with 
intensely abundant and hyperchromatic nuclei and non-cohesive cell masses (grade IV, 
poorly differentiated) (Nakashima et al., 1987). This four-tier system has not always 
been adopted, with a modified three-tier (well, moderately and poorly differentiated) 
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grading system occasionally used (Rastogi, 2018). With ES’ grades I and II being 
incorporated into a modified ‘well differentiated’ class to facilitate this simplification, 
but grouping tumours as grades I & II (favourable) vs III & IV (unfavourable) has been 
undertaken extensively in the literature (Pawlik et al., 2007). 
 Interestingly, whilst pre-operation biopsy of tumour samples has no correlation with 
post-transplant survival, comprehensive histological assessment of explant livers does 
give an accurate determinant of survival post liver transplant, with worst outcomes in 
the poorest differentiated tumours (Pawlik et al., 2007; Tamura et al., 2001). This may 
well confirm that comprehensive assessment of the whole tumour is required to reduce 
the sampling error that inevitably occurs from a biopsy. Tumour stage remains the most 
important factor when assigning appropriate treatment regimens in HCC. 
1.1.6 Regional Variations in HCC Prevalence 
Regional variations in HCC broadly reflect the differences in aetiology underlying 
carcinogenesis. South East Asian, Chinese, Sub-Saharan and East-African cancers 
account for >80% of the number of cases and are predominantly due to HBV and, to a 
lesser extent, Aflatoxins (Choo et al., 2016). The vertical transmission of HBV results 
in HCC diagnosis approximately a decade younger than those from North America and 
Europe, where HCV is acquired later in life (Mittal & El-Serag, 2013). Mittal & El-
Serag also state that alcohol consumption, HBV and HCV rates are higher, and 
potentially more carcinogenic, in men which may partially explain the male 
preponderance of HCCs. Zucman-Rossi et al have grouped these more aggressive 
tumours (HBV-associated, increased vascular invasion, poorer overall survival) together 
and called them a proliferation class, with the non-proliferation class being made up of 
HCV and alcohol-related disease which confers a less aggressive phenotype (Zucman-
Rossi et al., 2015). Alongside viral hepatitis, NAFLD is another common disease entity 
that is becoming increasingly responsible for both Eastern and Western HCC 
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development (Choo et al., 2016). In America, NAFLD is now the leading cause of 
chronic liver disease (Mittal & El-Serag, 2013).  
In the UK HCC mortality rates are steadily increasing, compared to the overall 
downward trend in both European neighbours and across the world. In the UK both men 
(+67.9%) and women (+57.1%) saw significant increases in mortality rates, compared 
to France (M: -14%, F: -12.6%), Germany (M: +15.6%, F: +1.3%) and Spain (M: -
14.7%, F: -39.2%) as well as significant decreases in Japan (M: -42.1%, F: -41.0%), 
Korea (M: -30.1%, F: -29.0%) and Hong Kong (M: -23.7%, F: -11.0%) thus 
highlighting global differences in HCC mortality data (Bertuccio et al., 2017). With 
such marked increases in UK HCCs, further work describing this cohort is vital to help 
improve patient outcomes. 
Owing to the global variations in the aetiology of HCC, Zucman-Rossi state: “the 
highly heterogeneous nature of HCC makes genomic classification of this disease and 
identification of clinically relevant biomarkers more challenging compared with other 
solid tumours like lung and colon cancers” (Zucman-Rossi et al., 2015). 
1.1.7 Genetics of HCC 
The genetic landscape of HCC is incompletely understood. Large multicentre studies of 
European patients with HCC are based on French and German patient cohorts (who also 
have a decreasing HCC-specific mortality rates, contrary to the UK) and are based on 
surgically resected tumours. The ability to sequence the exome, transcriptome and 
whole genome has allowed genetic variations, their associations with nucleic acid 
sequences and ultimately altered protein expression, to be correlated with disease 
characteristics.  Cell signalling pathways involved include altered telomere biology, cell 
cycle, Wnt/beta-Catenin, epigenetic, NRF2/KEAP1, RAS/ RAF/MAPK and 
AKT/mTOR pathways (Madduru et al., 2019; Nault et al., 2020).  
 17 
Driver mutations occur when random genomic alterations are clonally expanded 
because they have occurred in a ‘cancer gene’ (Hanahan & Weinberg, 2000; Stratton, 
2011). The neoplastic cells then have a survival advantage because of their increased 
ability to divide, can resist normal homeostatic control or otherwise demonstrate a 
hallmark of cancer. If a mutation does not confer a survival benefit, which occurs in the 
majority of cases, then these are termed passenger mutants (Stratton, 2011).  
Enormous effort researching the genetics of HCC has been undertaken using 
fresh/frozen tumour samples from surgical resection specimens and discovered that 
Telomerase activation is the most common mechanism for tumour initiation in HCCs, 
occurring in 70-90% (Nault et al., 2019). Recruitment for these studies has so far not 
included UK-based patients to any significant degree. Telomerase promoter mutations 
(pTERTMuts) are associated with alcohol driven HCCs in a western European cohort, 
indicating a potential aetiology-specific association (Schulze et al., 2015). Other groups 
have found an association between HCV-driven HCCs and pTERTMuts, demonstrating 
that there is incomplete understanding of the exact mechanisms involved in telomere 
biology and carcinogenesis (Ally et al., 2017). It is clear that more work is required to 
improve understanding of any potential associations.  
However, the available data provides an intriguing insight into how genetic alterations 
are associated with aetiological processes. Early work described the role of tumour 
protein 53 (TP53) mutations in Aflatoxin B1 associated HCCs and subsequent 
understanding of other cell-signalling pathway alterations have been facilitated by the 
technological advances (Nault et al., 2020).  
With the increased availability of next generational sequencing technologies, subgroups 
of HCCs have been found based on their genetic profiles. For HCCs the most 
commonly dysregulated driver pathway has been in aberrations in the Telomerase 
Reverse Transcriptase (TERT) gene occurring in 70-90% of all tumours (Nault et al., 
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2019; Schulze et al., 2016). This Telomerase enzyme is involved in altered Telomere 
maintenance via promoter mutations (60%), gain of function amplifications (5%) and 
Hepatitis B Virus (HBV) integration (5%).  Other candidate drivers that have been 
described include TP53, CTNNB1 and ARID1A (Schulze et al., 2015; Totoki et al., 
2014). These studies have focussed on fresh-frozen libraries of liver tissues, owing to 
the relative ease of using this resource when compared to FFPE archives. Further 
evidence of telomere biology alterations in liver disease has been shown with shorter 
telomere length and rare promoter mutations associated with NAFLD (Donati et al., 
2017).  
Recently irregularities in the diagnostic accuracy of cellular morphology alone for 
detecting fibrolemellar HCC have been highlighted, with some inter-reporter 
inconsistencies becoming apparent. Protein kinase cAMP-activated catalytic subunit 
alpha (PRKACA) FISH assays for a genetic rearrangement were positive in 99% (102 
of 103) of typical FL-HCC, and in 75% (9/12) of the diagnostically uncertain (initially 
categorised as ‘?FL-HCC’) when assessed with cellular morphology alone (Graham et 
al., 2018). Some tumours that are initially misdiagnosed as HCC later turn out to be FL-
HCCs containing the gene fusion when appropriately analysed, demonstrates the power 
of assessing a single genetic abnormality (Lalazar & Simon, 2018; Simon et al., 2015).   
1.1.7.1 UTAA in HCC 
Survivin and Telomerase have been described as the archetypal universal tumours 
antigens (UTAA) as they are expressed in a wide range of cancers and are a Hallmarks 
of Cancer (Hanahan & Weinberg, 2000, 2011). When any tumour expresses UTAA 
they are deploying mechanisms to evade normal physiological control by evading 
apoptosis (Survivin) or enabling replicative immortality (Telomerase) to promote 
tumourigenesis.  
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Survivin predominantly present in the nuclei of HCC tumours with IHC and correlates 
with proliferation indices (Ito et al., 2000). Indeed, it is the nuclear translocation of 
Survivin in HCCs from the cytoplasm of quiescent non-malignant liver cells that may 
constitute an important mechanism of cell proliferation and differentiation in 
carcinogenesis (Moon & Tarnawski, 2003). Significant positive correlations exist 
between IHC-detected nuclear Survivin and grade, microvascular invasion, mitosis, 
local recurrence and disease-free survival indicating the essential role Survivin may 
play in hepatocarcinogenesis (Fields et al., 2004). 
Telomerase activity is present in around 90% of HCCs, with promoter mutations being 
both responsible for this, and the most common genetic alteration in HCC (Nault et al., 
2019). Indeed, these promoter mutations are HCC specific, with none occurring in CCA 
(Quaas et al., 2014). Telomerase activity, as measured by the telomerase repeat 
amplification protocol (TRAP assay – a PCR based assessment of enzyme activity) has 
been linked to an increase risk of tumour recurrence after resection, suggesting a role in 
malignant tumour biology (Kobayashi et al., 2001). Telomerase protein, detected by 
IHC, in tumour tissues has been linked to tumour worse grade, the presence of a portal 
vein thrombosis and HBV insertion into the genome in a Chinese cohort (X. Zhou et al., 
2016). Whilst serum detection of telomerase mRNA has been proposed as an adjunct to 
AFP to increase the accuracy of HCC detection (El-Mazny et al., 2014). 
1.1.8 Treatment 
The treatment of HCC is complex and determined by tumour stage and underlying liver 
disease severity. There is a deficit of care between the most unwell patients (advanced 
tumour burden, advanced liver cirrhosis and poor liver function) and the treatment 
options they are offered. In simple terms: the patients most in need of therapy are not 
medically fit for surgical resection, and all treatment is therefore palliative in nature.  
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Curative options are more likely to be successful in early disease and in the UK, many 
centres use the Barcelona Clinic Liver Cancer (BCLC) staging of disease to guide 
treatment decisions (Llovet et al., 1999). Criteria that are measured to facilitate the 
BCLC stage are the size of the tumour, the presence and severity of cirrhosis and other 
markers of liver functionality as well as the patients’ ability to perform their activities of 
daily living (Hartke et al., 2017).  
1.1.8.1 Surgical. 
Surgical management offers the best chance of a cure for HCC, but is only offered to 
5% of patients based on their stage of disease at diagnosis (El-Serag, 2011). In the 
absence of cirrhosis, surgical resection of a portion of the tumour containing liver is the 
treatment of choice with long term cure possible (Forner et al., 2012).  
Liver transplantation is an option for some cases and offers the prospect of curing both 
the HCC and the underlying liver disease. However, the risk of tumour recurrence post-
transplant increases with tumour size and decisions are often based on the 
internationally recognised Milan criteria (C.-Y. Liu et al., 2015; Mazzaferro et al., 
1996). Patients with early-stage disease (BCLC stage A) defined by a single tumour 
being 5cm or less, or up to three tumours with the largest 3cm or less, with no vascular 
spread or extra-hepatic disease in the context of moderate to severe cirrhosis benefit the 
most from liver transplantation (Galle et al., 2018; C.-Y. Liu et al., 2015). Only a small 
minority of patients fulfil these criteria leaving the majority of patients’ very limited 
options, most of which are often palliative.  
1.1.8.2 Loco-regional therapies. 
Transarterial chemoembolisation (TACE) therapy involves the delivery of 
chemotherapy via a catheter to a vascular tumour. Conventional TACE uses a Lipiodol 
based emulsion to deliver a chemotherapeutic and embolising agents, whereas Drug 
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Eluting Bead TACE (DEB-TACE) uses chemotherapy loaded beads delivered into the 
tumour vasculature to release antineoplastic agents over a longer period of time whilst 
also embolising the tumour’s arterial supply (Raoul et al., 2019). TACE has become the 
treatment of choice in intermediate stage HCC as it is a life prolonging treatment but it 
can also be used as a down staging (bridging) therapy to reduce tumour size and 
facilitate liver transplantation.  
TACE has been quoted as achieving a successful downstage in 48% of cases with a 
tumour recurrence rate in the transplanted liver around 16% when reported in a recent 
meta-analysis of 950 patients (Parikh et al., 2015). There is no benefit of neo-adjuvant 
Sorafenib (a multi-kinase inhibitor) plus TACE compared to TACE alone prior to liver 
transplant for HCC, as patients’ tumours from the two groups demonstrated similar time 
to progression (Hoffmann et al., 2015). 
When not prescribed as a bridging therapy TACE is the most commonly used palliative 
treatment regimen when surgical treatment is not possible. For treating intermediate 
stage (BCLC stage B) HCC, DEB-TACE confers a median survival of 47.7 months 
when BCLC treatment guidelines are strictly adhered to (Burrel et al., 2012). However, 
it is acknowledged that these inferences can only be made when there is judicious use of 
BCLC criteria. TACE can be used out with intermediate stage disease, but less strict 
adherence to BCLC guidelines can mean patient outcomes may be compromised 
(Palmer et al., 2020; Raoul et al., 2019). 
Combining systemic therapies with DEB-TACE (Sorafenib and DEB-TACE) in 
intermediate (BCLC stage B) HCC demonstrates no reduction in time to progression in 
the dual treated arm of the trial when compared to DEB-TACE alone (Lencioni et al., 
2016). Further studies are on-going, exploring the role of immunotherapy being used in 
conjunction with loco-regional therapies, with initial results demonstrating combined 
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therapies are well tolerated, but significantly more work in this area is required (Greten 
et al., 2019). 
1.1.8.3 Ablative Treatment 
Radiofrequency ablation (RFA) and microwave ablation (MWA) are physical 
treatments that lyse cells by generating heat. The ablation is targeted using ultrasound or 
CT and a probe inserted into the tumour to deliver the thermal injury. RFA is able to 
deliver complete tumour necrosis and has similar outcomes compared to surgical 
resection in BCLC stage 0 (very early stage, single nodule tumour < 2cm) HCC, at a 
reduced cost (Galle et al., 2018). This study compared 3996 resection and 4424 ablated 
patients and concedes that the only benefit of surgical resection would be to provide 
tissue for histopathological analysis of high-risk features, such as vascular invasion, 
poor differentiation and satellite tumours. Judicious use of RFA in a clinically 
appropriate patient can be used in conjunction with surgical resection in intermediate 
(BCLC B, normally treated with locoregional therapy alone) stage HCC, demonstrating 
a combination of chemotherapeutic regimes may lead to better overall survival with a 
longer time to progression (Espinosa et al., 2018).  
1.1.8.4 Systemic therapies. 
First line treatment for advanced HCC (BCLC stage C) has been the multi-kinase 
inhibitor, Sorafenib, for more than a decade (Bouattour et al., 2019). Sorafenib targets 
tyrosine kinases, significantly improves overall survival from 7.9 to 10.7 months and 
results in a longer time to progression (5.5 vs. 2.8 months) when compared to placebo 
(Rimassa et al., 2019). Other immunotherapeutic options in HCC includes checkpoint 
inhibitors, currently offered after failed Sorafenib treatment, with further trials assessing 
the role of combination, or even first line use of this novel drug-class, (Onuma et al., 
2020) .  
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With positive results emerging from phase II/III trials for second line agents including 
the multikinase inhibitors Regorafenib, Lenvatinib and Cabozantinib as well as 
encouraging results from studies of the check point inhibitors including Ramucirumab, 
Nivolumab and Pembrolizumab clinical guidelines will doubtless change very soon to 
reflect these developments (Bouattour et al., 2019; Foerster & Galle, 2019). Significant 
potential for further improving therapies targeting the most commonly altered genetic 
variations in HCC, such as pTERTMuts, beta Catenin, TP53 and ARID1A driver 
mutations is highlighted by their presence in the majority of HCCs (Bouattour et al., 
2019).  
Clinically useful genetic aberrations that commonly occur in various tumours, including 
HCC, requires a ‘drug-able target’. For TP53 this requires the wild type confirmation of 
p53 to be stabilised and allows the protein to fold normally. The ability to induce 
conformational change in p53 mutants by the compound APR-246 results in apoptosis 
induction in tumour cells and has been involved in clinical trials (Parrales & Iwakuma, 
2015). The Wnt/beta-catenin pathway involves a large number of proteins and kinases 
with numerous targets being assessed in pre-clinical models and clinical trials. Various 
Tankyrase, Porcupine, Disheveled and beta-Catenin inhibitors are being researched in 
the pre-clinical setting (Krishnamurthy & Kurzrock, 2018). Further clinical trials 
exploring Porcupine inhibitors, Wnt antibodies, beta-catenin inhibitors, Notch 
signalling inhibitors, gamma secretase inhibitors and inhibitors of Hedgehog signalling 
are also being explored in a wide range of solid and haematological tumour types, 
further highlighting the potential for personalised medicine based on universally 
expressed tumour antigens (Krishnamurthy & Kurzrock, 2018). 
For Telomerase, the oligonucleotide inhibitor, Imetelstat, targets the active site template 
region of TERC and demonstrates anti-tumour activity (Nault et al., 2019). Imetelstat is 
known to accumulate in the liver, spleen and bone marrow and has been used in phase 
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I/II trials for acute myeloid leukaemia and myelodysplastic disease (Saraswati et al., 
2019). The small molecule Telomerase inhibitor, BIBR1532, has demonstrated positive 
pre-clinical results but further clinical studies are required (Tahtouh et al., 2015). Other 
examples of novel approaches for therapy includes immunotherapy targeted against 
Telomerase and Survivin. The multi-peptide vaccine strategies are in phase one trials 
for metastatic breast cancer (clinical trials identifier: NCT01660529) and advanced 
myeloma (clinical trials identifier: NCT00834665) with the results keenly awaited. 
1.2 Cholangiocarcinoma 
Cholangiocarcinomas (CCAs) are a wide-ranging and diverse group of malignancies 
that arise from biliary epithelial cells. Early work in this field did not differentiate 
between the different methods of classifying CCA, such as anatomical relationship, 
macroscopic growth pattern, microscopic features or classification by cell of origin 
(Krasinskas, 2018). As such there was significant room for improvement in 
international classification methods, and now a legacy of uncertainty regarding true 
rates of each tumour type. The most commonly used is the classification by anatomical 
site: intrahepatic, perihilar or distal (Krasinskas, 2018; Tyson & El-Serag, 2011; Wirth 
& Vogel, 2016). Confusingly the lack of consensus of nomenclature has resulted in a 
large number of approaches, with some authors using the intrahepatic/extrahepatic 
terminology when describing CCAs. As such there is an unreliable archive of classified 
tumours. Truly intrahepatic CCA (iCCA), are rare and account for roughly 10% of all 
CCAs, and 15% of PLCs. The majority of CCAs (~2/3) of extrahepatic 
cholangiocarcinomas (eCCA) are perihilar (pCCA) and the remaining ~1/3 are distal 
CCA (dCCA), but for convention both pCCA and dCCA have been grouped together as 
eCCA (Hemming, 2019, p219). 
The nomenclature is important for differentiating CCAs as there has been a variation in 
reported use of terms used to describe the same disease entity that has lead to moderate 
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confusion and requires an international standard to be adopted to clarify this issue 
(Tyson & El-Serag, 2011). A specific example being the perihilar/ Klatskin/ 
extrahepatic tumour – which is the same disease by a variety of different names – that 
has variably been included with the intrahepatic CCAs, considered an entity in its own 
right and occasionally with other, more distal, cholangiocarcinomas. This is important 
to note as there have been reported surges in incidence rates of iCCA compared to 
eCCA, where the perihilar lesions are included with true intrahepatic CCAs (A. 
Bergquist & von Seth, 2015; Tyson & El-Serag, 2011). Accordingly, as many as 91% of 
perihilar tumours may have been erroneously recorded as iCCAs thus contributing to a 
false inflation in the incidence of iCCA when compared to other subtypes of CCA 
(Tyson & El-Serag, 2011; Welzel et al., 2007).  
Intrahepatic cholangiocellular carcinomas arise from the second order bile ducts, or 
more peripherally within the liver parenchyma, with perihilar CCA originating from 
between the second order bile ducts and the cystic duct and finally distal CCAs are from 
the cystic duct to lower down the biliary tree (Banales et al., 2016). Other authors have 
concluded the differentiation between subtypes of CCA, in anatomical terms at least, as 
being in relation to the second order bile ducts alone differentiating between iCCA and 
eCCA (Krasinskas, 2018). There are ongoing efforts to standardise the diagnosis of 
CCA, based on anatomical location, despite the historical lack of clarity in this field. 
Intriguingly the original classification of diseases in the ICD-0 and in the case of hilar 
CCA, have not been consistently recorded throughout recent history (Bridgewater et al., 
2014). Leading to perihilar/hilar CCA coalescing independently with intrahepatic CCA 
and extrahepatic CCA across the published literature (Tyson & El-Serag, 2011).  
Intrahepatic CCAs can be further sub-classified by their histological features and 
whether or not they are producing mucin (Krasinskas, 2018). Large duct, type 1, iCCAs 
tend to be columnar, produce mucin and resemble the bile duct epithelium whilst small 
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duct, type 2, iCCAs resemble cholangiocytes and are more cuboidal in their shape. 
Small duct iCCAs are associated with some risk factors shared with HCCs, such as viral 
hepatitis and cirrhosis and large duct iCCAs share aetiology with more chronic biliary 
diseases, which will be discussed further below. The type of tumour that grows tends to 
reflect the clinico-pathological features that are seen when comparing small and large 
duct neoplasms. Small ducts growths tend to be mass forming in nature and the larger 
ducts grow in a periductal infiltrating pattern, resulting in strictures or other thickened 
biliary epithelial growths (Banales et al., 2016). 
1.2.1 Anatomical location 
The nomenclature describing the site of CCAs relating to their anatomical site in 
relation to the cystic duct and the second order bile ducts, as outlined in figure 2, 
adapted from (Banales et al., 2016).  
 
 
Figure 2. The anatomical locations of Cholangiocarcinoma.  
Intrahepatic (also known as peripheral tumours) occur in the smaller calibre biliary tree, 
as denoted by the occurring further downstream than the second division in the bile 
ducts. Hilar/perihilar neoplasms occur between the second order bile ducts and the 
cystic duct, which receives bile from the gallbladder. Distal tumours occur further 
downstream than the cystic duct and can frequently present earlier with obstructive 
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jaundice-type symptoms. Prognosis is best for dCCA, moderate for pCCA and poor for 
iCCA in terms of overall survival and tumour-specific mortality (Hang et al., 2019). 
1.2.2 Aetiology 
Unlike HCC 70% of CCA arise sporadically, without pre-existing liver or biliary 
disease (Vogel & Saborowski, 2017). This is in stark contrast to HCC, where the 
majority of cases are in the chronically inflamed, cirrhotic, liver. The remaining ~30% 
of CCAs arise on the background of chronic biliary pathology, in the UK most 
commonly in patients with primary sclerosing cholangitis (PSC) (Tyson & El-Serag, 
2011). The aetiology of CCAs can be broadly divided into sporadic, autoimmune, 
biliary, infectious, and environmental/ lifestyle associated.  
Intrahepatic CCAs (iCCA) and HCCs can share various risk factors, such as HCV 
infection, non-alcoholic fatty liver disease (NAFLD) and hereditary haemochromatosis 
(HH) (Welzel et al., 2007). Extrahepatic CCAs are more associated with biliary 
disorders that impede the normal flow of bile such as primary sclerosing cholangitis 
(PSC), cholelithiasis (gallstone disease) and congenital abnormalities of the bile duct 
(Vogel & Saborowski, 2017).  
Chronic inflammation of the biliary tree with biliary stasis, regardless of the underlying 
cause, is a significant risk factor when compared to a healthy population (Tyson & El-
Serag, 2011). Examples of conditions that cause this include: biliary cirrhosis, 
cholelithiasis, hepatolithiasis, choledocholithiasis, cholecystitis and cholecystectomy 
(Tyson & El-Serag, 2011; Welzel et al., 2007).  
Autoimmune conditions such as primary biliary cholangitis (PBC) and primary 
sclerosing cholangitis (PSC) are associated with the development of CCA. PSC is most 
strongly associated with malignant cholangiocellular growth, with an astonishing 1560-
fold increase in risk of developing CCA when compared to a background population (A. 
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Bergquist & von Seth, 2015; Wirth & Vogel, 2016). The lifetime risk of developing 
CCA in PSC is quoted at around 5 – 15%, but this may be an underestimation of the 
disease burden as post mortem diagnosis of CCA in PSC has been quoted to be as high 
as 41% (Levy et al., 2005). The annual risk of developing CCA in PSC is 0.5 – 1.5% 
with 50% of CCA tumours being diagnosed within one year of PSC diagnosis (A. 
Bergquist & von Seth, 2015). 
When considering infectious causes as risk factors for CCA there is considerable 
geographic variation – one example being that 20% of Taiwanese having 
hepatolithiases, compared to 1-2% of patients in the West. The biologically plausible 
relationship between stone formation, chronic irritation and inflammation that results in 
malignant transformation appears sound. However, given that up to 30% of 
hepatolithiases are associated with liver fluke infections in endemic regions, these risk 
factors may not be independent as there may be a synergistic relationship between 
associated risks. The two main culprits for liver fluke infection are O. viverrini and C. 
sinensis, both of which come from raw, undercooked or pickled scaly fish from SE Asia 
with both flukes recognised as being carcinogenic to humans (Tyson & El-Serag, 2011). 
Fluke infection plays a significant role in CCA development in endemic regions but do 
not account for Western disease. 
Other infectious risk factors associated with CCA development are the hepatitis viruses: 
HBV and HCV. The global burden of HCV is higher in Western countries, whilst HBV 
is more a disease of sub-Saharan Africa and South East Asia (Sia et al., 2017). Research 
into the role HBV and HCV play in iCCA development have unsurprisingly come to 
reflect the disease prevalence in the host country (Tyson & El-Serag, 2011).  
As most cholangiocellular carcinomas are sporadic without apparent risk factors there 
are limited screening tools available (Banales et al., 2016; Khan et al., 2012). Around 
30% of CCAs develop in patients with a chronic liver disease, such as PSC, and Khan et 
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al put it succinctly: “No benefit in screening for CCA in PSC has been proven and there 
is no robust screening test.”  
1.2.3 Incidence 
Globally, the highest rates of iCCA are found in North East Thailand with 113 cases per 
100,000 for men and 50 cases per 100,000 in women (Kirstein & Vogel, 2016). In 
Australia there are as few as 0.2 cases per 100,000 in men, and 0.1 per 100,000 in 
women, highlighting the significant geographical variation in cases (Tyson & El-Serag, 
2011). In Thailand the incidence is linked to aetiology as the rates of liver fluke 
infections are endemic, as mentioned above. 
The incidence of CCA also appears to vary based on the anatomical location of 
tumours. In the US the incidence of iCCAs have increased by 128% from 1973 – 2012 
to 1.6 cases per 100,000 people, with mortality tripling in the decade leading up to 2008 
(Kirstein & Vogel, 2016). In the UK there are 2.17 cases per 100,000.  
Regrettably, as mentioned above, it is quite common for reported rates of disease to not 
differentiate between iCCA, pCCA and dCCA, making accurate estimates of their 
respective rates difficult to determine (Bridgewater et al., 2014). Tyson and El-Serag 
put it succinctly: “misclassifications can substantially impact the findings of 
epidemiological studies. Consequently, no definitive statement can be made on the 
temporal trends of cholangiocarcinoma in most world regions,” (Tyson & El-Serag, 
2011).  
1.2.4 Stage 
The TNM classification is used to stage both iCCA and pCCA with a recent advance 




Figure 3. Evolving iCCA staging classification.  
From the 7th edition of the American Joint Committee on Cancer (AJCC) the TNM 
stage was incorporated and allows survival prediction and prognostic stratification 
(Banales et al., 2016). In both classifications there are 5 stages of detectable tumour, 
starting with the non-invasive tumour in situ (Tis), then the more recognisable stages T1-
4. The main differences between the 7th and 8th iteration are the introduction of size 
criteria for T1 tumours (without vascular invasion) and sub-categories to reflect this. 
There is also simplification of the T2 tumour stage, compared to the 7th edition. 
From the SEER (Surveillance, Epidemiology and End Results Cancer Registries) 
database, a large cohort of 11710 patients with CCA were studied from 1973 to 2015. 
Most tumours were hilar (i.e., pCCA, 48.0%) closely followed by iCCA (46.6%) with 
only 5.3% being dCCA (Hang et al., 2019). Across all CCA, most tumours are stage IV 
(53.2%) followed by stages II (21.0%) and stage I (18.6%) with 6.6% being stage III 
and 0.5% stage 0 (Hang et al., 2019). Regrettably 49.7% of tumours (from 5611 
patients) were so advanced that surgery was deemed inappropriate and therefore not 
undertaken. This is further evidence of the current unmet need for liver tumour patients 
as most present with advanced late-stage disease that are not amenable to curative 
treatment. 
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Given the previously reported issues with tumour location (iCCA vs. eCCA) another 
report has estimated that iCCA account for 6-10%, pCCA for 60% and dCCA 30% (A. 
S. Khan & Dageforde, 2019). For pCCA there is also the modified Bismuth-Corlette 
classification system for pCCA that considers the location of the stricture and 
contributes to other staging systems, but should not be considered a staging system in 
its own right (A. S. Khan & Dageforde, 2019). 
1.2.5 Grade 
Cholangiocarcinoma is usually graded as well, (~15-20%), moderately (~40-55%) or 
poorly differentiated (~30-40%) with similarity to normal cholangiocytes decreasing 
with worsening grade  (Hang et al., 2019; Ma et al., 2019). Tumour grade is an 
independent prognostic predictor for both overall survival and cancer specific survival 
in iCCA (Ma et al., 2019). Poorly differentiated, high grade, tumours are also 
significantly associated with positive lymph node metastasis, another adverse clinical 
feature of iCCA (Martin et al., 2019).  
1.2.6 Genetics of CCA 
The genetics of CCA varies in sporadic versus infection associated cases with different 
mutational profiles reported with liver fluke (O. viverrini) related or unrelated CCA 
(Kongpetch et al., 2015). Viverrini-related CCA have mutations in TP53, KRAS, 
SMAD4, MLL3, RNF43, PEG3 and ROBO2 whereas epigenetic modulators such as 
BAP1, IDH1/2 and PBRM1 are more frequently mutated in non-viverrini-related CCAs 
(Kongpetch et al., 2015). However, TP53, ARID1A and KRAS mutations have also 
been shown in fluke-independent CCAs, demonstrating that molecular classifications 
may be of more relevance than aetiological cause, in this era of personalised medicine 
(Stavraka et al., 2019). So far, the role of immunotherapy in CCA has involved small 
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study numbers with modest responses to checkpoint inhibition in a selected cohort, and 
further studies are ongoing  (Kelley et al., 2020). 
Recurring evidence exists that drug-able pathways such as Ras/Raf/MEK/ERK, 
P38/MAPK, PI3K/mTOR pathways metabolic alterations (IDH1/2) as well as 
chromatin remodelling (ARID1A/ PBRM1/BAP1) have been identified by next 
generation sequencing to be involved in carcinogenesis (Xie et al., 2016). 
Druggable molecular aberrations occur in iCCA with FGFR small molecule kinase 
inhibitors (FGFR2 fusions in 7-14% of iCCA), mutant IDH inhibitors (IDH1/2 mutants 
in 23-28%), HDAC inhibitors such given the BAP1 (9-12%) and ARID1A (15-36%) 
presence, MET kinase inhibitors (MET-HGF in 7%), Mcl-1 selective inhibitors (Mcl-1 
in 16-21%), MEK inhibitors (KRAS (11-25%) and AKT/mTOR inhibitors (PI3K-AKT-
mTOR in 4-8%) all being described (Rizvi & Gores, 2017). Identification of druggable 
targets such as these will help guide molecular sub-classification of CCA and is likely 
to increase in the future (Kirstein & Vogel, 2016). There is evidence that, in animal 
models, Beta-catenin and Wnt signalling drives CCA growth, with small molecule Wnt 
inhibitors reduces tumour growth and increases apoptosis (Boulter et al., 2015). 
1.2.6.1 UTAA in CCA 
There have been a few studies of UTAA in CCA. Survivin has been reported in CCA 
previously in a series of 24 consecutive cases with 4 cases demonstrating strong nuclear 
protein with IHC which corresponded to a reduced overall survival (11 vs. 20 months, 
p= 0.033) (Javle et al., 2004). These results were not reproduced in a Chinese cohort of 
patients, where no correlations between Survivin levels and clinical features were found 
(Chang et al., 2004). Previous work combining both human CCA and animal models 
has found Survivin to be preferentially expressed in human tumour cells and also 
present in over 80% of tumour epithelial cells in a rat model of CCA (Boulter et al., 
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2015). In addition to this, biliary excretion of Survivin has been used, in combination 
with serum CA 19-9, to help differentiate between benign and malignant biliary 
obstruction in human studies, indicating that Survivin may play a role in 
cholangiocarcinogenesis (Y. Liu et al., 2017).  
Interestingly a carcinogenic toxin (Thioredoxin) secreted by liver fluke O. viverrini has 
been shown to up-regulate anti-apoptosis genes, including Survivin, in a cholangiocyte 
cell culture model (Matchimakul et al., 2015). In other cholangiocyte cell culture 
models, putative anti-tumour compounds (Guggulesterone and Curcumin) successfully 
induced caspase-dependent apoptosis and downregulated Survivin levels, as detected by 
Western Blot (Koprowski et al., 2015; Zhong et al., 2015).  
Telomerase protein has been detected in iCCA and pre-neoplastic lesions, using in situ 
hybridisation and in a separate study, telomerase activity has been detected in CCA 
biopsy samples (using the TRAP assay) indicating its potential role in CCA (Itoi et al., 
2000; Ozaki et al., 1999). Furthermore, quantitative PCR has also detected hTERT 
mRNA in both HCC and biliary tumour tissues whilst noting its absence in background 
tissue and GIST tumours (Udomchaiprasertkul et al., 2008).  
Serum hTERT mRNA has been detected in 85% of CCA patients, and is absent in 
healthy volunteers, indicating a potential role as a biomarker (Leelawat et al., 2006). 
However, more recent research assessing the expression of hTERT mRNA in cell lines 
and primary human hepatocytes (PHH) has found that Telomerase is present in 
cholangiocytes but at significantly lower levels than PHHs (Qin et al., 2018). These 
findings vary between cell lines, so should be interpreted with caution (Lie-A-Ling et 
al., 2006; Qin et al., 2018). A recently developed telomerase inhibitor, KML001, is well 
tolerated in advanced CCA patients but has failed to demonstrate anticancer effects (Jo 
et al., 2019). 
 34 
1.2.7 Prognosis 
Complete surgical resection currently the only curative treatment option in CCA (Ting 
et al., 2016). Whilst chemotherapy, loco-regional therapies or radiotherapy can prolong 
survival, patients with more advanced disease are precluded from surgical management 
(Raoof et al., 2017). Comprehensive assessment of the extent of tumour disease, by 
cross sectional imaging, as well as ensuring adequate liver function are necessary to 
ensure operations are undertaken on appropriate patients (A. S. Khan & Dageforde, 
2019). Adverse features include tumour number, tumour size, vascular invasion, lymph 
node metastasis, advanced tumours stage at diagnosis, metastatic disease, poor tumour 
grade, male gender and increased age (Ma et al., 2019; Raoof et al., 2017; Wang et al., 
2013).  
The presence of adverse clinical features (multifocal disease, large vessel vascular 
invasion and/or metastatic spread) determine whether or not a CCA is technically-
resectable. Median survival in CCA is 24 months, but a dismal 3.9 months in untreated, 
unresectable disease (Krasinskas, 2018). In patients with unresectable CCA given 
chemotherapy, overall survival increases to 8.1 months with Gemcitabine and is further 
lengthened with the addition of Cisplatin to 11.7 months. Five-year survival rates for 
surgically resected tumours ranges from 25 – 50% with poorer outcomes in patients 
with positive surgical margins giving a median survival of 12-21 months in these cases 
(A. S. Khan & Dageforde, 2019).  
1.2.8 Treatment 
This section will review the treatment options for iCCA only.  
1.2.8.1 Surgical 
Surgery is the only curative option but requires that sufficient functional liver will 
remain post-procedure and that the disease is not late stage (A. S. Khan & Dageforde, 
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2019). Around 12-40% of iCCA are surgically resectable at presentation, but this 
requires a highly technical and extensive operation (Mazzaferro et al., 2020). Nearly 
80% of resectable iCCA require an extended hepatectomy and 29% of cases undergo 
extra-hepatic bile duct resection (Bridgewater et al., 2014). A recent meta-analysis has 
found that down-staging tumours (with chemotherapy, radiotherapy or TACE) prior to 
resection significantly improves overall survival from 12 to 29 months, P< 0.001 
(Kamarajah et al., 2020). Tumours with pathologically or clinically positive lymph 
nodes benefit from chemotherapy post resection. In clinically positive LN metastatic 
disease, combining surgery and chemotherapy significantly improves survival compared 
to surgery alone (+10.1 months) or chemotherapy alone (+10.6 months) indicating the 
benefit of a combined approach (Martin et al., 2020).  
Liver transplantation for iCCA remains controversial. In highly selected cohorts, liver 
transplantation may be of benefit and is not currently offered to patients, but this 
remains a contentious issue. Intrahepatic tumours <2cm (very-early iCCA) have a 5-
year recurrence rate of 18%, compared to 61% for multifocal tumours, or tumours >2cm 
in size (Vogel & Saborowski, 2017). In transplantation for iCCA, irrespective of the 
tumour size, >50% of patients have recurrence within 2 years with 2-year survival 
(48%) and 5-year survival (23%) reflecting an aggressively recurrent disease  (Mosconi 
et al., 2009). In the rare cases of very-early iCCA in patients that are not resection 
candidates (e.g., due to cirrhosis) a multicentric single arm clinical trial is currently 
under way to confirm the effectiveness of liver transplantation (Mazzaferro et al., 2020). 
In the more commonplace cases with iCCA >2cm with no evidence of vascular spread, 
or extrahepatic disease, neoadjuvant chemotherapy has been used as a bridging 
treatment to transplant, and recommenced 4-6 weeks post-transplant, achieving an 
impressive 5-year overall survival rate of 83% (Lunsford et al., 2018). This is further 
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evidence that liver transplantation may become a standard treatment in selective cases 
of iCCA. 
1.2.8.2 Locoregional Therapies 
Locoregional treatments can be used with life prolonging intent or to achieve tumour 
downstaging to facilitate surgery. In stage III disease, confined within the liver, 
locoregional therapies (RFA/TACE/TARE) can be used to treat patients with palliative 
intent (Bridgewater et al., 2014). In lymph node positive iCCA, there is no survival 
benefit of surgery compared to TACE, with fewer adverse outcomes in the non-operated 
cohort (Scheuermann et al., 2013). However, adverse clinical measures such as a highly 
vascular tumour, or Child Pugh B cirrhosis are poor prognostic features when TACE is 
used, highlighting the importance of judicious patient selection for medical therapies 
(Vogl et al., 2012). Intrahepatic CCA are not usually hypervascular (unlike most HCCs) 
but can demonstrate some degree of vascularity on angiography, further complicating 
whether or not these tumours are amenable to TACE (Bridgewater et al., 2014). 
Convincing evidence for the role of neoadjuvant TACE and TARE in iCCA is currently 
lacking and requires further research (Massironi et al., 2020; Mazzaferro et al., 2020). 
Other down staging techniques are available, such as pre-surgical selective internal 
radiation therapy (SIRT) in conjunction with chemotherapy in iCCA in achieving an 
18% rate of conversion to R0 resection with no significant toxicity (Mazzaferro et al., 
2020).  
1.2.8.3 Systemic Therapies 
Combination chemotherapy (Gemcitabine & Cisplatin) improves overall survival 
(compared to Gemcitabine alone) from 8.1 months to 11.7 months when there is 
extrahepatic disease (A. S. Khan & Dageforde, 2019; Valle et al., 2010). Another 
combination therapy is Gemcitabine and Oxaliplatin which increases overall survival to 
12.4 months, with fewer side effects that may be better tolerated by patients (Massironi 
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et al., 2020). There is also increasing evidence that combination therapies give better 
survival statistics, regardless of whether it is dual-drug treatment, or a combination of 
chemo-radiotherapy (Bridgewater et al., 2014). 
Promising targets for personalised medicine in iCCA include FGFR small molecule 
kinase inhibitors, IDH mutant inhibitors and checkpoint inhibitors (PD-1) that are 
currently under investigation as potential treatment options (Massironi et al., 2020; 
Rizvi & Gores, 2017). Checkpoint inhibition may be clinically useful in selected cases 
of CCA, with further results expected imminently, (Kelley et al., 2020). 
1.3 Mixed Hepatocellular-Cholangiocellular Tumours 
Mixed Hepatocellular-Cholangiocellular tumours are a rare form of PLC, comprising 
around 1% of all liver tumours (Moeini et al., 2017). By their very nature, expressing 
characteristics of both CCA and HCC, mixed (sometimes called combined) liver 
tumours are a diverse group displaying varying similarities to HCCs and CCAs. When 
comparing mixed tumours with HCCs and CCAs, mixed tumours display intermediate 
overall survival and prognostic behaviours, as they are sandwiched between the poorer 
prognosis of CCA and the relatively better prognosis of HCC (A. Q. Wang et al., 2016). 
Mixed tumours have traditionally been graded like CCAs and have a poorer prognosis 
than HCCs (Joseph et al., 2019). 
However, at the genetic level, mixed tumours are more akin to HCCs despite some 
similarities with CCAs being present. The tumour suppressor TP53 and ARID1A are 
commonly altered in both CCA and mixed tumours but pTERTMuts, BRAF and FGFR2-
BICC1 alterations are specific to mixed tumours (Moeini et al., 2017). 
The polymorphous nature of mixed tumours makes classification somewhat difficult, 
however the WHO recognises both the classical and the less common stem cell 
phenotypes of mixed HCC-CCA (Stavraka et al., 2019). A significantly rarer tumour 
 38 
type called a collision tumour is found to have both CCA and HCC occurring separately 
with no transition region from one cellular morphology to another (Stavraka et al., 
2019). 
1.3.1 Aetiology 
There is currently no international consensus on the aetiological causes of mixed PLC 
(Stavraka et al., 2019). The most recent WHO classification has placed all PLCs on a 
spectrum, with HCC and CCA at the extremes and mixed tumours, with all their 
inherent heterogeneity, somewhere in between (Sciarra et al., 2020). Most mixed 
tumours occur in the context of cirrhosis with viral hepatitis, autoimmune diseases, fatty 
liver disease, alcohol consumption and congenital cystic diseases of the hepatobiliary 
tree also playing a significant role (Mok et al., 2016). 
1.3.2 Incidence 
The demographic profile of mixed tumours is incomplete because of its rarity (Stavraka 
et al., 2019). It is known that mixed tumours account for 1.1% of PLCs (53 of 5049) 
with three tumour subtypes (Yoon et al., 2016). Type A/type I mixed tumours (also 
called collision tumours) are when simultaneous HCC and CCA are coincidentally 
detected, type B/II are when the tumour is truly transitional with elements of both HCC 
and CCA intermingled with type III being a fibrolamellar HCC with mucin producing 
glands within the same tumour (Jarnagin et al., 2002). Allen & Lisa are responsible for 
the alphabetical (and excluded FL-HCC appearing tumours from their initial analysis) 
and Goodman et al for the numerical nomenclature (Allen & Lisa, 1949; Goodman et 
al., 1985). 
Mixed tumours appear to occur in approximately equal measure across both sexes (52% 
M, 48% F) and share demographic and clinical features of CCA (Jarnagin et al., 2002). 
When previously there was increasing data that mixed tumours should be considered as 
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distinct entities from both CCA and HCC, and not a subclass of each respective parent 
(Wachtel et al., 2008). But genomic profiling of mixed tumours has highlighted more 
similarities to HCCs with pTERTMuts and TP53 both occurring in 80% of cases (Joseph 
et al., 2019). Clearly mixed tumours are highly complex in their nature and are not yet 
fully described.  
1.3.3 Genetics 
As mixed tumours possess morphological features of both CCA and HCC, it would be 
prudent to assume the genetic profiles also reflect this. Gene expression profiling, DNA 
copy number and exome sequencing of another cohort of mixed tumours highlight 
classical-type mixed tumours express genetic components of both HCC and iCCA 
whilst iCCA and HCCs are completely distinct entities (Moeini et al., 2017). Mixed 
tumours with stem cell features are more HCC-like, but still possess some 
characteristics of iCCA. Indeed, current diagnostic advice highlights the high degree of 
heterogeneity in morphology, immunophenotype, molecular biology and clinical 
features mixed tumours possess, making diagnosis difficult (Sciarra et al., 2020).   
Given the clinical course and prognosis of mixed CCA-HCC is more similar to CCA 
with staging and treatment algorithms reflecting this, it is surprising to learn the most 
recent evidence actually indicates to opposite. With pTERTMuts, and TP53 alterations in 
80% of mixed tumours (in common with HCCs) but no IDH1/2, FGFR2 or BAP1 
(similar to iCCAs) found with next generation sequencing technologies, it appears 
mixed tumours are more similar to HCC than previously thought (Joseph et al., 2019). 
However, these findings are somewhat uncertain as other researchers have used online 
compendiums of genetic data (GeneCards) and found that mixed tumours are 
predominantly a subtype of CCA (Mok et al., 2016). Some genetic commonality does 
exist between HCC, iCCA and mixed tumours, such as ARID1A and TP53 alterations 
but most differences are more nuanced, as shown in table 1 (Stavraka et al., 2019).  
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Table 1. Genetic alterations in hepatocellular carcinoma (HCC), cholangiocellular carcinoma (CC) and combined 
HCC-CCA (cHCC-CC).  
 
1.4 Universal Tumour Associated Antigens 
The Universal Tumour Associated Antigen (UTAA) describes the presence of proteins 
found widely expressed in malignancies (Gordan & Vonderheide, 2002; Paschen, 
2009). UTAA are a diverse group of proteins that are rarely found in healthy adult 
homeostasis yet appear to flourish in, and are detectable across, a wide range of solid 
organ and haematological malignancies (Altieri, 2008). Similar mechanisms are 
deployed for the evasion of normal homeostatic control by a wide range of malignant 
neoplasms and the antigens associated with them have been detected across a variety of 
tumour types. This has lead to UTAA being described as possessing the Hallmarks of 
Cancer (Hanahan & Weinberg, 2000, 2011).  Resisting cell death and enabling 
replicative immortality are two of the six proposed mechanisms that are required for 
cancerous cells to evade homeostatic control (Hanahan & Weinberg, 2000, 2011) with 
the ability of cancerous cells to inhibit apoptosis (Survivin) or to enable replicative 
immortality by increasing telomere length (Telomerase) being archetypal methods by 
which tumours achieve these Hallmarks of Cancer.  
There has been some characterisation of Survivin, in cancers of the lung (Y. Xie et al., 
2012), brain (Fangusaro et al., 2005), cervix (Zannoni et al., 2014) and breast (Stoetzer 
et al., 2013) where it has been associated with poorer prognosis, resistance to current 
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therapies and higher recurrence rates (Altieri, 2008). There is ongoing work to describe 
the exact mechanisms by which Survivin has these effects in tumour biology. 
The rate-determining enzyme for telomere extension, Telomerase, has been reported to 
be present in up to 98% of cancer cell lines and 90% of 101 biopsies from twelve 
tumour types (Kim et al., 1994). Telomerase catalyses the addition of the hexameric 
repeat (TTAGGG) to the ends of telomeres thus reversing the natural shortening that 
telomeres undergo during cell division. This lengthening of telomeres increases the 
theoretical Hayflick limit that ultimately results in cellular senescence after a finite 
number of cell divisions.  
1.5 Survivin 
Survivin was first described in 1997 in malignantly transformed cell lines as well as 
being found in foetal tissues (Ambrosini et al., 1997). Survivin has also been reported as 
being the fourth most commonly transcribed protein that is elevated in human cancers, 
indicating its clinical relevance across a number of tumour subtypes (Velculescu et al., 
1999). 
Survivin is a member of the inhibitor of apoptosis (IAP) family of eight genes and, at 
142 amino acids in length (16.5kDa) is the smallest. It has a number of functions within 
the cell (Wheatley & Altieri, 2019) and is characterised by the presence of a single copy 
of the Baculovirus IAP Repeat (BIR) that is required for apoptosis inhibition 
(Athanasoula et al., 2014). There is incomplete understanding of the roles undertaken by 
Survivin in various cellular compartments and processes, and it appears that this curious 
‘adaptor protein’ is able to interact with, and transport, other proteins to their required 
destination (Wheatley & Altieri, 2019).   
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1.5.1 Historical information & discovery 
Survivin was first described in foetal tissues, solid organ tumours and haematological 
malignancies in the late 1990s (Ambrosini et al., 1997). With undetectable levels of 
Survivin mRNA in terminally differentiated adult tissues (with the exception of thymus 
and to a lesser extent, placenta and testes) and a re-appearance in adult malignancies, 
Survivin has courted interest as a potential biomarker and therapeutic target for more 
than 20 years. More recent work has also found Survivin in components of the immune 
system, such as B and T lymphocytes, and occasionally in cells with a high turnover 
rate, such as the basal keratinocytes of the skin as well as the cells of the gastrointestinal 
tract (Dallaglio et al., 2014; Lorenzetti et al., 2019).  
1.5.2 Structure & Function 
Survivin is vital for physiological cell division as homozygous deletion is incompatible 
with embryonic development (Altieri, 2010). The structure of the 142 amino acids is 
integral to Survivin’s numerous functions. With an N-terminal baculovirus inhibitor of 
apoptosis repeat (BIR, aa 20 - 90) containing a zinc-binding domain, linked to a C-
terminal alpha helix (aa 98 – 142) that facilitates homo-dimerisation of the Survivin 
monomer, this small protein has a complex structure, as determined by X-Ray 
crystallography (Noel et al., 2000; Wheatley & Altieri, 2019). Alongside this alpha 
helix, three other proteins can associate and create the chromosomal passenger complex 
(CPC) whose presence is essential for mitosis to occur.  
In normal cell division, the constituent parts of the CPC comprise three proteins 
(Survivin, Borealin and the inner centromere protein: INCEPT) and an enzyme (Aurora 
B kinase) which are essential for chromosome condensation, spindle assembly, ensuring 
microtubule-kinetochore alignment and cytokinesis (Jeyaprakash et al., 2007). A tri-
helical bundle forms from each of the three non-enzymatic component parts and in 
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addition to Aurora B kinase forms a novel enzymatic subunit whose exact functions are 
difficult to fully assess, given the interdependence of the constituent parts, but are 
nonetheless vital for their functionality (Jeyaprakash et al., 2007).  
Survivin is involved in a positive feedback loop by utilising the alpha helical binding 
region to detect phosphorylated histone during mitosis (as a part of the CPC). This 
recruits chromatin whilst activating Aurora B which in turn phosphorylates Survivin, 
resulting in activation and ensuring chromosomal orientation during mitosis (Kelly et 
al., 2010; Wheatley & Altieri, 2019). The CPC localises to the chromosomes, then the 
inner centromere during mitosis and is intricately involved in the orchestrated 
movement of the microtubules, mitotic spindle assembly and cytokinesis required for 
cellular division (Athanasoula et al., 2014; Rosa et al., 2006). Maximal expression of 
the CPC occurs in the G2/M phase of the cell cycle with interruption of this association 
resulting in a loss of apoptosis inhibition (F. Li et al., 1998).  
The exact location of Survivin during mitosis is somewhat contentious as there is 
evidence that demonstrates both tubulin (microtubule and centrosome) association and 
Survivin residing within in the CPC, both of which are detectable with novel tracer-
technologies that can track Survivin movements in real time and confirmed their likely 
presence in these distinct subcellular pools (Beghein et al., 2016). These distinct 
subcellular pools are felt to play differing roles throughout the cell cycle and remain 
incompletely understood. Expression of Survivin has been demonstrated in peroxisomes 
(Beghein et al., 2016), mitochondrial (Dohi et al., 2004), cytoplasm (Shimamoto et al., 
2009), and the nucleus (Dallaglio et al., 2014).  
Apoptotic pathways are classified as intrinsic or extrinsic depending on the mechanisms 
involved. Extrinsic pathways are triggered by ligation of the ‘death receptors’ of the 
Tumour Necrosis Factor-Receptor (TNF-R) family, whilst intrinsic pathways are 
triggered by stimuli (such as irradiation or cytotoxic drugs) that leads to cytochrome-C 
 44 
release from mitochondria, ultimately triggering caspase-9 activation (Athanasoula et 
al., 2014). Survivin is unable to interact with caspases by itself but can interact with 
XIAP or hepatitis B virus X-interacting protein (HBXIP) to inhibit caspase activation 
and thus reduce apoptosis (Peery et al., 2017; Wheatley & Altieri, 2019). The Survivin-
XIAP complex stabilises XIAP and increase their anti-caspase potency, whilst 
sequestering XIAP from the pro-apoptotic smac/DIABLO, which remains within the 
mitochondria which is itself retained by intra-mitochondrial Survivin (Athanasoula et 
al., 2014). 
The role of Survivin in cancer centres on the loss of normal, cell cycle dependent, 
expression. De-repression of the naturally cyclic Survivin expression results in 
continuous synthesis throughout the cell cycle (Wheatley & Altieri, 2019). This results 
in the unrestrained expression of Survivin in cancerous tissues. There are mentions in 
the literature of sometimes contradictory findings when classifying subcellular 
localisation in tumours when comparing survival statistics, or disease stage. 
Specifically: cytoplasmic positive staining in CRC being associated with more 
advanced disease stage and poorer overall survival, (Shimamoto et al., 2009). This is 
contradicted by correlations between nuclear positivity of both premalignant and 
malignant skin lesions (highest expression in poorly differentiated squamous cell 
carcinoma) when compared to normal skin (Dallaglio et al., 2014).  
Yet more complexity, and confusion, arises when considering that some published 
works have not differentiated between subcellular locations of positive staining as 
peroxisomal and mitochondrial localisation will be indistinguishable from cytoplasmic 
pools of Survivin, unless specifically searched for (Wheatley & Altieri, 2019). Needless 
to say, there is much scope for expanding these fields of study to potentially clarify the 
independent roles played by Survivin during cellular respiration, and how these are 
exploited in both pre-cancerous and cancerous growths.  
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1.5.3 Isoforms & Location 
Six isoforms of Survivin have been described with varying degrees of understanding as 
to their exact cellular function, with a further 4 (as yet undetected) hypothetical 
isoforms (Sah & Seniya, 2015). Wild type, DeltaEx3, 3alpha and 3B appear to have 
anti-apoptotic actions, whilst 2B has reduced anti-apoptotic functionality owing to a 
truncated functional (BIR) domain and 2Alpha have apparent pro-apoptotic properties 
(Mishra et al., 2015; Sah & Seniya, 2015). However, some conflicting results have 
emerged as to the precise interactions between the variants, with a theorised role for 
heterodimers between WT Survivin and the 2alpha or 2B isoforms, being inconsistently 
demonstrated by various research groups and isoforms 2alpha, 2B and 3B apparently 
not interfering with cellular division in any capacity (Athanasoula et al., 2014). There is 
clearly potential for more work to be done to elucidate the mechanisms involved in 
these processes. 
Wild type Survivin associates with microtubules of the mitotic spindle in the G2/M 
phase of the cell cycle that results in a breech in the apoptotic checkpoint, where 
aberrant cells would normally proceed to programmed cell death (F. Li et al., 1998). 
The subcellular location of Survivin was thought to be either microtubule associated or 
as a chromosomal passenger complex, however in HeLa cells roughly 80% of Survivin 
is cytosolic, with the remaining 20% being nuclear (Fortugno et al., 2002).  
Various authors have described poor outcomes when nuclear Survivin has been 
detected. Hasby & Mokhtar found that 90% of HCCs (n=20) expressed nuclear Survivin 
in a small Egyptian cohort of patients, with an increased expression in poorer grades of 
tumour, and less prevalent in cirrhotic control samples, when measuring IHC staining 
intensity (Hasby & Mokhtar, 2010). In a larger cohort of German patients with 
oesophageal squamous cell carcinoma (n = 84), nuclear expression was detected in 80 
% (n = 67) and associated with shorter overall survival (p= 0.003) whereas cytoplasmic 
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Survivin was noted in 63% of cases (n = 53) and had no prognostic relevance 
(Grabowski et al., 2003). Similarly, when studying colorectal cancer, Nuclear Survivin 
was correlated with metastatic disease (p = 0.026) whilst cytoplasmic staining did not 
correspond to any disease parameter (Jakubowska et al., 2016).  
In non-small cell lung cancer, there has been sufficiently contradictory evidence on the 
prognostic relevance of nuclear Survivin that a meta-analysis was undertaken to assess 
the overall results (Y. Xie et al., 2012). Eight hundred and twenty-three patients were 
included in the pooled analysis and IHC was used to assess the location of Survivin in 
the tumour tissues. When the results were viewed overall, there was no significant risk 
of having nuclear Survivin staining (HR = 1.54, 0.79 – 3.02) but when taking into 
account the ethnicity of the study participants, nuclear Survivin was associated with 
reduced survival in Caucasians with NSCLC, HR = 2.38 (1.60 – 3.43). The authors 
conclude that nuclear Survivin is associated with poor prognosis in Caucasians with 
NSCLC, which introduces the potential for a potential genetic, or even geographical 
variation in Survivin expression rates.  
However, cytoplasmic Survivin has been reported in 69/71 (97.2%) of cases of locally 
advanced cervical cancer with a mere 7 cases of nuclear staining in the same cohort 
(9.8%) (Zannoni et al., 2014). Women with high cytoplasmic levels had a shorter 
disease-free survival (5-year DFS 80.8% vs 55.3%, p = 0.033), a positive lymph node 
status (p = 0.036) and residual tumour (p = 0.016) with no correlation between nuclear 
expression of Survivin and disease characteristics.  
It is apparent from the literature that Survivin is detected in a wide range of tumours, 
and in some pre-malignant lesions, with varying implications for tumour stage, grade, 
or size as well as prognosis.  
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1.5.4 Pathophysiology 
As described above, accumulations of Survivin have traditionally been described as 
either nuclear or cytoplasmic in nature, but the real location of these fractions is more 
nuanced. As mentioned above: nuclear, cytoplasmic, mitochondrial and peroxisomal 
stores have been described previously (Athanasoula et al., 2014; Beghein et al., 2016). 
The role of inter-compartmental shuttling of Survivin has been proposed as a potentially 
key step in carcinogenesis. Nuclear Survivin is transported to the cytoplasm because of 
a nuclear export signal (NES) with in a leucine-rich region of the molecule, and is 
exported by the evolutionarily conserved export receptor Crm1 (Knauer et al., 2007). 
NES-region knock out studies and NES-specific antibodies have abrogated Survivin’s 
ability to be exported from the nucleus and inhibit apoptosis, which was confirmed in a 
small IHC-based cohort of CRC patients, who had poorer prognoses with cytoplasmic 
Survivin (Knauer et al., 2007). However, these findings have not been replicated in 
other tumour types, with a plethora of tumours correlating a worse prognosis with 
nuclear expression of Survivin. The importance of intermolecular interactions when the 
CPC is formed is highlighted by the findings that both deltaEx3 and 2B isoforms have a 
reduced affinity for Borealin and hence do not locate to the CPC (Noton et al., 2006). 
The relevance of Survivin’s interactions during physiological and pathological 
processes become apparent when targeted therapies are considered. The broad 
categories include the inhibition of partner-protein interactions, homodimerisation, gene 
transcription, as well as inducing degradation of Survivin mRNA, or exploiting 
Survivin’s peptide sequence by using a vaccine-based immunotherapeutic approach (F. 
Li et al., 2019). 
1.5.4.1 Detection/ Promoter variants 
In 2004, Xu and colleagues sequenced cancerous cell lines and compared them to 
normal counterparts noting a few single nucleotide polymorphisms (SNPs) present in 
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the promoter region of the BIRC5 gene encoding Survivin (Y. Xu et al., 2004). The 
most intriguing of these SNPs (31 base pairs upstream of the transcription start site, 
position -31, C to G ‘mutant’) results in increased expression of both Survivin mRNA 
and protein and has subsequently been assigned the unique positional code rs9904341. 
As had previously been noted, there are several CDE/CHR transcriptionally sensitive 
regulatory repressor domains that control transcription in the G1 phase of the cell cycle. 
These can be found in the promoter region of Survivin (CDE: -6, -12, -171. CHR: -42) 
carrying the sequence motifs GGCGG and ATTTGAA respectively (F. Li et al., 1998). 
Mutations in these repressor domains would result is de-repression of Survivin in the 
G1 phase resulting in increased transcription and hence, higher levels of both mRNA 
and protein. 
1.5.4.2 Protein Expression & Detection 
Commercially available enzyme linked immunosorbent assay (ELISA) kits have been 
used to detect Survivin in peripheral blood samples specimens in a variety of cancers. 
There has been reported success in correlating serum Survivin in pancreatic cancer that 
correlated with disease parameters such as perineural invasion, venous invasion, lymph 
node spread metastasis, cell differentiation and recurrence (Dong et al., 2015). Serum 
Survivin was also found to be higher in patients with malignant (compared to benign) 
brain tumours, and also associated with the GG promoter at the -31 position (Kafadar et 
al., 2018). The relationship between a hepatobiliary tumour subtype (Gall bladder 
carcinoma) has been correlated with higher Survivin levels with adverse 
clinicopathological features such as advanced stage of disease and moderate/poor 
differentiation of tumour cells (Nigam et al., 2014). 
However, these findings need to be taken in context of other reports claiming that serum 
Survivin is not useful in the identification of patients with cancer. Jakubowska and 
colleagues reported higher serum Survivin in healthy controls compared to patients with 
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colorectal cancer (81.8% compared to 38.2%), albeit in a small single centre study of 55 
patients with CRC with 22 control subjects (Jakubowska et al., 2016). Jia and co-
workers have stated unequivocally similar views in their paper titled ‘Survivin is not a 
promising serological maker for the diagnosis of hepatocellular carcinoma’ (Jia et al., 
2015). This somewhat damning statement is backed by evidence from two separate 
commercially available ELISA kits (R&D and Abnova) that found no significant 
difference when measured in HCC patients and healthy controls, and also found an 
extremely low correlation coefficient (0.0064, p=0.481) when comparing identical 
serum samples with the different kits (Jia et al., 2015).  
1.5.4.3 Global Variation 
When Turkish brain tumours were assessed for the -31C/G promoter variant 
(rs9904341) and compared with serum levels of Survivin, significantly higher levels 
were detected in the GG homozygotes (Kafadar et al., 2018). However, rs9904341 GG 
homozygous breast cancer patients in Egypt had a better prognosis and lower levels of 
serum Survivin, indicating some potential differences between tumour type or 
geographic variation (Motawi et al., 2019). In a case-control study of Serbian paediatric 
Wilm’s Tumours found GG homozygotes were at a higher risk of developing cancer, 
and those with cancer and the GG variant had a poorer prognosis (Radojevic-Skodric et 
al., 2012). 
However, a recent meta-analysis of case-control studies across a broad range of cancers 
has found Asian rs9904341 CC homozygotes are significantly more likely to develop 
cancer, with no equivalently significant relationship in Caucasians (Moazeni-Roodi et 
al., 2019).  More work describing potential ethical variations is required, especially as 
no studies have been undertaken in the British population thus far.   
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1.6 Telomerase 
Telomerase is the enzyme required for telomere extension, and is conserved across 
many eukaryotic species (Wu et al., 2017). The enzyme facilitates the lengthening of 
telomeres, thereby increasing a cells ability to continue dividing beyond the 
physiologically pre-determined number of cell divisions. Eukaryotic DNA polymerase 
exploits an RNA primer when initiating DNA synthesis in the 5’ to 3’ direction and 
when it is later removed, this leaves up to 200 nucleotides uncopied (Singh et al., 2015). 
The aptly named end replication problem describes these missing 100-200 base pairs 
per cell division (Musgrove et al., 2018). Constant shortening of linear chromosomal 
ends during each cellular division ultimately results in cell cycle arrest, senescence or 
apoptosis (Singh et al., 2015). Therefore, a mechanism to halt or reverse this division-
shortening effect has been shown to increase the number of cellular divisions, and 
immortalising the cell.   
Telomerase has been detected in germline cells, haematopoietic cells, stem cells as well 
as in rapidly renewing cells and in cells with a high mitotic rate (Leão et al., 2018). 
Initial work described the expression of Telomerase in predominantly embryonic and 
adult germline tissues, such as foetal and adult Testes and ovaries, and their absence in 
oocytes and sperm (Wright et al., 1996).  In normal human cells Telomerase remains 
unexpressed, however it has been quoted as having detectable levels of activity in 
98/100 immortal cell lines as well as in 90/101 human cancers (Kim et al., 1994). 
1.6.1 History & Discovery 
Early work describing the presence of Telomerase in yeast, Tetrahymena, by Greider & 
Blackburn was undertaken in 1985 (Greider & Blackburn, 1985). This work has more 
recently earned them the 2009 Nobel Prize in Physiology/Medicine, an honour they 
shared with Szostack for the simultaneous nature of their work on the enzyme (Szostak 
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& Blackburn, 1982). The initial findings demonstrated Telomerase to be a 
ribonucleoprotein that required the presence of both the catalytic protein, encoded by 
hTERT, as well as the RNA subunit, hTERC or hTR, to be functionally active (Shay & 
Wright, 2019). Over the decades since the breakthrough discovery of Telomerase it has 
been found to be conserved across as a wide range of species and the structure in 
humans was finally described in 2018 using cryo-electron microscopy (Nguyen et al., 
2018). Whilst the sequences of the catalytic component of Telomerase (TERT) are 
conserved over many species, there is considerable divergence in the sequences of 
integral Telomerase-RNA (TR/ TERC) across species (Musgrove et al., 2018; Nguyen 
et al., 2019). These differences highlight the fact that telomerase physiology is 
incompletely understood. However, there is evidence that the human TR/TERC 
(hTERC) is expressed in a wide range of tissue types whilst the catalytic subunit 
(hTERT) is only present in the malignant or premalignant state (Leão et al., 2018). This 
further emphasises importance of understanding the role played by hTERT in human 
tumours, and whether it can be used as a potential biomarker. As hTERT is widely 
expressed across a range of neoplastic growths, any findings in liver tumours may have 
implications beyond this one organ.  
Telomerase facilitates the hexameric repeat (TTAGGG) being added to the ends of 
telomeres, thus reversing the natural shortening that telomeres undergo during cell 
division. As approximately 100 - 200 base pairs are lost from chromosomal end-
sequences with every cellular division (Singh et al., 2015). Telomere extension 
increases the theoretical Hayflick limit thus delaying the ultimate state of cellular 
senescence by extending the finite number of cell divisions that can occur (Shay & 
Wright, 2011). Hence the cellular clock is being reset, allowing cells to develop 
replicative immortality.  
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1.6.2 Structure 
Structural studies of human Telomerase have been challenging due to its very low 
abundance (Nguyen et al., 2019). The telomerase ribonucleoprotein includes the 
catalytic telomerase reverse transcriptase (TERT) and telomerase RNA component 
(TR/TERC) that includes the internal template required to extend telomeres (Musgrove 
et al., 2018). The ribonucleoprotein complex has a characteristic called repeat addition 
processivity (RAP) that allows translocation of and realignment to the RNA template to 
allow multiple TTAGGG repeats to be added to the 3’ chromosomal end, the specifics 
of which are still under study (Musgrove et al., 2018). Various other proteins interact 
with the TERT-TERC complex, in humans these are called small Cajal body 
ribonucleoprotein (scaRNP) which includes dyskerin, NOP10, NHP2 and possibly 
GAR1 (Chan et al., 2017). 
The Telomeric DNA complex, and support machinery includes the Shelterin complex 
(Leão et al., 2018). The Shelterin complex includes TRF1, TRF2, POT1, TIN2, RAP1 
and TPP1 and is able to locate Telomeres by TTAGGG recognition motifs in TRF1, 
TRF2 and POT1 (Singh et al., 2015). TRFs 1 and 2 bind double-stranded DNA, POT1 
binds ssDNA and TIN2 and TPP1 mediate shelterin assembly and TERT recruitment 
(Chan et al., 2017). Hence, recruitment of TERT-TERC complexes to the chromosomal 
ends is due to the presence of the Shelterin complex of proteins and is stabilised by 
dyskerin (Chan et al., 2017; Nault et al., 2019). 
1.6.3 Pathophysiology 
The pre-determined number of cellular divisions that are possible in terminally 
differentiated somatic cells is due to the length of telomeres. There is a shortening of 
between 100 - 200 base pairs during each cellular division because of the removal of the 
RNA primer/template from the DNA template, leaving an uncopied single strand of 
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DNA exposed and uncopied into the daughter cell (Singh et al., 2015). As Telomerase is 
able to extend telomeres a new equilibrium is reached in malignant cells with a balance 
between telomere extension and degradation being achieved and therefore extending the 
previously finite number of cellular divisions into the realms of the infinite.  
1.6.3.1 Telomerase Promoter Mutants 
The promoter region of a gene is upstream of the 5’ transcription start site and facilitates 
the binding of RNA polymerase, alongside other transcription factors that allows 
transcription to initiate. Mutations in the promoter regions (pTERTMuts) can disrupt 
normal cellular processes and can result in an increase or decrease of mRNA, and 
subsequent protein expression (de Vooght et al., 2009). 
Whilst pTERTMuts were initially found in familial and sporadic malignant melanoma 
there have been cases reported in a wide range of cancers, including approximately 60% 
of hepatocellular carcinomas (Nault et al., 2013) making it the most common genetic 
aberration in HCCs, (Zucman-Rossi et al., 2015). The mutations in question are -
124/C228T and -146/C250T, are mutually exclusive, and are associated with increased 
Telomerase expression and activation in other tumour types such as glioblastoma, 
urothelial carcinoma, oligodendroglioma, medulloblastoma and thyroid carcinoma 
(Huang et al., 2015).  
Mutations in the promoter region of the hTERT gene (-146/C250T and -124/C228T) 
creates a new consensus motif that facilitates transcription machinery binding to the 
promoter region of the gene (Akincilar et al., 2016). The E-Twenty-Six (ETS) family of 
transcription binding motifs has 27 members, with a specific member (GABPA) 
demonstrating C250T and C228T specific binding and increases in transcription of 
Telomerase (Akincilar et al., 2016). These pTERTMuts are heterozygous and occur in 
transcriptionally active, unfolded chromatin (Stern et al., 2015). Clinically, pTERTMuts 
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are highly correlated with increased transcription as well as increased Telomerase 
activity (Huang et al., 2015).  
Telomerase promoter mutations occur in a wide range of tumour types, stages and 
grades and are thought to be an early driver mutation for tumour development (Leão et 
al., 2018). The presence of these mutations in pre-neoplastic nodules of cirrhotic 
patients, as well during the metaplastic processes Hepatic Adenomas undergo to 
progress to HCC, confirms that this can be an early step in tumourigenesis in liver 
tissues (Nault et al., 2013). Also, pTERTMuts occur with increasing frequency from low 
grade though to high grade dysplastic nodules as well as in early HCCs, further 
evidencing the early-carcinogenic nature of this common genetic alteration (Nault & 
Zucman-Rossi, 2016). Intriguingly the prevalence of pTERTMuts in HCCs varies with 
geographic region, with more mutants in Western populations (around 60%) compared 
to those studied in the East (~30%) (Huang et al., 2015; Schulze et al., 2016).  
Techniques used to identify pTERTMuts include Sanger sequencing PCR products from 
fresh frozen tumour tissues (Nault et al., 2013), next generation sequencing of frozen 
tumours (Nault et al., 2017) as well as sequencing DNA extracted from formalin fixed 
paraffin embedded (FFPE) tissues (Huang et al., 2015). Analysis of the archived (FFPE) 
tissues has used amplification of specific sequences with polymerase chain reaction 
(PCR) and either analysis by restriction fragment length polymorphism (RFLP) or, less 
frequently, Sanger sequencing. Notably the majority of small-scale studies have used 
the PCR-RFLP approach rather than more modern techniques.  
1.6.3.2 Other Genomic Alterations 
Telomerase expression is under the control of genes that are known to be highly 
expressed in the liver (Nault et al., 2019). Viral insertion into hepatocyte DNA is 
another mechanism that can increase telomerase expression and occurs in around 26% 
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of HBV related HCCs (Nault et al., 2013; Paterlini-Bréchot et al., 2003). In Asian HCC 
studies, Telomerase is upregulated by one of two mechanisms: pTERTMut can occur, 
giving an extra binding site for the ETS, or HBV is inserted in to the telomerase 
promoter region which accounts for the lower rates of pTERTMuts seen in Asian 
populations (Nault et al., 2019). 
Telomeric DNA can fold back on itself and a single stranded can invade the telomeric 
DNA, creating a t-loop, that is further protected from degradation by the Shelterin 
complex (Cesare & Reddel, 2010). This Telomerase-independent telomere protective 
mechanism occurs in up to 10-15% of all cancers and is called an alternative 
lengthening of telomeres (ALT) pathway that is now detectable (Zhang et al., 2019).  
1.6.3.3 Telomerase Enzyme Detection 
The Telomerase Repeat Amplification Protocol (TRAP assay) was originally developed 
by Kim et al to assess Telomerase activity (Kim et al., 1994; Singh et al., 2015). 
Essentially the TRAP assay measures Telomerase function by amplifying the 
Telomerase extension products using polymerase chain reaction (PCR) which are then 
detected by gel electrophoresis (Mender & Shay, 2015). As the amplification step 
greatly increases sensitivity of detection, this accounts for the fact that ~85-89% of 
fresh human tumour biopsies, and 98% of malignant cell lines, as well as ovaries and 
testes have detectable telomerase activity (Kim et al., 1994; Singh et al., 2015). 
Correlating telomerase activity with IHC data has found that cells with detectable 
Telomerase activity have a positive nuclear signal for TERT protein whilst those with 
undetectable telomerase activity do not (Singh et al., 2015).  
A limitation of the TRAP assays being that either fresh tissues or cell lines are required 
for the purposes of analysis. Hence telomerase activity from archived FFPE material is 
currently unavailable for assessment. 
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1.6.3.4 Protein Expression 
To be able to explore the potential use of Telomerase as a biomarker of tumour 
development, various detection methods are possible across a range of sample types. In 
peripheral blood samples these include ELISA and analysis of small extracellular 
vesicles (exosomes) amongst others. Serum detection with ELISA has been undertaken 
in non-small cell lung cancer patients with a lower probability of survival observed in 
patients who expressed Telomerase compared to non-expressers (Targowski et al., 
2010).  
More recent work has been undertaken when exploring the role exosomes play in 
carcinogenesis. Exosomes are small vesicles secreted by every tissue and found in all 
bodily fluids that were initially thought to be a waste product of cellular regeneration (P. 
Li et al., 2017). Telomerase positive exosomes can alter hTERT negative fibroblasts in 
to hTERT positive fibroblasts, thus demonstrating how these curious, subcellular 
vesicles can seed malignant characteristics in to a host cell (Gutkin et al., 2016). Whilst 
analysis of the exosomal expression of hTERT mRNA from serum has been described 
across a wide range of malignancies little is known of any role exosomal Telomerase 
plays in PLC, (Goldvaser et al., 2017). 
Immunohistochemical and immunofluorescence detection of TERT has been 
undertaken in a wide range of tumour types, using a very diverse array of antibodies and 
detection methods. There is a lack of consensus in the published literature as to exactly 
what constitutes a positive control for TERT expression. Online repositories such as the 
Human Protein Atlas, and UniProt, state the RNA levels are detectable in lung, GI tract, 
Testis and lymphoid tissues (thymus, appendix, spleen, lymph node, tonsil and bone 
marrow) but protein levels are undetectable. Manufacturers of various monoclonal and 
polyclonal antibodies have not reached consensus the cellular and subcellular location 
of TERT expression for the purposes of a positive control. Some have stated that Tonsil 
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is a positive control, others have created genetically altered cell lines to overexpress 
TERT and use these as a positive control. There has been extensive evidence of the 
presence of TERT (by detection of the enzymatic activity, using the TRAP assay) that 
has been corroborated with Western blot data reporting similar detection in a variety of 
tumours, and in some adult tissues (Kim et al., 1994). Human testes appear to be one of 
the few normal human tissue types that have detectable TERT activity as well as 
detectable protein levels, that also stain positively in the nuclei of spermatocytes and 
maturing spermatids (Hiyama et al., 2001). 
Owing to an incompletely understood physiological role of TERT, there is some 
evidence from the literature that other pools of Telomerase may well be present, outside 
the confines of the nucleus. Up to 20% of TERT is found in mitochondria and may 
migrate from the nucleus in states of oxidative stress to perform TERC-independent 
functions that are protective to the host mitochondria and increase tumour-cell survival 
(Chiodi & Mondello, 2012). This non-nuclear pool of TERT also complicates the 
staining of tumour tissues as they are otherwise indistinct from other extra-nuclear 
components, and can appear in the cytosol as well as the nucleus (Fujimoto et al., 2001; 
Y. Yang et al., 2002). 
However, a small number of authors feel the detection of Telomerase using IHC may 
well be intrinsically flawed, owing to technical issues with the primary antibody (Y. L. 
Wu et al., 2006). Meaning that Telomerase IHC data should be interpreted with caution 
(Kim et al., 2013). 
1.7 Exosomes 
Exosomes were discovered as small vesicles jettisoned from maturing reticulocytes 
(Harding et al., 1983; Pan & Johnstone, 1983). The size of these vesicles being between 
30-100nm and are part of the continuum of small particles of various sizes, 
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compositions, densities and bud from every cell and detected in every bodily fluid ever 
tested (Raposo & Stoorvogel, 2013). The importance of defining the origin of exosomes 
and differentiating them from their mimickers, microvesicles (MVs), is because the 
MVs can bud directly from the cell-membrane whilst exosomes are small packages of 
genetic material that come from the multi-vesicular endosome (MVE) that are 
endosomal in origin and are normally destined for lysosomal degradation (Raposo & 
Stoorvogel, 2013).  
Hence there are some unique features of exosomes such as the presence of the trans-
membrane tetraspanins (CD9, CD63, CD81, CD82) that have been used as a 
confirmatory biomarker as well as the lack of internal degradation machinery that 
allows for the presence of RNAs such as mRNA, microRNA and non-coding RNAs 
(Cheng et al., 2019). Other behavioural properties of exosomes include the ability to 
influence transcriptional activities of cells by the transfer of mRNA, e.g., resulting in 
detectable Telomerase proteins being found in non-malignant cells (Gutkin et al., 2016). 
Vesicles either fuse to the recipient cell’s plasma membrane, or are endocytosed, thus 
allowing the transfer of the genetic material from the original cell to any recipient cell 
capable of uptake (Harding et al., 2013; Raposo & Stoorvogel, 2013). This ability to 
transfer genetic material from one cell type to another has been proposed as a 
mechanism of tumourigenesis. These unique characteristics allow exosomes to be 
exploited as potential biomarker source for a variety of cancers. 
An increasing body of evidence is accumulating to implicate exosomes with epithelial 
to mesenchymal transition (EMT) as well as in cancer associated fibroblasts (CAFs) 
both of which are present in the tumour microenvironment (TME) (Chen et al., 2019). 
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1.7.1 Exosomal Survivin 
Exosomal Survivin in detectable from cell culture and has even been implicated in 
exosomal internalisation, as blocking exosomal Survivin results in a reduction of 
internalised vesicles (Gonda et al., 2018). In cell culture models there is differential 
detection of Survivin in exosomes, depending on the cell line of origin. Survivin was 
the most commonly isolated IAP (by western blot analysis) when compared to XIAP, 
cIAP1, cIAP2 and Survivin as it was present in all six cell lines analysed (Valenzuela et 
al., 2015). 
Tantalisingly, the potential locations Survivin can now be found in has expanded 
because of the exosomal proportion. This extracellular pool of Survivin confirms its 
status as a tumour associated antigen as it can modulate the TME and permit tumour 
growth (S. Khan et al., 2015). However there remains a considerable amount of work to 
record and reporting the role exosomal surviving may, or may not, play in human 
cancer growth.  
1.7.2 Exosomal Telomerase 
Given the lack of degradation machinery within exosomes, it is unsurprising that 
telomerase has also been reported in these small vesicular bodies. Cancer cell lines that 
express hTERT (and have detectable Telomerase activity) can also secrete exosomes 
have been transfected into hTERT-negative fibroblasts cells (Gutkin et al., 2016). The 
previously hTERT-negative somatic cells start expressing detectable telomerase activity 
within 24 hours (Gutkin et al., 2016). This is a truly remarkable finding and neatly 
demonstrates the ability of exosomes to seed immortality traits to other cells. The 
authors of the paper remarked on the increased replicative ability of these transfected 
somatic cells, and note the reversal of senescence in a small proportion of the cell 
populations. 
 60 
This same group has expanded their work into a clinical cohort of 133 patients with 
various solid and haematological tumour types, not including liver cancers, and found 
varying levels of exosomal mRNA accordingly (Goldvaser et al., 2017). The serum-
derived exosomes make for an ideal study material as serum samples are routinely taken 
for clinical assessment and do not require special processing or storage methods. 
Intriguingly the serum exosomal levels correlated well with the patients’ disease 
progress, with a corresponding drop in detectable mRNA following curative surgical 
resection. Obviously, there is considerable work yet to be done in this field, as well as 
some novel research analysing the role exosomes play in PLC.  
1.8 Project Aim 
The aim of this project is to elucidate the role universal tumour antigens play in primary 
liver tumours. Assessing known genetic alterations in promoter sequences, and levels of 
transcribed UTAA RNA, and proteomic expression will all be explored and correlated 
with clinical data. Comparing UTAAs in tumour and background liver will allow me to 
ascertain whether genetic alterations are germline or somatic in nature. Whilst using 
paired samples for protein quantification will allow individual protein levels to be 
compared for each patient, as well as exploring correlations with clinical parameters.  
Ultimately this project will confirm that UTA are indeed tumour-specific and find that 
promoter mutants, or protein levels can be used as a potential biomarker in future 
clinical practice.  
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2 Material & Methods 
There is an inherent bias in studying tissues from patients that have been selected to 
undergo surgical treatment. This selection bias is unfortunately unavoidable, but every 
effort has been made to include samples from every patient that has been cared for at 
University Hospitals Plymouth since the hepatobiliary service commenced in 2005. As 
no previous research assessing hepatic neoplasms has been undertaken, at the basic 
science level, in the region this also has implications for the potential impact of the 
work. This exploratory descriptive work aims to initiate liver cancer research in the 
South West that will hopefully have local, regional, national and international 
implications for the greater understanding of hepatic carcinogenesis. 
2.1 Archived Clinical Material 
2.1.1 Ethical Stipulations 
The Research Ethics Committee (REC) approval for use of the archived tissues for my 
research was given with support of the confidentiality advisory group (CAG) allowing 
Health Research Authority (HRA) approval for the project. To satisfy the CAG that this 
research would not inappropriately use data from patients, the Caldicott Guardian 
(Consultant Cardiothoracic Surgeon, Mr Adrian Marchbank) stipulated that every 
consent form signed by the patient prior to their operation must be visually inspected to 
ensure that each patient did not actively opt out of participating in research. There is a 
small box on the consent form the patient can mark should this be their wish. This was 
achieved with the help of the Research, Development and Innovation (RD&I) 
department at University Hospitals Plymouth as the overwhelming majority of medical 
records were still in the paper-based format. Notes were requisitioned reviewed in the 
RD&I offices. On the rare occasion that the consent form for the liver resection 
operation was missing from the archives this patient was excluded from further 
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participation. The opportunity to view the medical notes to review the consent form for 
each surgical procedure has facilitated a review of the past medical history of all of the 
patients who underwent surgery.  
A requirement for ethical approval as stated by the REC is that I, the researcher, must 
be blinded to the origin of the donor tissues. Fortunately, helpful colleagues in the 
Department of Cellular and Anatomical Pathology at University Hospitals Plymouth 
were able to randomise the tissue samples, thus fulfilling this criterion. Different sample 
numbers were given for each research activity (i.e., DNA extraction and IHC) and in the 
order in which tissue blocks were processed. As such, there was no correlation between 
samples DNA 001 and IHC 001. If a repeat analysis was required (due to insufficient 
DNA extraction) then a new study number was issued to the repeat sample to minimise 
any other source of bias.  
Finally, the use of tumour samples for research must not deplete the archive available 
for the potential use in future patient care. Meaning that larger specimens (resection 
tissues rather than biopsy samples) are more appropriate as the volume of tissue 
available for use is considerably larger than biopsy samples. 
2.1.2 Auditing Potential Recruits 
Once ethical approval for research was granted, it was possible to undertake an audit of 
all liver specimens held on the UHP databases. As the Hepatobiliary surgical service 
was established in 2005 this was the start point for recruitment purposes. As only larger 
surgical specimens will yield a sufficient volume of poor-quality liver tissues, these 
were the initial targets for use.  However as there is no code recorded for ‘liver 
resection’ or ‘wedge resection of liver’ all liver tissues screened, hence manual 
checking of the database of samples was required.  
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All histopathological specimens receive a primary and secondary diagnostic code. In 
this case, the primary diagnostic code (T-62000) denotes that the tissues originate from 
the liver, the accompanying secondary diagnostic code is given for the tissue diagnosis 













Table 2 includes all biopsy and surgical resection specimens from 2005 until August 
2017. Each individual sample also receives a unique sample number that can be 
searched on the hospital laboratory information management system (LIMS), which at 
UHP is iLab. The details held of iLab include the sample type (biopsy, surgical 
resection specimen) as well as descriptive terms for the tissue analysis, the size of the 
tumours and whether there is vascular or perineural invasion. An example to illustrate 
the importance of cross referencing the iLab reports is demonstrated in one case: a 
fibrolamellar HCC being coded as ‘Carcinoma, NOS.’ Whilst being labelled as a 
carcinoma is technically correct a more accurate method of recording the tumour types 
Number Diagnosis Secondary Code 
445 Adenocarcinoma, metastatic, NOS M-81406 
369 Adenocarcinoma, NOS M-81403 
114 Hepatocellular carcinoma, NOS M-81703 
4 Hepatocellular carcinoma, fibrolamellar M-81713 
43 Cholangiocarcinoma M-81603 
23 Carcinoma, metastatic, NOS M-80106 
11 Carcinoma, NOS M-80103 
11 Adenoma, NOS M-81400 
11 Bile duct adenoma M-81600 
6 Liver cell adenoma M-81700 
6 Transitional cell carcinoma, NOS M-81203 
4 Small cell carcinoma, NOS M-80413 
3 Malignant melanoma, NOS M-87203 
2 Neuroendocrine carcinoma M-82463 
1 Clear cell adenocarcinoma, NOS M-83103 
1 Carcinosarcoma, NOS M-89803 
1 Squamous cell carcinoma, NOS M-80703 
1055 Total  
Table 2. The diagnostic codes for all liver specimens (biopsy and surgical resection) at Derriford 
Hospital from 2005 until September 2017. 
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is required for research purposes. The abbreviation ‘NOS’ refers to samples being ‘not 
otherwise specified.’ 
This method of screening has relied on correct coding by the reporting pathologist. 
However, this is a potential cause of bias at this screening stage as highlighted by one 
case being added to the database after the patient was met in follow up clinic, having 
had their tumour erroneously coded.  
Further analysis of the archive search results separated out the surgical resection 
specimens from the biopsy samples. Surgical resection specimens FFPE tissues are 
typically 15x10mm in size, which is a significantly larger amount of tissue than can be 
provided from a single needle biopsy. As mentioned above: biopsy samples were felt to 
be inappropriate for use in research as their inclusion and processing may deplete the 
tissue archive completely.  
Searching through the euphemistically coded ‘Adenocarcinoma, NOS’ and ‘Carcinoma, 
NOS’ yielded further cases of primary liver neoplasms. The decision tree can be seen in 
figure 4 and outlines how the 1055 samples were reduced to samples that could be used 
in research – the colour red denotes excluded samples.  
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Figure 4 All 1055 samples from the tissue archive at UHP between 2005 & 2017.  
Upon closer review of the 117 resection specimens in figure 4, 11 of the CCA were 























































recruited prospectively from clinic, resulting in 52 HCCs as well as 6 FL-HCC. All of 
the potential primary liver neoplastic surgical resection specimens have been recorded 
with the culmination of this advanced screening being shown in table 3.  
 Neoplasm Number 
Hepatocellular carcinoma 52 
Fibrolamellar Hepatocellular carcinoma 6 
Mixed Hepatocellular-Cholangiocellular carcinoma 7 
Cholangiocellular carcinoma 36 
Adenoma 10 
Total 111 
Table 3 Surgical resection specimens of primary liver neoplasms by tumour sub-category. 
 
2.2 Prospectively Recruited Patients 
Seventy-four patients have been recruited into the Inflammatory Liver Biobank (REC 
reference: 15/LO/0948), including two cases of follow up bloods when a second set was 
taken prior to a second intervention. Five of these prospectively recruited patients 
underwent surgical resection for HCC and have been included in the final study figures 
in table 3. Of the 74 patients, 49 samples were taken from patients undergoing treatment 
for a primary hepatic pathology with the remaining 26 samples from patients who had 
surgical excision of a colorectal metastasis. Control groups include both healthy 
volunteers (n=10) and stable cirrhotic patients under six monthly HCC-surveillance 
(n=10). 
2.3 Research Cohort 
The research cohort for tumour resections includes 111 patients is shown in table 4. It is 
worthwhile to remember that there are selection biases due to these patients being 
offered an operation and that were deemed medically fit enough to undergo this 
treatment. Clinical follow up includes patients who died within one month of their 
operation. Viral hepatitis per tumour category: HCC (one dual Hepatitis B&C, 7 
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Hepatitis C, one Hepatitis B), CCA (one each Hep B and C), Mixed tumour (one dual 
Hep B&C, 3 Hep C). Metabolic risk factors include the clinical characteristics diabetes 
mellitus, and obesity in addition to histological features: NAFLD & steatosis.  
 
Table 4. Clinical characteristics of the study cohort. 
Regrettably the medical records for biomarkers (such as AFP, CA19-9 and CEA) were 
incomplete so this data has not been included. Of the 58 HCCs, at least 19 were missing 
an AFP, and of the 36 CCAs there was no record of an AFP value in at least 14 cases 
and no recorded CA19-9 from a minimum of 23 patients. 
2.3.1 Haematological Samples 
Four vacutainers of serum (BD Vacutainer® SST™ II Advance, Thermo Scientific™) 
and two EDTA (BD Vacutainer® K2E 7.2mg, Thermo Scientific™) blood samples were 
taken from each patient. The samples were gently inverted 10 times after venesection 
with the serum samples requiring 30 minutes at room temperature. After inversion, 
EDTA samples were immediately stored at 4 degrees Celsius until further processing. 
Both serum and plasma samples were then centrifuged at 2500g for 10 minutes at 4 
degrees Celsius. Plasma and Serum samples are stored in 1ml aliquots; buffy coat and 
red blood cells are stored separately in various volumes, determined by the amount 
available in each individual sample. All blood samples are stored in 2-dimensional 
barcoded blood tubes (1.0ml External Thread Next-Gen Jacket Tube with 2D code on 
Neoplasm HCC FL-HCC CCA Mixed Adenoma
Total 52 6 36 7 10
Male 40 (76.9%) 4 (66.7%) 16 (44.4%) 5 (71.4%) 1 (10.0%)
Female  12 (23.1%) 2 (33.3%) 20 (55.6%) 2 (28.6%) 9 (90.0%)
Age (range) 67 (41 - 84) 33 (22 - 42) 64 (44 - 83) 60 (47 - 72) 37 (27 - 51)
Months follow up (range) 47 (0 - 130) 94 (21 - 159) 35 (0 - 129) 31 (3 - 76) 88 (30 - 138)
Fibrotic 26 (50.0%) 0 (0.0%) 9 (25.0%) 6 (85.7%) 3 (30.0%)
Cirrhotic 16 (30.7%) 0 (0.0%) 1 (2.8%) 6 (85.7%) 0 (0.0%)
Viral Hepatitis 9 (17.3%) 0 (0.0%) 2 (5.6%) 4 (57.1%) 0 (0.0%)
Metabolic Risk Factors 28 (53.8%) 0 (0.0%) 15 (41.7%) 3 (42.9%) 8 (80.0%)
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Tube Base & Linear Barcode, HRN on side, with Screw Cap, Brooks Automation Ltd) 
all of which are kept at minus 80 Celsius.  
2.3.2 Tissue Samples 
Regrettably, there was no provision in place at UHP for sampling fresh tumour for 
research purposes. Space in the Histopathology department was deemed insufficient to 
allow for a ‘hot desk’ to be used for sample cut up on an ad hoc basis as, and when, 
research samples came from theatres. FFPE tissue samples from patients who were 
prospectively recruited were processed in the same manner as the archived tissue 
samples.  
2.4 DNA from FFPE Tissues 
In the National Health Service formalin fixed paraffin embedded (FFPE) tissues are 
kept for 30 years after removal from a patient. Given the huge archive of tissues a single 
hospital would create, and the associated inventory costs, it has become increasingly 
popular to store samples off site, more recently for UHP samples, in a climate-
controlled site in mid-Wales. Tissue blocks that could potentially be used for research 
have clinical details such as tumour size, tissue morphology and surgical resection 
margin stored indefinitely on the digital databases. These archives can be searched for 
by their individual case number on the iLab system to assess their suitability for use in 
research, as well as recording clinical details from the formal histopathological reports. 
Characteristics such as size of resection specimen can be cross-referenced to ensure 
only samples of adequate size are included for research. The tissue blocks are shipped 
from the storage unit to UHP by a hospital-approved courier.  
To avoid any potential breach of confidentiality the tissue blocks are stored and 
processed within the Department of Cellular and Anatomical Pathology at UHP. Blocks 
from various parts of the tumour or background liver were each given a unique 
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designation when being prepared with the key to this is readily available on the 
database.  
Using a microtome (Leica RM 2135) in the Pathology Department at University 
Hospitals Plymouth, 5µm slices of tissue were cut from the tissue blocks. The first few 
slices were discarded to avoid oxidative damage affecting the tissues under analysis. 
Three 10µm curls of tissue are taken from the FFPE tissue block and were sealed in 
sterilised 1.5ml Eppendorf tube immediately. Tissue from the tumour, as well as 
background tissue (where possible) from the same patient was taken to explore any 
differential expression between the background liver tissue and the any neoplastic 
growth. To reduce the chance of contamination between samples; gloves were worn 
throughout the handling process, the cutting blade (Thermofisher Scientific MX35 ultra) 
changed for every tissue block and any surface that has come into contact with the cut 
tissue was cleaned with 90% alcohol between tissue blocks. Tissue curls were sealed in 
sterile Eppendorf tubes, figure 5. The liver tissue is generally brown in colour with the 
surrounding paraffin being white. 
 
Figure 5. Eppendorf tubes containing tissue curls extracted from FFPE archived materials.  
FFPE tissue curls were transported to the university research labs and the commercially 
available kit (QIAamp DNA FFPE Tissue Kit, Qiagen) was used to extract DNA from 
these samples following the protocol from QIAamp DNA FFPE Tissue Handbook, as 
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outlined briefly below. Buffers AL and ATL were heated to 70 degrees Celsius in a 
water bath to dissolve precipitates.  
Deparaffinisation was undertaken with 1ml of xylene and vigorous vortexing (ZX3 
Vortex Mixer, Fisherbrand) for 10s, following by centrifugation at full speed 
(Centrifuge 5418, Eppendorf) for two minutes at RT. Occasionally a small amount of 
tissue remained unprocessed and was filtered out during centrifugation steps, as 
outlined in fig 6. The presence, or otherwise, of this material did not impact on 
subsequent results obtained.  
 
Figure 6 Spin columns used for DNA extraction from FFPE tissues. The clear eluate in left image. Some tissue 
remains in the filter after processing in the right image. 
The supernatant was removed by pipetting with care taken to ensure the pellet remained 
undisturbed and 1mL of ethanol (purity > 99.8%, Honeywell) was added to the tissue 
pellet. The vortexing, centrifuging steps and supernatant removal steps were repeated to 
remove the ethanol. Residual ethanol was encouraged to evaporate as the Eppendorf lid 
was left open and the samples were heated to 37 Celsius in a heat block for ten minutes. 
The tissue pellet was then re-suspended in 180µL of Buffer ATL, with the addition of 
20µL of proteinase K and briefly mixed by vortexing. This mixture was then incubated 
at 56 Celsius in a heat block for one hour, followed by a further hour incubating at 90 
Celsius for another hour to partially reverse formaldehyde modifications.  
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The samples were cooled to RT and briefly centrifuged to remove drops from inside the 
lid. Buffer AL (200µL) was added, mixed by vortexing, and followed by the addition of 
200µL of ethanol and further, brief, vortexing. The lysate was again briefly centrifuged 
to remove droplets from inside the lid and was then transferred into a spin column 
within a 2mL collection tube. This spin column was then centrifuged at 6000g 
(8000rpm) for one minute, with the flow through/eluate discarded. Wash steps (Buffer 
AW1 then AW2) were undertaken with the addition of 500µL of wash buffer AW1, 
followed by centrifugation at 6000g and discarding the flow through. The process was 
repeated with the addition of 500µL of wash buffer AW2. The spin column membrane 
was then dried by centrifuging at 20,000g/14,000rpm for three minutes in a new, sterile, 
2mL collection tube. The column was then placed in a sterile 1.5mL Eppendorf with 
80µL of Buffer ATE (elution buffer) used in the elution step and allowed to equilibrate 
for five minutes at RT. Finally, the sample was spun at full speed (20,000g/14,000rpm) 
for one minute with the eluate being kept. Two microlitres of eluted DNA was placed 
on the NanoDrop™ 2000 spectrophotometer (Thermo Scientific™) to assess both the 
quality (260/280 ratio) and quantity (concentration, in ng/µL) of extracted DNA. 
Samples were labelled and stored at -20 Celsius until required.  
2.5 Sequence Amplification 
The published literature was searched for primer pairs that had been successfully used 
for the polymerase chain reaction (PCR) targeting short DNA sequences of the 
promoter regions. The information is outlined below in tables 5 & 6. Which can be 
compared to a recent meta-analysis that reports the use of PCR-RFLP or TaqMan 
assays, rather than Sanger sequencing, as the preferred method of detection for Survivin 
SNPs (Moazeni-Roodi, Ghavami and Hashemi, 2019). As can be demonstrated from 
table 5, the preferred source of DNA for assessing the Survivin promoter is whole 
blood, rather than FFPE tissues. 
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Tissue of Origin 
(reference) 







et al., 2012) 
FFPE tissue 151 RFLP Surv F1 R1 
Gastric Cancer 
 (Yang et al., 2009) 
Whole blood 151 RFLP Surv F1 R1 
Urothelial Cancer  
(Wang et al., 2009)  
Whole blood 341 RFLP Surv F2 R2 
Breast Cancer 
(Rasool et al., 
2017) 
Whole blood 341 RFLP Surv F2 R2 
HCC (Bayram et 
al., 2011) 
Whole blood 341 RFLP Surv F2 R2 
Ovarian Cancer 






RFLP Surv -31 F3 R3 
Surv -625F + R 
Colorectal Cancer 
(Yamak et al., 
2014) 
FFPE tissue 329 RFLP Surv -31 F3 R3 
Surv - 241 F + R 
Surv -625 
Table 5 Research resources for Survivin -31G/C SNP detection.  
Sanger sequencing the PCR product of the pTERT region was more commonly 
undertaken, as well as using a variety of sources of sample DNA, as shown in table 6. 










(GBM) (Purkait et al., 2016) 
FFPE & 
Frozen 
163 Sanger Short TERT 
Malignant Melanoma 
 (Horn et al., 2013) 
Whole 
blood 
163 Sanger Short TERT 
Low Grade Glioma 
 (Chan et al., 2015) 
FFPE 163 Sanger Short TERT 
13 Tumour types 
(Huang et al., 2015) 
FFPE 190 Sanger TERT F3 R3 
Follicular Thyroid Adenoma 
(Wang et al., 2014) 
Frozen NS Sanger hTERT Promo F + R 
Bladder Cancer, Glioblastoma. 
(Liu et al., 2013) 
NS 235 Sanger hTERT Promo F + R 
HCC & HCAs  
(Nault et al., 2013) 
Frozen 163 Sanger Short TERT 
Bladder Cancer (Pivovarcikova 




NS NGS and 
Sanger 
hTERT Promo F + R 
Table 6 Research resources for determining Telomerase promoter region SNP detection. 
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2.5.1.1 Initial Work 
Oligonucleotides were ordered in and trialled using CRC FFPE tissues as the template 
DNA, with the polymerase (Dreamtaq) that had been used by other members of the lab 
undertaking PCR with cell culture samples. When creating a mastermix for n samples, 
enough reaction volume was made for n+2 reactions, to ensure enough reaction mixture 
for a no-template negative control and to allow for pipetting error. Initial PCR 
preparation was undertaken on the bench top, but this was quickly moved to a laminar-
flow hood to avoid contamination of constituent components and thus erroneous results. 
The initial reaction mixture, as shown in table 7. 
Component Volume for one 50µL reaction Final concentration 
DreamTaq 5 µL 1X 
dNTPs (2µM) 5 µL 0.2µM 
Forward Primer (10µM) 0.5 µL 0.1µM 
Reverse Primer (10µM) 0.5µL 0.1µM 
Template (max 200 ng) 1µL As required 
Polymerase 0.25µL 1 U 
Ultrapure, distilled water. 37.75µL - 
Table 7. Reagents for PCR using DreamTaq polymerase. 
With reaction conditions as outlined in Table 8 using the Labtech GS4 G-Storm, Gene 
Technologies Thermal Cycler: 
Step Temperature (Celsius) Time 
Initial denaturation 95 3 minutes 
40 cycles of steps 1-3: 
1. Denature 95 30 seconds 
2. Anneal 52 30 seconds 
3. Extend 72 1 minute 
Final extension 72 5 minutes 
Hold  4 Indefinite 
Table 8. Reaction conditions for PCR using DreamTaq polymerase.  
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PCR products were run on a 2% Agarose gel with a 100base pair ladder (Gene Ruler, 
ThermoFisher) and loading dye (Loading Dye 6X Orange DNA, ThermoFisher) and 
distilled water. Small volumes of PCR product (4 µL) were mixed with loading dye 
(Loading Dye 6X Orange DNA, ThermoFisher) and run alongside to assess the size of 
PCR product. Optimisation for Dreamtaq included altering magnesium concentrations 
as well as the quantity of template DNA added and gradient PCR.  
2.5.2 Optimisation 
2.5.2.1 Primer Selection 
There was poor reproducibility and results from extensive work with longer PCR 
products (>200 base pairs) so efforts were concentrated on targeting shorter sequences 
in the promoter regions of both Survivin and Telomerase. There were also a number of 
potential target sequences but regions around Survivin -31 and Telomerase -124 
(C228T) & -146 (C250T) were focussed on. Given that most DNA taken from FFPE 
tissues is of a poor quality and fragmented at around 250 base pairs, there were 
limitations on the selection of potential primer pairs (Dedhia et al., 2007). 
2.5.2.2 Gradient PCR 
The primer sequences (composed of nucleotides G, C, T and A) were known, but early 
work found that some of reactions needed further optimisation. Approximate annealing 
temperature (Ta) for the primers selected for PCR was estimated using the calculated 
melting temperature (Tm) in degrees Celsius as demonstrated by the equations below: 
Tm = 4(G+C) + 2(A+T).  
Also;  
Ta = Tm -5  
As previously used (Roux, 2009).  
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The Ta was used as the mid-point for the gradient PCR to assess various annealing 
temperatures simultaneously. There was also the opportunity to focus on smaller 
temperature steps (less than one degree Celsius) or create a grid of temperatures and 
alter a secondary component of the reaction, like magnesium concentration, as shown in 
figure 7, (Najafov et al., 2017).  
 
Figure 7. A grid pattern for altering two components of PCR simultaneously. 
2.5.2.3 Template DNA 
The quantity of template DNA used in the PCR reaction was polymerase dependent, as 
advised by the manufacturers. Generally, between 100 – 200ng of DNA was added to 
the PCR reaction, and only in exceptional circumstances, such as repeated failures of 
results, was this amount of template DNA increased. 
2.5.2.4 Enzyme Selection 
Owing to the relatively short and frail nature of the FFPE DNA, not all of the 
commercially available polymerase enzymes were able to amplify certain primer pairs.  
For Survivin the Accuprime™ Pfx polymerase (Thermo Scientific™) yielded the highest 
success whilst for the Telomerase promoter region the best candidate was the KAPA2G 
Fast Hotstart ReadyMix polymerase. Other enzymes that were trialled included: Q5 
High Fidelity Polymerase (New England Biolabs), Accuprime™ Taq DNA Polymerase, 
High Fidelity (Thermo Scientific™).  
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2.5.2.5 Universal Primers 
In an attempt to increase the read length of the PCR product for Survivin (151 base pair 
sequence) a universal primer was added on to the 5’ end of the primers (Kelley and 
Quackenbush, 1999). The increase in size of the universal primer would, theoretically, 
have resulted in a PCR product that was longer than the original sequence by the same 
number of base pairs. Sadly, the quantities of PCR product that resulted were too low 
(i.e., significantly below the 100ng minimum required) to allow for Sanger sequencing.  
Initial results from sequences were delivered using primers for the 151 base pair 
sequence the chromatograms demonstrated the region of interest being as little as 20 
bases from the start of the sequence. In an attempt to increase the read length, universal 
primers were added on to the 5’ end of the original oligonucleotides to lengthen the 
PCR product.  
The two universal primers chosen (M13-21 and M13-29) did not cause any primer-
dimer or form hairpin loops (due to inverted repeats) when run on online software 
platforms such as OligoEvaluator (Sigma-Aldrich) and Multiple Primer Analyzer 
(Thermo Scientific). The oligonucleotides that were used are outlined below in table 9. 
Primer Name Oligonucleotide Sequence 
Survivin 31 F1 AAGAGGGCGTGCGCTCCCGACA  
Extended F1 M13-21F 
(Ext. F1) 
TGTAAAACGACGGCCAGTAAGAGGGCGTGCGCTCCCGACA 
Survivin 31 R1 GAGATGCGGTGGTCCTTGAGAAA 
Extended R1 M13-29R 
(Ext. R1) 
CAGGAAACAGCTATGACCGAGATGCGGTGGTCCTTGAGAAA 
Table 9. The addition of universal primers (Extended F1/R1) to the underlined oligonucleotide sequence for a primer 
pair, Survivin F1 R1, that have been previously used in assessing the Survivin promoter region. 
Underlined regions in the above table highlights the same oligonucleotide sequence 
with the addition of the universal primer at the 5’ end of the sequences, which are not 
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underlined. Gradient PCRs were undertaken with the added universal primers using the 
annealing temperatures of between 60 and 72 Celsius. 
2.5.3 Survivin Promoter 
The reaction volume was dictated by the polymerase used for PCR, as such for 
Accuprime a reaction volume of 50uL was required. Master mixes were created on ice 
and included an additional volume to allow for pipetting error. Each mastermix was 
created for 12 reactions, which included a no template negative control for quality 
assurance. For each reaction the following quantities were used, as advised by the 
manufacturer and is shown in table 10. 
Component Volume for one 50µL reaction Final concentration 
10X AccuPrime Pfx Reaction Mix 5 µL 1X 
Forward Primer (10µM) 0.75 µL 0.15µM 
Reverse Primer (10µM) 0.75µL 0.15µM 
Template DNA (max 200 ng) 2µL As required 
AccuPrime Pfx DNA Polymerase 0.4µL 1 U 
Ultrapure, distilled water. 41.1µL - 
Table 10. Reagent for the Accuprime Pfx polymerase for PCR. 
For optimisation of the reaction for maximal PCR product, a gradient PCR was 
undertaken using the same template DNA and reaction mixture in one thermal block. 
There was a heated lid, maintained at 112 Celsius. Once the thermocycler had 
completed the thermal block was held at 10 Celsius until the PCR products were placed 





Step Temperature (Celsius) Time 
Initial denaturation 95 2 minutes 
35 cycles of steps 1-3: 
1. Denature 95 15 seconds 
2. Anneal 52 - 64 30 seconds 
3. Extend 68 1 minute 
Final extension 68 5 minutes 
Table 11. Reaction conditions for gradient PCR targeting the Survivin promoter region, using the Accurprime Pfx 
polymerase. 
Following the reaction conditions outlined in table 11, the optimal annealing 
temperature for the Survivin promoter was found to be 62 Celsius. 
2.5.4 Telomerase Promoter 
As the Accuprime Pfx polymerase enzyme was successful in sequencing FFPE DNA 
from the Survivin promoter region, it was trialled with primers targeted to the 
Telomerase promoter region with disappointing results. Despite considerable attempts 
at optimisation there was a distinct lack of single clear bands when viewed after gel 
electrophoresis. Gradient PCR, Touchdown PCR and variable concentrations of 
Magnesium yielded poor results.  
When trying to recapitulate the experiment to sequence the promoter region of 
Telomerase, having had difficulties with alternative polymerase enzymes, the KAPA2G 
enzyme was purchased. Given that it was used in two separate publications using two 
different primer combinations it was felt that exploring this as a potential polymerase 
was essential (Chan et al., 2015; Huang et al., 2015).  
The reaction volume required for the KAPA2G polymerase was 25µL. Mastermixes 
were also made for a total of 12 reactions with one volume for the no template negative 
control and one volume spare. The reaction volumes are outlined below, as advised by 
the manufacturer, in table 12. 
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Component Volume for one 
25µL reaction 
Final Concentration 
2X KAPA2G Fast Hotstart 
ReadyMix 
12.5µL 1X 
Forward Primer (10µM) 1.25µL 0.5µM 
Reverse Primer (10µM) 1.25µL 0.5µM 
Template DNA 1µL As required, <100ng total 
Ultrapure, distilled water 9µL - 
Table 12. Reagents for the KAPA2G Fast Hotstart PCR. 
Gradient PCR was undertaken with two sets of primers (yielding 163 and 190 base pair 
products) using the KAPA2G polymerase. Initial temperatures for the annealing steps 
were between 56.1 and 63.1 Celsius in ~1-degree increments. A more focussed gradient 
PCR analysing annealing temperature steps 60.1 - 63.9 Celsius was undertaken to 
clarify the best annealing temperature and can be seen in table 13.  
Step Temperature (Celsius) Time 
Initial denaturation 95 3 minutes 
45 cycles of steps 1 - 3. 
1. Denaturation 95 15 seconds 
2. Annealing 56.1 - 63.1 15 seconds 
3. Extension 72 1 second 
Final extension 72 10 minutes. 
Table 13 Reaction conditions for a gradient PCR targeting the Telomerase promoter region. 
Reaction mixtures for Telomerase promoter gradient PCRs. After successfully 
producing enough PCR product to send for sequencing, the following final reaction 
conditions were used for all following reactions.  
Following optimisation, the best annealing temperature was found to be 60 Celsius. 
Once the Thermocycler had completed the program the thermal block was held at 10 
Celsius until the PCR products were placed on ice or stored at 4 Celsius. 
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2.5.5 PCR Quality Assurance 
A 2% Agarose gel (Topvision Agarose Thermo Scientific™) was used to confirm the 
presence of the correct size of amplification product using added SYBR™ Safe DNA 
Gel Stain (Thermo Scientific™) using a 100 base pair DNA ladder Generuler 100BP 
Plus (Thermo Scientific™) and analysing with the gel imager (Labtech GS4 G-Storm, 
Gene Technologies Thermal Cycler) (Promega Guide to Agarose Gels., 2018). Gels 
were made with 1X TAE buffer and loaded with a small volume of PCR product: 6 µL 
for Survivin (with 1uL of added loading dye 6X Orange DNA loading dye, Thermo 
Scientific™), and 3 µL for Telomerase promoter PCR products. No additional loading 
dye was required for the KAPA2G reactions as it was already included in the reaction 
mixture. 
A clean, single band on the gel was required for sequences to be processed further 
providing the no-template negative control remained did not demonstrate a band, thus 
implying there was no contaminants in the mastermix.  
2.5.5.1 PCR Purification 
Once the PCR product has demonstrated a single, clean, band on a 2% agarose gel, it 
was concentrated for ease of sequencing. The PCR products were purified using a DNA 
clean and concentration kit (DNA Clean & Concentrator-5 Zymo Research) as outlined 
briefly below. 
In a 1.5mL Eppendorf, five volumes of DNA binding buffer was added to one volume 
of PCR product and briefly vortexed and centrifuged to remove contents from the inside 
of the lid. The mixture was then transferred to the spin column, which was placed inside 
a collection tube and centrifuged at full speed for 30s. 200µL of wash buffer was added 
to the column and centrifuged at full speed for 30s. The flow-through was discarded and 
the wash step was repeated again. Finally, 15µL of distilled water was added to the 
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column matrix and incubated at RT for one minute. The spin column was transferred to 
a sterile 1.5ml Eppendorf and centrifuged at full speed for 30s to elute the PCR product. 
The Quality and quantity of this purified PCR product was then assessed using a 1.5µL 
volume (NanoDrop™ 2000 spectrophotometer Thermo Scientific™). Only samples with 
260/280 ratios greater than 1.8 were used for further analysis. 
2.5.5.2 Sanger Sequencing 
To enable bi-directional sequencing, 2µL of the forward primer (10nM) was added to 
100ng of purified PCR product in a sterile 1.5mL Eppendorf tube. The addition of 
sterile nuclease/RNase free distilled water was added to give a final volume 14µL. This 
was process was repeated with the reverse primer to enable bi-directional sequencing 
from a single, purified, PCR product. A barcode label was placed on each sample, 
provided by LGC Genomics GmbH, and these were then posted for Sanger Sequencing.  
2.5.5.3 Sequence Analysis 
Once the sequenced files were made available by LGC, a genome database was 
searched for similar sequences and this demonstrated that the correct target had been 
amplified. The software package, Macvector, has been used to check the quality of the 
sequences and find the region of interest (ROI) with confirmation of sequence requiring 
bi-directional concordance. Visual inspection of the chromatograms was undertaken, 
with evidence of contaminated and uncontaminated samples shown in figure 8.  
 
Figure 8. Chromatograms from MacVector with evidence of contamination (left) compared to an uncontaminated 
sequence. Note the low confidence (red bars, >1% error in the left image) compared to the high-confidence (green 
bars, <1% error in the right image) in base calls.  
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Chromatogram data was compared to reference database (Genome Reference 
Consortium Human genome build 37, GRC37) to assess for polymorphisms in the ROI. 
GRC37 was used in favour of GCR38 as the SNPs referenced throughout the literature 
in the Telomerase promoter region remained in their respective positions (-124 and -146 
upstream of the transcription start site) instead of the right-shift that is understood to 
have taken place with later editions of GRC (National Centre for Biotechnology 
Information, 2017).  
2.6 Immunohistochemistry 
Formalin Fixed Paraffin Embedded (FFPE) tissue sections were cut at 4 µm by the 
Department of Cellular and Anatomical Pathology at University Hospitals Plymouth 
and mounted on positively charged glass slides. Optimisation of primary antibody was 
performed on various non-liver tissue sections. For Survivin, the positive control was 
human tonsil, for Telomerase normal testis was used. Negative controls were run in 
parallel with the positive control and normal liver by omission of primary antibody.  
The indirect staining method with the avidin-biotin complex and 3,3′-Diaminobenzidine 
(DAB) tissue staining, with Mayer’s haematoxylin as counterstain, for assessment of 
tissue expression of tumour antigens. 
2.6.1 Antibody Selection 
Online resources, such as Biocompare, as well as the published literature were searched 
for potential primary antibodies for IHC. Preference was given to antibodies that have 
previously been published using immunohistochemistry on paraffin (IHC-P) tissues. 
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219, (de Graaff et al., 2017) 














8, (Yang et al., 2017) 
TERT Antibody (A-6), 







4, (Zhou et al., 2017) 
Table 14. Published literature was consulted to screen potential IHC antibodies for detecting Telomerase and 
Survivin in human tissue samples. 
2.6.2 Optimisation 
2.6.2.1 Selection of Positive Controls 
Using FFPE tissues allows for the assessment of cellular morphology as well as being 
able to stain for various proteins and assessing their expression in various subcellular 
localisations. To ensure appropriate positive and negative controls were used in staining 
a mixed approach was used in the assessment of potential positive controls.  
Manufacturers tend to include a putative positive control in their literature, but 
Torlakovic and colleagues have stated that these can be “both imprecise and inadequate 
in providing the information needed” for reproducibility in the assessment of sensitivity 
and calibration of IHC staining (Torlakovic et al., 2015). Thus, a combination of 
methods was used to ascertain a true positive control, given that intracellular location 
would, hopefully, vary across tumour grades and stages.  
Online resources, such as Uniprot and The Human Protein Atlas (HPA) were used in the 
first instance. The vast quantities of data available on the HPA reference a wide range 
of common tumour and tissue subtypes, but this is not exhaustive, as many cellular and 
subcellular expression patterns remain undocumented (Cornish et al., 2015). An idea of 
the expected cellular expression and subcellular location of staining in tissues can be 
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found by combining both online resources and the published literature as shown in table 
15. 
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publication (Zhou et 
al., 2017) 
Table 15. Published positive controls for IHC.   
Confidence in the Survivin antibodies was boosted by their significant use in peer-
reviewed publications. However, Telomerase antibodies have fewer references and 
there is less consensus on exactly what tissues should stain positive for this protein. 
Online resources state that there should be no expression of Telomerase in Tonsillar 
tissues, yet this is regularly cited as an appropriate positive control.  
Combining online resources and the literature allows clarifies the detection of 
Telomerase in tissues (such as testis, ovary, placenta) with western blot and confirms 
the functionality of the telomerase enzyme using the telomerase repeat amplification 
assay (Kim et al., 1994). Optimisation of potential antibodies was undertaken in these 
potential tissue types.  
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2.6.2.2 Retrieval Buffer 
For the purposes of optimisation both Tris-EDTA and Citrate buffers were trialled to 
ascertain which gave the best results. Tris-EDTA 10X concentrated stock was made by 
adding 24g of Triz (Sigma-Aldrich®) and 2g of EDTA (Sigma-Aldrich®) to 1L of 
deionised water at pH 9, using 5M HCl (Sigma-Aldrich®). A 1:10 dilution was made 
with distilled water for use in the antigen retrieval stage of IHC.  
Citrate buffer 1X working stock was made with the addition of 2.1g Citric acid (Sigma-
Aldrich®) to 1L deionised water at pH 6 using 5M NaOH (Sigma-Aldrich®).  
2.6.2.3 Primary Antibody Dilutions 
The Survivin primary antibody was diluted to 1:400 in 1X TBS-T. The Telomerase 
antibody was also diluted to 1:400, but in a 2% Goat serum (v/v) TBS-T.  
2.6.2.4 Blocking Steps 
A number of blocking steps were used in the optimisation process to reduce background 
staining. Endogenous peroxidase was blocked with 3% Hydrogen Peroxide (Fisher 
Scientific) in Methanol (VWR®).  
For routine staining, a second blocking step was used. Serum from the host species of 
the secondary antibody was used in a 1:100 dilution in TBS-T. One drop (50uL) of 
serum was added to 5mL of TBS-T and gently mixed by vortexing and 150uL was 
added to each slide mounted section of tissue. Using serum from the host secondary 
(Horse for Survivin, Goat for Telomerase) can help reduce background staining  
(Ramos-Vara, 2005).  
To block nonspecific binding of endogenous Biotin, samples were incubated 
sequentially with Avidin D solution and then with a Biotin solution (both: Vector 
Laboratories) to give a near-irreversible binding in the Avidin-Biotin complex  
(Bratthauer, 2010). 
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In an attempt to reduce background-staining, serum from the host species for the 
biotinylated secondary was diluted to a concentration of 2% (v/v) when diluting the 
Telomerase primary antibody. Alternatively, the Survivin primary antibody was diluted 
in TBS-T.  
2.6.2.5 Biotinylated Secondary & Detection 
An IgG specific universal kit was purchased and used in the detection of the primary 
antibody. The Vectastain Elite ABC HRP Kit (Peroxidase, Universal. Vector 
Laboratories) was used in the detection of Mouse/Rabbit IgG with horse anti-rabbit 
/mouse secondaries and normal horse serum used for this isotype of antibody. For 
Telomerase a Mouse anti human IgM primary antibody, a separate biotinylated 
secondary (Goat anti mouse) and serum (goat) was substituted, keeping the same ABC 
complexes and detection technique that was provided in the Elite ABC HRP kit. 
Detection was with 3,3'-diaminobenzidine (DAB) solution (Sigma-Aldrich®; #D4293) 
made up in distilled water (with vortexing) and the addition of the urea tablet provided, 
with further vortexing. The DAB solution was made up and used within 1 hour.  
2.6.2.5.1 Isotype Specificity 
In theory there should be minimal isotype crossover between anti-IgG and anti-IgM 
secondary antibodies with the IgM and IgG primary antibodies, respectively. However, 
with manufacturer of the Telomerase 2C4 antibody stated there is crossover, with 12% 
of IgM primary antibodies being detectable using an anti-IgG secondary. Using this 
method for staining has the potential to vary from batch to batch and the vendor could 
not guarantee consistency of results if an anti-IgG secondary was being relied on to 
detect an IgM primary antibody. Hence the decision was made to use isotype specific 
primary and secondary antibody combinations to overcome this potential issue.  
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2.6.2.6 Reducing Background Staining 
Various blocking steps were used throughout the optimisation process. These included, 
blocking with secondary antibody host animal serum, using secondary host sera to 
dilute primary antibody to a working concentration, shortening primary antibody 
incubation times, diluting the antibodies (primary and secondary) and DAB dilutions 
were all explored to give the best possible staining in positive control tissues. This work 
was felt to be critical given that subcellular location was to be described in tumour and 
background tissues. 
2.6.2.7 Telomerase IHC Optimisation 
The optimisation processes for the Survivin IHC involved fewer steps, compared to the 
Telomerase antibody, confirming a higher confidence in the data generated. Regrettably 
there has not been an equivalent quantity of published research assessing the use of IHC 
to assess tissue expression of Telomerase, perhaps due to poorer quality antibodies 
available, which necessitated significant optimisation steps as will be discussed later. 
There are fewer published works that have used IHC for Telomerase protein 
quantification to draw from as potential sources of antibody. In fact, there are some who 
question the quality, sensitivity and specificity of the antibodies that are commercially 
available and state that “hTERT immunohistochemistry data should be interpreted with 
caution,” as a result (Wu et al., 2006; Kim et al., 2013).  
However, as a key step in a rat HCC model being the nuclear translocation of 
Telomerase (Chen and Kong, 2010). Also, other researchers focussing on nuclear 
positivity when detecting Telomerase with IHC in various tumour served as a basis for 
our IHC interpretation of these results (Lotfi et al., 2014; Saeednejad Zanjani et al., 
2019).   
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There is increasing evidence that non-tumour tissues can possess Telomerase activity 
with typically cited examples being testis, ovary, placenta and thymus tissues (Hiyama 
et al., 2001). An obvious starting point in the optimisation process is the selection of 
both a positive control tissue, and an antibody that that detects appropriately. Small 
volumes of antibodies were purchased, used at 1:100 dilution, on the five different 
tissue types as outlined in figure 9. 
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Figure 9. Four different antibodies used on five different tissue types to find a suitable positive control. Citrate 
antigen retrieval was used for all with antibodies used at 1:100 dilution. Imaged at 200X. 
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With expert review, the most consistent antibody was felt to be the Novus, with best 
staining in normal testis. Other, less referenced, antibodies either gave extremely vague 
(A6, C12) or non-specific positivity (Abcam) compared to the Novus Antibody. Further 
optimisation, including blocking steps, can be seen in figure 10.  
 
Figure 10. Goat blocking serum for diluting primary antibody. 
Numerous steps were introduced to reduce the non-specific background staining from 
the Novus antibody. As outlined in figure 10 a 2% goat serum block was used, and the 
protocol was altered from overnight incubation with primary antibody (4 Celsius) to a 
one-hour (RT) incubation step which greatly reduced the non-specific staining. 
To ensure consistency with previously published work, figure 11 demonstrates 
positively staining spermatids, with less intensely stained primary and secondary 
spermatocytes. The left panel shows a 1:400 dilution of primary antibody in 2% goat 
serum, incubated for one hour at RT, on normal testis with spermatocytes, spermatids 
and spermatozoa staining positively at 200X magnification with 100micron scale bar. 
Right panel shows a previously published image of human testis with staining in the 
spermatocytes (Hiyama et al., 2001). 
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Figure 11. Telomerase expression in testicular tissues.  
Therefore, the positive control tissue was decided as normal Testis, with a primary 
antibody diluted to 1:400 in a 2% (v/v) goat serum.  
2.6.2.8 DAB Supply 
Initial purchases of SIGMAFAST™ 3,3’-Diaminobenzidine tablets worked very well 
for detection of Survivin protein in tonsil and liver tissues. Owing to unforeseen delays 
in receiving delivery from the manufacturer an alternative source was required for 
detecting Telomerase. Repeated rounds of optimisation were necessary to ensure 
comparable staining with an adequate substitute.  
2.6.3 Experimental Procedure 
Sections were incubation at 60 °C for thirty minutes to de-waxed the slides, followed by 
two five-minute washes in xylene (Fisher Scientific) and two further five-minute 
washes in 100% ethanol (VWR®). Sections were then washed in running tap water for 
five minutes before blocking by submersion in 3% hydrogen peroxide (Fisher 
Scientific) in methanol (VWR®) for 30 minutes at RT, then washed in running water for 
10 minutes. Antigen retrieval was performed by pre-treatment with either EDTA buffer 
(6.8 mM EDTA, 19.81 mM Tris base) pH 9.0 or citrate buffer (10 mM citric acid) pH 
6.0. Sections were boiled in pre-treatment buffer for 30 minutes and then washed under 
running water for 10 minutes before equilibration in Tris buffered saline-Tween-20 
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(TBST) buffer (0.05 M Tris base, 8% NaCl, 0.045% Tween-20) pH 7.6 for five 
minutes. Next, sections were blocked in 1% normal horse/goat serum in TBS-T buffer 
for 30 minutes at RT followed by an avidin-biotin block (Vector Laboratories Ltd; #SP-
2001) to block nonspecific binding of endogenous biotin consisting of a 15-minute 
incubation with Avidin D solution at RT, a brief one-minute wash in TBS-T and then a 
15-minute incubation with Biotin solution. Finally, sections were drained of biotin 
solution and incubated in primary antibody diluted in TBS-T (Survivin)/ TBS-T + 2% 
Goat serum (Telomerase), overnight at 4 °C (Survivin) / one hour RT (Telomerase).  
Sections were washed twice by immersion in TBS-T for five minutes and biotinylated 
secondary antibody (Vectastain® Universal Elite ABC kit; #PK-6200; Vector 
Laboratories Ltd) applied for 30 minutes at RT. Sections were washed twice by 
immersion in TBS-T for five minutes and incubated with biotinylated HRP (Vectastain® 
Elite ABC Reagent; Vectastain® Universal Elite ABC kit) for 30 minutes at RT 
according to manufacturer’s protocol. Sections were again washed twice by immersion 
in TBST for five minutes before incubation in 3,3'-diaminobenzidine (DAB) solution 
(Sigma-Aldrich®; #D4293) for 5 minutes to allow detection of protein and then washed 
for 10 minutes under running water. Counterstaining of sections was performed with 
application of Mayer’s haematoxylin solution (Sigma-Aldrich®; #MHS1) for two 
minutes and excess removed by washing under running water for 10 minutes. Finally, 
sections were washed twice for five minutes in 100% ethanol, followed by two five-
minute washes in xylene and then mounted onto coverslips using DPX mounting agent, 
(Sigma-Aldrich®; #06522), applied facedown, inspected to ensure no air bubbles were 
obscuring the tissue, then turned face-up to allow the mounting media to set.  
2.6.4 Digital Assessment of Immunohistochemistry 
Whole tissue sections were scanned using the Glissando Slide Scanner (Objective 
Imaging) at 40X magnification and stored on encrypted hard drives (diskashur2, HDD 
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iStorage) to facilitate compatibility with NHS security protocols. Individual sections 
were assessed and sufficient data points were included to ensure the software was able 
to triangulate the position of tissue sections on the glass slides. Data was stored in the 
“.svs” format and assessed using a Lenovo ThinkCentre (Intel CORE i5 vPro 8th Gen 
processor) desktop computer. 
The open source free-to-use software, QuPath (https://qupath.github.io) version 0.1.2, 
was used in the assessment and quantification of the scanned images. Version 0.1.2 is 
the most recent stable edition QuPath that runs glitch-free and has been used in other 
published articles (Bankhead et al., 2017; Loughrey et al., 2018). Subsequent 
development editions of QuPath – so called ‘milestone’ versions – are more up to date 
but may require ‘bug-fixes’ and caution has been advised by their creator. Hence the 
more stable version of the software was used. Online tutorials were extremely 
informative and outlined the main features of the software package (Bankhead, 2018). 
QuPath’s positive cell detection, along with the addition of smoothed features, creates 
67 different parameters for assessing individual cells in the study tissues. Random trees 
classifiers were used on each image, utilising the interactive nature of the software to 
learn the various tissue types present. As cells are classified based on morphological 
and environmental features representative regions of tumour, background liver, 
inflammatory cells, stromal tissues and necrotic tissue were used, when present, for this 
optimising process. Detection classifiers were created that identified various cellular 
subtypes that could then be assessed for DAB staining intensity. 
Tumour cells were classified as being negative (-), weakly positive (+), moderately 
positive (++) or strongly positive (+++) based on the intensity of DAB nuclear 
positivity. It is important to note that the software is unable to differentiate between true 
nuclear staining (denoted by haematoxylin overlaid by DAB) from any 
artefactual/incidental haematoxylin/DAB overlay, unless trained to do so by a classifier. 
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If there is nonspecific staining that overlays haematoxylin, this could be erroneously 
interpreted as a positively stained nuclei, as was evident when using the Telomerase 
antibody.  
The intensity of staining was determined using pre-set values (<0.2 was negative, ≥0.2 
but <0.4 for +, ≥0.4 but <0.6 for ++ and ≥0.6 for +++) for Survivin quantification. For 
Telomerase an optimisation process was required and intensity measures of adjusted 
accordingly (<0.3 was negative, ≥0.3 but <0.5 for +, ≥0.5 but <0.7 for ++ and ≥0.7 for 
+++) as described later. Short sequences of code were written (using the ‘script’ 
function) to ensure these optimisation steps were included for each image assessed and 
that each object selected was appraised to ensure consistent results. The addition of 
“selectAnnotations();” into the code meant that when an area of tissue was highlighted 
for assessment, regions could be excluded if there were potential contaminants such as 
ink present, or a tissue fold that would give a false reading. Small areas (approximately 
5000 cells) were used to ensure the accuracy of positive cell detection, and that cells 
were being classified appropriately prior to whole slide assessment.  
Internal positive controls (predominantly inflammatory cells) were useful in ensuring 
the quality of the IHC undertaken, and were excluded from the analysis of staining 
intensity owing to a quirk in the software that means only tumour cells were assessed 
for this characteristic. As each individual classifier was trained to recognise 
inflammatory cells, the intensity of non-tumour cells is ignored by the current iteration 
of the QuPath algorithm. This script was then run on a whole slide basis, with care 
being taken to avoid the outer rim of the tissue as this could give a false positive reading  
(Reichling et al., 2019).  
The whole slide-image was assessed using the individual script of code that relied on 
the unique classifier that had been created for each tissue sample. This ensured the 
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sensitivity of tumour/background/inflammatory cell detection was tailored to each 
individual slide and therefore ensured maximal accuracy in this measurement. 
2.6.4.1 Project Size & Classifier Clarifications 
The Project is the file name for samples that are assessed together. The classifier is the 
tool that undertakes this assessment and can either be used across a number of samples 
(in a project) or can be created for each individual tissue sample being assessed. 
Assessment of tissues have been made after dividing them into groups based on 
histological subtype and using a single classifier to detect similar cells across a number 
of slides in one project (Reichling et al., 2019) or assessed a whole project 
simultaneously, having identified individual cells of interest on each slide when creating 
the classifier (Morriss et al., 2020). A third method of assessing tissues has also been 
published and involves teaching the object classifier for cell subtypes on each slide  
(Stålhammar et al., 2019). There are limited reports of the time required for these 
processes to be undertaken but the range cited for slide assessment varies from less than 
one minute (using the powerful Intel Xeon Gold 6128 CPU processor) to ten minutes 
per slide (K. Liu et al., 2019; Morriss et al., 2020). 
The potential benefits of being able to teach the classifier a wide range of 
morphologically diverse tumour types in training and validation cohorts. This would 
allow a powerful computer to use machine learning to detect malignant cells based on a 
very large training cohort as demonstrated by the 843 training and 212 validation cases 
Liu et al studied when studying nasopharyngeal carcinoma (K. Liu et al., 2019).  
However, as the ethical stipulations associated with this project mandate that the 
researcher be blinded to the patient characteristics and outcomes when studying the 
tissues, histological subgroup analysis was not appropriate as this would have involved 
a complex, partial, un-blinding process that would have violated these stipulations.  
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2.6.4.2 Creating an Object Classifier 
The process of teaching QuPath what cells to classify as tumour, inflammatory cell, 
stoma or background liver is intuitive and relatively simple. A visual guide is outlined 
in figure 12.  
With the page viewed in landscape, in the top left image, a yellow box has been drawn 
and will be used to teach QuPath how to process of detection and assigning cell classes 
within it. The ‘positive cell detection’ tool has been used in the top right image, where 
haematoxylin and DAB overlay each other. Note the arrowheads in the upper left of the 
image – these are not tumour cells but are being detected as a ‘positive’ cell by the red 
colouring. In the bottom left picture, the previously arrow-headed stromal cells have 
been highlighted in a drawn on blue ring (see arrow) and assigned as ‘stroma.’ QuPath 
has now learned that cells appearing similar to these (non-tumour) cells are re-classified 
within this optimisation box. Another arrow in the centre of the bottom left image is 
teaching QuPath what tumour cells look like. Other shapes (both in red and blue) have 
been drawn into this space over similar looking (either tumour or stroma) to better 
educate the software.  
Finally, the intensity-assessment is made (see bottom right image) across the whole 
tissue sample (note no box around the small number of cells as in the three other 
images) that gives blue (negative), yellow (+), orange (+ +) and red (+ + +) staining 
values. Pre-set and manually entered intensity values can be used for this step. Both the 
stroma and any negatively staining cells have been assigned the colour blue in this 




Figure 12. Creating an object classifier in QuPath.  
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Once the image has been processed in its entirety, the processed image is quality 
controlled by visual inspection and, if it appears satisfactorily accurate, QuPath is then 
able to report Allred and H-scores. The time taken to teach the object classifier for a 
new image is approximately 1-2 minutes, with the following full slide assessment 
taking about 4-8 minutes, depending on the size of the data file. This is comfortably 
within the ten minutes previous researchers have quoted for the full assessment of each 
sample (K. Liu et al., 2019; Morriss et al., 2020). 
2.6.4.3 Trial Datasets 
Survivin stained tissues were the first to be assessed using the QuPath software in this 
cohort. A consultant Histopathologist with a subspecialty interest in hepatic pathology, 
Dr Jemimah Denson, assessed the tissues for their intensity of staining, and the 
percentage of cells staining positively. Dr Denson assessed a small cohort of randomly 
selected samples and the respective scores compared with those reported by QuPath.  
When the test cohort was assessed on QuPath and compared to Dr Denson’s 
quantification it quickly became apparent that attempting to use a single classifier 
across different tumour types would result in poor quality data. Examples of these 
issues include the computer slowing down considerably and intermittently crashing 
when the project size (number of images added to one file) was larger than ten images. 
As, on average, ten images account for between 30GB and 40GB of data that were open 
and being assessed simultaneously the available computer power meant an alternative 
approach would be necessary.  
Intracellular accumulation of lipoproteins is present in hepatocytes to varying degrees 
from different patients. These accumulations are associated with chronic liver 
dysfunction and their presence varies widely in across tissue samples. An advantage of 
creating individual detection classifiers means that the presence of these inclusions can 
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be accounted for when assigning a particular morphological feature to a tumour cell or 
normal hepatocyte.  
After re-assessing the staining of a small cohort of slides, there was considerable 
agreement between the algorithm and Dr Denson’s assessment. The quality of the 
Survivin antibody is readily apparent, and had been used in peer-reviewed publications 
more than 200 times, at the time of selection, including for the use of IHC on FFPE 
samples.  
2.6.4.4 Optimising Telomerase IHC interpretation 
The Survivin cohort was analysed using the pre-set values for staining intensity on 
QuPath. Regrettably when the same approach, using the installed values for staining 
intensity, was attempted in a test cohort of Telomerase IHC tissues the resulting data 
was inaccurate. An optimisation phase for assessing the Telomerase antibody-staining 
intensity was required that necessitated a range of cut off scores for to be tested and 
compared with Consultant Histopathologist, Dr Denson’s, scores. The parameters are 
outlined in table 16. 
Intensity Scores Negative 1+ 2+ 3+ 
Pre-Set <0.2 ≥0.2 but <0.4 ≥0.4 but <0.6 ≥0.6 
Alternative 1 <0.3 ≥0.3 but <0.5 ≥0.5 but <0.7 ≥0.7 
Alternative 2 <0.4 ≥0.4 but <0.6 ≥0.6 but <0.8 ≥0.8 
Table 16. Parameters used for optimising staining positivity for Telomerase IHC. Intensity measures are arbitrary 
units based on the optical density sum.  
A small batch of ten randomly selected samples was assessed using an object classifier 
whose only difference was the gated values for intensity scores outlined in table 16. 
This meant that there was minimal sample processing (i.e., none - other than the 
intensity values altering) between runs to ensure the only variable that changed between 
assessments was the staining intensity score. These results were then compared with Dr 
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Denson’s assessment of the tissues meaning the best fit for staining intensity was 
Alternative 1.  
This is perhaps a reflection of the less published antibody used in the assessment of 
Telomerase (used in 18 previous publications, not 219 as per the Survivin antibody) or 
maybe even the fact that Telomerase IHC may not be as readily interpreted, or indeed 
vary widely between antibodies (Kim et al., 2013). 
2.6.4.5 Quantifying Tissue Staining 
Appropriate scoring systems are required to fully describe the extent of tissue positivity 
(or otherwise) when assessing immunohistochemical data. To reduce whole slide image 
data to a simple, transferrable, interpretable format requires a scoring system, or 
systems, that have been designed to convey this information. There are two classical 
assessment methods: The Histological score (H-score) and the Allred scoring systems. 
Both the Allred & H-scores were initially devised to assess breast cancer tissues to 
differentiate between negative and strongly positive expression, and various levels in 
between (McCarty et al., 1986; Allred et al., 1998). This has helped researchers and 
clinicians convey degrees of tissue positivity for steroid receptor status since the late 
1980s. The H-score, out of 300, is calculated by the following formula (McCarty et al., 
1986): 
H-score (0-300) = 0*(% 0 intensity) +1*(% 1+ intensity) + 2*(% 2+ intensity) + 3*(% 3+ intensity) 
H-scores have been used in non-breast cancer research studies to quantify tissue 
staining metastatic liver disease from uveal melanoma and metachronous colorectal 
cancers  (Tamagawa et al., 2013; Gardner et al., 2014). The Allred score incorporates 
both the proportion of cells (proportion score, PS) and the intensity of staining (intensity 
score, IS) as outlined from Allred’s original paper studying breast cancer receptor 
staining in figure 13, (Allred et al., 1998). The Allred score = PS + IS.  
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Figure 13. Visual representation of the proportion score (PS) and the Intensity score (IS) giving the combined Allred 
Score. 
Proportion scores of 0 is for no staining, a score of 1 is for up to 1% of cells being 
positive, for between 1-10% of cells (score 2), 10.1-33.3% (score 3), 33.4-66.6% (score 
4) and 66.7-100% (score 5). The intensity of staining requires finite values to be 
interpreted (which QuPath accounts for) with values of 0, 1, 2 and 3 depending on how 
intensely stained the cells are, to give an Allred score from 0-8. This method has been 
used to study steatohepatitis in hyperlipidaemia, as well as the epidermal growth factor 
receptor status in colorectal cancer research (Rokita et al., 2013; Sturzeneker et al., 
2019). 
The Allred score was devised to assess Oestrogen receptor positivity in breast cancer 
and has been used in conjunction with Progesterone receptor status since the 1990s 
(Rhodes et al., 2020). Breast tumours are considered negative with an Allred score of 2, 
or lower, and have been stratified as low-expressing (Allred score 3-5) and high 
expressing scores (Allred 6-8) to further characterise both the extent and intensity of 
protein level (Campbell et al., 2016). In one case series 27% of breast cancers had an 
Allred score of 0 and 66% a score of 8, indicating the non-normal distribution of 
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staining intensity as shown in figure 14, (Rhodes et al., 2020).
 
Figure 14. Allred scores for Oestrogen and Progesterone receptors in Breast cancer.  
These scores were manually assessed and highlight the near-binary expression of 
Oestrogen receptors in this cohort of breast cancer specimens. There is clearly the 
potential for digital pathology to undertake some of this semi-quantification, especially 
when assessing a normal/near-normal distribution of protein expression. If Allred scores 
are normally distributed, dividing up the samples in no, low and high expression could 
yield greater accuracy in results. Figure 14 also gives a good representation of the 
positively staining (weak through to strong expression) found when semi-quantifying 
IHC. 
As significant numbers of cells are counted, and assessed, in QuPath, both scores will 
be used in the subsequent analysis to compare results. There is also precedent for sub-
categorising the intensity of tumour-expressing protein levels when prognosticating 
tumours with higher expression of Oestrogen or Progesterone (Campbell et al., 2016). 
There has also been a phase II/III trial in breast cancer patients using the cut off values 
of 6-8 for ‘ER rich’ tumours, and tailoring their therapy accordingly, (Ellis et al., 2010).  
2.7 ELISA 
Biobanked serum samples were thawed and used to in conjunction with commercially 
available enzymes linked immunosorbent assay (ELISA) kits.  
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2.7.1  Survivin ELISA 
Serum Survivin levels were tested using the Human Survivin Quantikine® kit (R& D 
Systems®) using the manufacturers protocol as detailed below. Owing to the uncertain 
effect serum would have on the ELISA, experiments were repeated with both the 
provided diluent, and then with a 10% (v/v) healthy volunteer serum as the diluent for 
the standards. All samples, including controls, were run in duplicate. 
2.7.1.1 Preparation of Standards 
The Quantikine® standard was reconstituted from the lyophilised form with addition of 
900µL of deionised water, to give a stock concentration of 20,000 pg/mL, and allowed 
to completely reconstitute for 15 minutes. Subsequently, 100µL of this stock 
concentrate was added to 900µL of calibrator diluent, RD6-47, to give a high-standard 
concentration of 2000pg/mL, and mixed by pipetting. Serial dilutions were then made 
using equal parts calibrator diluent (500µL) and the mixed preceding concentration, as 
outlined in table 17. The calibrator diluent was used as the zero standard. 
Vial Volume of Diluent 
(µL) 




A 900 100, Stock concentrate 2000 
B 500 500, vial A 1000 
C 500 500, vial B 500 
D 500 500, vial C 250 
E 500 500, vial D 125 
F 500 500, vial E 62.5 
G 500 500, vial F 31.3 
H 1000 N/A 0 
Table 17. ELISA reagents using the Survivin Quantikine® kit (R& D Systems®). 
For the repeat experiment to ascertain the effects, if any, of serum on the assay, the 
standards were diluted in 10% (v/v) healthy volunteer serum in the provided calibrator 
diluent. Reconstitution of the lyophilised standard was undertaken with deionised water 
only. The low standard (vial H) was 10% (v/v) healthy volunteer serum only.  
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The Quantikine Immunoassay Control Group 8 (catalogue number QC23, R& D 
Systems®) was used for an assessment of the assay function. Controls are present in 
low (143 – 360 pg/ml), medium (385 – 1015pg/ml) and high (834 – 1815 pg/ml) 
concentrations having been prepared in diluted porcine serum and subsequently 
lyophilised. The control samples contain numerous recombinant human cytokines in 
each vial.  
2.7.1.2 Experimental Procedure 
Microplates were removed from storage at -20 Celsius and left to equilibrate to RT. 
Room temperature assay diluent (RD1-9) was added to each well (100 µL) with equal 
volumes of standard, control or sample per well, to give a total volume of 200µL in 
each well. An adhesive strip was then used to cover the wells which were then 
incubated at RT for two hours on a horizontal orbital microplate shaker (Thomas 
Scientific, 0.12” orbit at 500 ± 50rpm). Well contents were then aspirated and washed 
with 400 µL (1x concentration) wash buffer for a total of four wash cycles using a 
multichannel pipette. Residual liquid was removed with inversion between steps, with 
blotting against clean paper towel after the last wash step. 
Human Survivin conjugate (200 µL) was then added to each well, covered with a new 
adhesive strip and incubated at RT for two hours on a horizontal orbital microplate 
shaker (Thomas Scientific, 0.12” orbit at 500 ± 50rpm). Aspiration and wash cycles 
(x4) were repeated. Substrate solution (200µL) was added to each well and the samples 
were covered and incubated at RT on the benchtop whilst being protected from light, for 
thirty minutes. Following this 50 µL of Stop solution was added to each well allowing a 
homogenous change in colour from blue to straw-yellow. Optical density (OD) was then 
measured within 30 minutes at both 570 nm and 540 nm with the recorded reading 
corrected for the 570 nm wavelength (540 nm – 570 nm) to correct for optical 
imperfections in the plate.  
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For calculating the relative differences in absorbance between wells, the 540 nm-570nm 
readings were used and each reading had subtracted the zero-standard (0 pg/mL) 
reading to demonstrate relative differences in absorbance.  
2.7.1.3 Calibration Curves 
Samples were run in duplicate and calibration curves were calculated for each ELISA 
run. These calibration curves can be seen in figures 15 & 16, depending on the diluent 
used. Error bars demonstrate the standard deviation.  
 
Figure 15. Standard curve used to correlate optical density (OD) with concentration using the calibrator diluent. 
To account for other, serum, effects these experiments were repeated, as shown in 
figure 16.  
 
Figure 16. Standard curve used to correlate optical density (OD) with concentration using 10% (v/v) healthy 
volunteer (HV) serum in calibrator diluent. 
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2.7.2 Telomerase ELISA 
Serum hTERT was detected using the Human Telomerase Reverse Transcriptase 
(TERT) ELISA Kit (abx251454, abbexa®). Samples and standards were run in 
duplicate and the effect serum had on the assay was ascertained by running the 
experiment with calibrator diluent (as provided by the manufacturer) and in 10% (v/v) 
healthy volunteer serum.  
2.7.2.1 Preparation of Standards 
To ensure all of the lyophilised powder was used, the dry powder was centrifuged 
briefly to ensure there were no residues in the cap of the vial. To the lyophilised 
powder, 1 mL of Sample/Standard diluent was added and mixed by pipetting and then 
allowed to sit for 15 minutes at RT. Care was taken to avoid mixing by vortexing as this 
would destabilise the protein. Once reconstituted, each standard was used immediately 
and then discarded to ensure optimal accuracy in measurement. Subsequent serial 
dilutions of the standards are outlined in table 18. 
Vial Volume (µL) of additional 
Sample/Standard Diluent 
Volume (µL) & 
source of standard 
Final Concentration 
(ng/mL) 
A N/A 1000, Standard. 10 
B 500 500, vial A 5 
C 500 500, vial B 2.5 
D 500 500, vial C 1.25 
E 500 500, vial D 0.63 
F 500 500, vial E 0.31 
G 500 500, vial F 0.16 
H 500 N/A 0 
Table 18. Standards prepared from the ELISA Kit (abx251454, abbexa®).  
For the repeat experiment to ascertain the effects, if any, of serum on the assay, the 
standards were diluted in 10% (v/v) healthy volunteer serum in the provided 
sample/standard diluent. The low standard (vial H) was 10% (v/v) healthy volunteer 
serum only.  
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2.7.2.2 Experimental Procedure 
All reagents and kit components were equilibrated to room temperature before use. Into 
each well, 100 µL of standard, sample or zero control was added, covered with adhesive 
strip and incubated at 37 Celsius for 90 minutes. Following this incubation step, the 
liquid contents was discarded and (without a wash step) 100 µL of the biotin conjugated 
antibody was added to each well. A new adhesive coverslip was added and then 
incubated at 37 Celsius for a further 60 minutes.  
The well contents were discarded and three washes with 1X wash buffer were 
undertaken using a multi-channel pipette, with a 90 second soaking period for each 
wash step. Well contents were completely removed (with inversion) after each stage and 
after the final wash step the plate was inverted and blotted against clean absorbent paper 
towels. 100 µL of HRP working solution was then added to each well, covered with 
new adhesive plastic and incubated at 37 Celsius for 30 minutes.  
The well contents were discarded and five wash steps, as described above, was 
undertaken. TMB substrate (90 µL) was added to each well, covered and incubated at 
37 Celsius, in dark conditions, for 20 minutes. Stop solution (50 µL) was then added to 
each well with a concurrent colour change to a homogenous straw-yellow. Absorbance 
measurements were undertaken at 450 nm immediately.  
For calculation of the relative absorbance, the zero-standard (0 ng/mL) reading was 
subtracted from the recorded reading from each well, at 450 nm.  
2.7.2.3 Calibration Curves 
Samples were run in duplicate and mean values were taken, as can be seen in figures 17 
& 18.  
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Figure 17. Standard curves used to correlate OD with concentration using only calibrator diluent with the 
Telomerase ELISA Kit (abx251454, Abbexa 
Standard curves for samples run in duplicate using provided diluent (not 10% HV 
serum) are shown in figure 17. The OD reading for the 10 ng/ml high standard was 
lower than expected, so both calibration curves (one including the 10ng/ml reading and 
one excluding it) are shown.  
When the calibration curve was run in 10% HV serum, the results were disappointing, 
as can be seen in figure 18. 
 
Figure 18. The standard curve used to correlate OD with concentration using 10% HV serum as calibrator diluent 
from the Telomerase ELISA Kit (abx251454, Abbexa. 
As can be seen from the calibration curve in figure 18, there is no clear relationship 
between telomerase concentration and optical density when the standards are diluted in 
10% healthy volunteer serum. Some OD values were negative, and so a log-log graph 
cannot be calculated.  
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2.8 Exosome Work 
Exosomes were extracted from biobanked serum samples using a commercially 
available kit that exploits the precipitation method as has been reported previously 
(Gutkin et al., 2016; Goldvaser et al., 2017). Choosing the precipitation method over 
ultracentrifugation was prudent as processing could be undertaken using routine bench 
top equipment and currently has the maximal exosomal yield when compared to other 
methods of retrieval (Patel et al., 2019).  
2.8.1 Experimental Procedure 
2.8.1.1 Exosome Isolation 
The Total Exosome Isolation Reagent, from Serum (Invitrogen, catalogue number 
4478360) was used and the procedure followed was, briefly, outlined below. Serum 
samples were removed from the -80 Celsius freezer defrosted and placed on ice. Serum 
samples were centrifuged at 2000 x g for 30 minutes at 4 Celsius to remove cells and 
debris. The supernatant of clarified serum was transferred to an RNAse/DNAse free 
Eppendorf tube, taking care to not disturb the cellular pellet, and placed on ice. 
Workable volumes of clarified media (250 μL) had 0.2 volume equivalents (50 μL) of 
Total Exosome Isolation reagent added to them and were mixed vigorously by pipetting 
until a cloudy, homogenous, solution was present. The reaction mixture was then stored 
at 4 Celsius for 30 minutes. Following this step, the reaction mixture was then 
centrifuged at 10000 x g for 10 minutes at room temperature. The supernatant was 
discarded to leave a yellow/orange pellet of exosomes in the bottom of the Eppendorf. 
A single wash step involved the addition of 1x PBS (Thermofisher) and then carefully 
removing the PBS whilst the exosomal pellet remained at the bottom of the Eppendorf 
tube. The Exosomal pellet was resuspended in 500 μL QIAzol (Qiagen) with care taken 
to work in a fume hood and work with filtered tips. The resuspension phase can take up 
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to 15 minutes with larger exosomal pellets and involves mixing extensively by 
pipetting. 
2.8.1.2 RNA Extraction 
2.8.1.2.1 Exosomal RNA 
Chloroform (Sigma Aldrich), 100μL, was added to the samples when under the fume 
hood with a p1000 filtered pipette and mixed by shaking manually for 15 seconds. 
Samples were then centrifuged at 12000 x g for 15 minutes at 4 Celsius. Following 
centrifugation, the clear upper phase was transferred to a new RNAse/DNAse free 
Eppendorf tube for RNA extraction. Care was taken to not aspirate the white middle 
layer (protein) or touch the sides of the Eppendorf tube whilst pipetting to minimise 
contamination at this stage. PCR grade Isopropanol (Sigma Aldrich) (250μL) was added 
to the samples and mixed by flicking the Eppendorf tubes. The samples were then 
stored overnight at -20 Celsius to facilitate RNA precipitation.  
The following day the samples were removed from -20 Celsius and centrifuged at 
12000 x g for 10 minutes at 4 Celsius. The supernatant was removed, discarded, and 
then 500μL of 75% molecular grade ethanol (Sigma Aldrich) was added to the stable 
RNA pellet. Samples were then centrifuged at 7500 x g for 5 minutes (4 Celsius) and 
then the supernatant was carefully removed and discarded. At this stage the RNA pellet 
was less stable so some of the dilute ethanol was left in the Eppendorf and left to air-dry 
on the bench top.  
The RNA pellet was then resuspended in 40μL nuclease free molecular grade water 
(who/where) then incubated at 56 Celsius on a heatblock (Dri-Block DB 2D, Techne) 
for 10 minutes. Following this step, the RNA could be quantified and quality assessed 
using a NanoDrop™ (2000 spectrophotometer Thermo Scientific™) comparing nucleic 
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acid contents to the nuclease free water used for the final dilution step. Extracted RNA 
was either used immediately or stored at -80 Celsius prior to further experimentation.  
2.8.1.2.2 Cell Lines 
The Huh7.5 cell line was used as a calibrator for qPCR. The TRIzol extraction method 
was used for RNA extraction, with spin-column purification using Direc-zol RNA 
Miniprep (Zymo Research, catalogue number R2050). The experimental procedure is 
outlined briefly below.  
Growth media was removed and 0.3mL of TRIzolÔ reagent (Invitrogen, catalogue 
number 15596026) was added per 1x106 cells directly into the culture dish, with 
homogenisation by pipetting. Samples were then incubated for five minutes at RT. 
Equal volumes (0.3mL per 1x106 cells) of ethanol (purity > 99.8%, Honeywell) was 
added to the lysed sample. The liquid was then transferred to a Zymo-Spin IICR 
Column (Zymogen) in a new DNase/ RNase free collection tube. The sample was 
centrifuged (10000 x g, 30 seconds, RT) and the flow-through discarded.  
DNase 1 treatment was undertaken and the reagents were mixed in a separate Eppendrof 
tube: 6µL of DNase 1 to 75µL of DNA digestion buffer, and mixing by gentle 
inversion. The addition of RNA Wash Buffer (400µL) into the spin column, with 
centrifugation (10000 x g, 30 seconds, RT), discarding the flow through and then the 
addition of the DNase 1 mix. Incubation in the spin column for 15 minutes at RT.  
Then 400µL of Direct-zol RNA PreWash was added to the column, centrifuged (10000 
x g, 30 seconds, RT), and the flow through was discarded. The Pre-Wash step was 
repeated once more. Washing the RNA by addition of 700µL RNA Wash Buffer to the 
column and centrifuged (10000 x g, 1 minute, RT), followed by transfer of the column 
into a sterilised DNase/ RNase-free Eppendorf. The RNA was eluted with the addition 
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of 50µL of DNase/ RNase-free water, followed by centrifugation (10000 x g, 30 
seconds, RT).  
The RNA was assessed using the NanoDrop™ 2000 spectrophotometer (Thermo 
Scientific™) to assess both the quality (260/280 ratio) and quantity (concentration, in 
ng/µL) of extracted RNA. Only RNA with a 260/280 ratio >1.8 was used for 
subsequent experiments. Aliquots were stored at -80 Celsius.  
2.8.1.3 Reverse Transcription 
The reverse transcription of RNA to cDNA was done using Applied Biosystems™ 
High-Capacity cDNA Reverse Transcription Kit with RNAse Inhibitor (Catalogue 
number 4374967) as outlined below.  
Kit components were thawed on ice and a 2X mastermix was created as outlined in 
table 19, making n+1 aliquots for n samples. 
Component Volume per reaction 
10X Reverse Transcription Buffer 2.0 μL 
25X dNTP Mix 0.8 μL 
10X Reverse Transcription Random Primers 2.0 μL 
MultiScribe™ Reverse Transcriptase 1.0 μL 
RNAse Inhibitor 0.5 μL 
Nuclease Free Water 3.7 μL 
Total Volume 10.0 μL 
Table 19. Reverse transcription reaction volumes for the Applied Biosystems™ High-Capacity cDNA Reverse 
Transcription Kit with RNAse Inhibitor.  
The 2X mastermix was mixed with gentle vortexing and centrifugation. The final 
reaction was assembled with the addition of 1 μg of RNA added to 10 μL of the 2X 
mastermix and additional nuclease free water to make a final reaction volume of 20 μL 
in nuclease free Eppendorfs. The blank, no template control, reaction mix had 10 μL of 
nuclease free water added to 10 μL of the 2X mastermix to ensure no contamination had 
occurred that would be alter the experimental findings. 
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After briefly centrifuging the reaction mixtures to eliminate air bubbles and ensure 
reaction mixtures were in the bottom of the Eppendorfs, they were placed on ice.  The 
Thermal Cycler (Labtech GS4 G-Storm, Gene Technologies) was set with the following 
steps: table 20.  
Settings Step1 Step 2 Step 3 Step 4 
Temperature 25 °C 37 °C 85 °C 4 °C 
Time 10 minutes 120 minutes 5 minutes ∞ 
Table 20. Reverse Transcription reaction conditions for Applied Biosystems™ High-Capacity cDNA Reverse 
Transcription Kit with RNAse Inhibitor.   
Once the reaction was complete samples were stored at 4 Celsius until processed for the 
qPCR.  
2.8.1.4 qPCR 
Quantitative PCR was undertaken using the Applied Biosystems™ TaqMan™ Fast 
Advanced Master Mix (catalogue number 4444557) and TaqMan™ gene expression 
assay probes for Survivin (BIRC5, Assay ID Hs00977611_g1, catalogue number 
4331182), Telomerase (TERT, Assay ID Hs00972650_m1, catalogue number 4331182) 
and the housekeeping gene hypoxanthine phosphoribosyltransferase 1 (HPRT1, Assay 
ID Hs02800695_m1, catalogue number 4331182). Each of the assay probes contained 
the FAM™ reporter dye labelled TaqMan™ minor groove binder (MGB) moiety and 
were purchases in 250 reaction quantities. The specific assays were selected because 
they targeted nucleic acids that spanned more than one exon with respective amplicon 
lengths of 113 base pairs (BIRC5), 57 base pairs (TERT) and 82 base pairs (HPRT1).  
The experimental reagents were used in the following quantities as outlined in table 21. 




Component Volume per reaction (µL) Final Concentration 
Mastermix 10.0 1X 
Assay Probes 1.0 1X 
Nuclease-free water 7.0 - 
cDNA 2.0 - 
Total volume 20 µL - 
Table 21. TaqMan qPCR reaction mix. 
With the reaction conditions in a Lightcycler 480 (Roche) thermocycler as outlined in 
table 22. 
Step Temperature (Celsius) Time Ramp Rate 
Hotstart 95 2 min 4.4 
45 cycles of 1 & 2.   
1. Denature 95 15 sec 4.4 
2. Annealing 60 1 min 2.2 
Followed by a single cooling step 
Cooling 40 30 sec 2.2 
Table 22. Reaction conditions, as outlined by for use with the TaqMan and custom TaqMan Gene Expression Assays. 




3 Promoter Sequencing Results. 
3.1 Introduction 
As detailed in chapter 2, DNA from archived samples was often of poor-quality samples 
and difficult to sequence, often requiring multiple cycles of PCR reaction, gel analysis, 
purification of PCR products and finally sending samples off for Sanger sequencing. 
DNA extracted from very early samples (DNA 1 – 6) were of such poor quality that 
repeat processing was required, so these study numbers do not feature in any examples 
as the tissues were re-anonymised when extraction and processing of DNA was 
undertaken. Visits to the Derriford Combined Laboratories (DCL) proved very helpful 
as a similar technique (DNA extraction from FFPE samples and PCR amplification) is 
used clinically for the assessment of methylation status of brain tumours for the O(6)-
methylguanine-DNA methyltransferase (MGMT) DNA repair gene and assessing 
epidermal growth factor receptor (EGFR) mutations in lung cancer (Bethune et al., 
2010; Thon, Kreth and Kreth, 2013). 
3.1.1 Survivin PCR Optimisation 
Initial sequencing work was undertaken targeting the promoter region upstream of the 
Survivin transcription start site. Some considerable optimisation was required to ensure 
an appropriate PCR product was achieved consistently. 
3.1.1.1 Primer Selections 
Initial reactions were undertaken using previously published primer pairs/reaction 
conditions to explore potential combinations for use in the whole cohort. In figure 19 
DNA extracted from FFPE colorectal carcinomas (samples 16c and 17a) were run on a 




Figure 19 highlights bands that are present at roughly halfway between 100 and 200 
base pairs when the SurvF1R1 primer pair (annealed at 57 Celsius, 151bp PCR product) 
was used, confirmed with DNA from two separate tumour samples. The smaller PCR 
product (128 base pairs) was non-detectable in both reactions, indicating a failed 
experiment when annealed at 55 Celsius.  
Alternative PCR primer pairs were also trialled as outlined in figure 20. As figure 20 
demonstrates, there were inconsistent results with the larger (329bp) PCR product, with 
some reproducibility (lower half) with some primer-dimer in the negative control lane. 
Expected PCR products for the primer pairs known as Han-625 (125 base pairs) and 
Han-31 (329 base pairs) when run in duplicate should have yielded reproducible results 
Figure 19. A 2% Agarose gel for the PCR products in test samples 16c and 17a. 
Figure 20. A 2% Agarose gel for the PCR products using DNA from sample 11c. 
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when annealed at 57 Celsius (Han et al., 2009). In the top panel, there is primer-dimer 
(present faintly in the negative control lane) and only one of two repeats have given an 
expected PCR product size, with a number of other non-specific bands also present. In 
the lower part of figure 20, there is also primer dimer present, but more consistent 
bands, if a little fuzzy, are present in both lanes. The inconsistent and non-specific 
nature of the results shown in figure 20 indicated that perhaps the best candidate for 
further use was the SurvF1R1 primer pair.  
Sequences of fewer than 150 base pairs have not been recommended for Sanger 
sequencing by the LGC Genomics, meaning primer pairs that gave sequences shorter 
than this were potentially viable but preference would be given to a larger PCR product 
if this was technically feasible to produce this. Fortunately, SurvF1R1 gave a sequence 
of 151bp in size and the potential to further increase the PCR product size using 
universal primers, as discussed below.  
3.1.1.2 Gradient PCR & Enzyme Selection 
Initial experiments used polymerases that were available within the lab group 
(Dreamtaq) failed to register consistent results. Small aliquots of Accuprime PFx and 
Q5 polymerases were trialled and gave promising initial results.  
Gradient PCR reactions facilitate a relatively rapid optimisation process for defining the 
best annealing temperature for PCR reactions. To maximise the potential primer 
combinations available to use for reactions, gradient PCR reactions were also 
undertaken with other promising primer-pairs. Given the Han-31 primer pair gave a 329 
base pair product size, this would have made sequencing easier if it worked sufficiently 
well. As can be seen in figure 21 the desired PCR product size of 329 base pairs has not 
been achieved and there is also evidence of primer-dimer – as shown by the <100bp 
band in the negative (no template) control sample.  
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Figure 21 fails to replicate previous successful PCR reactions, despite annealing over a 
wide range of temperatures. Given that previous groups have struggled to reproduce 
PCR reactions for targets >200 base pairs, it was felt the Survivin-31 F1R1 primer pair 
(yielding a 151 base pair PCR product size) should be used for subsequent experiments.  
There were encouraging results from an alternative polymerase, Q5, and one of the 
initial gels is shown in figure 22.  
Regrettably when this experiment was repeated, there was no reproducibility of the PCR 
products. 
Figure 21. A 2% Agarose gel from a gradient PCR reaction using the ‘Han -31’ primers and the Accuprime 
polymerase. 
Figure 22. A 2% Agarose gel from a gradient PCR using the ‘Surv F1R1’ primers and the Q5 polymerase.  
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Accuprime PFx polymerase was found to give the best results when annealing at 
62.1℃, as shown in figure 23 so was ultimately adopted as the enzyme of choice for 
PCR reactions sequencing the Survivin promoter region. 
There is some non-specific smear-artefact in the bands observed in figure 23 with the 
exception of lane 11 (annealing at 62.1 Celsius) and as such, this temperature step was 
selected for use with the SurvF1R1 primers, and the Accuprime Pfx polymerase. 
 
Figure 23. A 2% Agarose gel from a gradient PCR using the ‘Surv F1R1’ primers and the Accuprime Pfx 
polymerase. 
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3.1.1.3 Universal Primers 
In an attempt to increase the read length of the PCR product a universal primer was 
added on to the 5’ end of the forward primer (Kelley and Quackenbush, 1999). A 
number of hybrid primers were created with universal primer added to the 5’ end of 
either the forward or reverse primer, resulting in a larger PCR product that would 
theoretically neatly navigate this issue, figure 24 and table 23.  
 
Figure 24. Left side: A 2% Agarose gel with annealing temperatures as follows: Red (61.1℃), Yellow (61.9℃), Blue 
(63.1℃) and Purple (64.0℃). The layout outlined in the top half of the panel is replicated in the bottom half. Ext 
denotes the extended primer with F1 and R1 being the unaltered originals: Ext-R1 is the extended version of the R1 
primer, Ext-F1 is the extended version of the F1 primer. Notably the ExtF1-ExtR1 combination failed to produce a 
PCR product at every annealing temperature tested. 
The universal primers are each 18 base pairs long, giving the predicted PCR product 
sizes outlined in table 23 and the gel from PCR reactions in figure 24. There was some 
success in creating a larger PCR product using both the extendedF1-R1 (ExtF1-R1) and 
F1-extended R1 (F1-ExtR1). Regrettably the quantities of PCR product created in these 




Predicted PCR product 





Table 23. Predicted PCR product sizes of various primer pairs, including the additional universal primers. 
 121 
3.1.2 Telomerase Optimisation 
Experience gained from optimising PCR reactions for the Survivin promoter was 
transferred to the optimisation for the Telomerase promoter region. This streamlined the 
optimisation process as fewer primer pairs and enzymes were trialled as a PCR product 
of around 200 bases was the desired goal. 
3.1.2.1 Primer Selection 
Recently published papers used predominantly two pairs of primers when undertaking 
Sanger Sequencing of higher quality DNA (from frozen tissue or extracted from whole 
blood) and these were purchased for experiments (Nault et al., 2013; Huang et al., 
2015; Purkait et al., 2016). Primer pairs called ‘short TERT’ and ‘TERT F3R3’ yielding 
163 and 190 base pair sized PCR products respectively.  
3.1.2.2 Gradient PCR and Enzyme Selection 
As both the Accuprime and Q5 polymerases were readily accessible these combinations 
were trialled, as outlined in figure 25. 
 
Figure 25. A 2% Agarose from PCR using Accuprime Pfx & Q5 polymerases. 
However, these early results were beset with problems of a lack of reproducibility. 
Thus, the literature was consulted for an appropriate enzyme that had previously been 
used with these primer pairs. Both Chan et al and Huang and colleagues used KAPA 2G 
DNA Polymerase to great effect, so an aliquot of this was purchased for 
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experimentation (Chan et al., 2015; Huang et al., 2015). Gradient PCR reactions using 
both primer pairs can be seen in figure 26.  
 
Figure 26. A 2% Agarose Gel of gradient PCR comparing primer pairs and the KAPA 2G polymerase. 
Nonespecific PCR products and smearing was noted using the Short Tert primer pair 
(top panel). Fewer problems were observed with the F3R3 primers (lower panel) and 
annealing at 60℃ gave a consistently good PCR product. A more focused gradient PCR 
reaction was undertaken and can be seen in figure 27. 
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Figure 27. An abbreviated 2% Agarose Gel of a focused gradient PCR comparing primer pairs using the KAPA 2G 
polymerase. 
The strongest band was consistently found when combining the Tert F3R3 primer pair 
(bottom panel) and annealing at 60.1 Celsius, giving a PCR product size of just under 
200 base pairs in size. Hence reaction conditions for sequencing were set using 60 
Celsius, F3R3 primers and the KAPA 2G polymerase. 
3.1.3 Results from MacVector 
Once the reaction conditions were determined, large-scale processing was undertaken to 
ensure DNA from all samples were sequenced. Once the reactions had been undertaken, 
gels run, PCR product purified, a specific mass of PCR product, in addition to either a 
forward or reverse primer, and sent for Sanger sequencing there was a repository of 
sequence data available for interpreting. MacVector software was used to analyse files 
in the “.ab1” format.  
3.1.3.1 Survivin Promoter 
3.1.3.1.1 Quality Assurance 
Visual inspection of chromatograms was necessary to ascertain the quality, or 
otherwise, of the sequence data generated. Examples of both high and low-quality 
sequence data can be seen in figure 8.  
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To ensure the sequences were accurate enough for further assessment, the BLAST 
search function of MacVector was used which facilitated the comparison of the ‘Query’ 
(PCR product) with the NCBI database, as shown in figure 28.  
 
Figure 28. Output data from MacVector software comparing the PCR product ‘Query’ to the NCBI reference 
database ‘Subject’. The single error is during an AA base repeat otherwise giving 103/104 bases in sequence (>99% 
accurate) that is recognised as homologous to Human Survivin (gene: BIRC5). 
Each chromatogram was visually inspected to ensure further analysis was appropriate. 
A small number of initial sequences were fully assessed using the BLAST assessment 
tool and have been populated to give the table 24.  
Sample PCR Product Size Sequence Orientation Ref Seq Result 
F7a 103 Forward >99% (103 of 104) 
R7a 101 Reverse 99% (99 of 100) 
F7b 106 Forward >98% (102 of 104) 
R7b 103 Reverse 99% (99 of 100) 
F8a 99 Forward 98% (98 of 100) 
R8a 99 Reverse 99% (99 of 100) 
F8b 103 Forward 98% (98 of 100) 
R8b 101 Reverse 98% (98 of 100) 
F9b 106 Forward >99% (103 of 104) 
R9b 101 Reverse 100% (100 of 100) 
F11b 107 Forward >99% (103 of 104) 
R11b 101 Reverse 100% (99 of 99) 
F11c 107 Forward >99% (103 of 104) 
R11c 101 Reverse 100% (100 0f 100) 
Table 24. Forward (F) and reverse (R) sequences from early results (study sample numbers 7-11) are compared to a 
reference database for Survivin PCR products. The reference sequence ‘Ref Seq’ result demonstrates the percentage 
of sequence homology between PCR product and the reference database. 
Generally, there was excellent agreement between the PCR product and the reference 
database, with the majority of cases giving >98% sequence homology.  
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A green bar above a sequence position means a Phred quality score >20 (i.e., <1/100 
chance of an error) whilst a red bar above a number indicates a higher (>1/100) chance 
of an error occurring when assigning a base – see below.  
3.1.3.1.2 Finding the ROI 
The sequence was assessed by ensuring an appropriate level of quality based on the 
Phred-called chance of an error – see below. Once sequences were deemed an 
acceptable level of quality, the region of interest was found using the search function on 
MacVector. For Survivin this was TCGC_GGA in the forward sequence and 
GTCC_GCG for the reverse direction with the underscore representing the -31 position 
of interest. Only when there was complementary agreement (i.e., C in the forward and 
G in reverse) would the status of the -31 position be ascertained.  
3.1.3.1.3 Example Sequences 
Chromatograms in figure 29 show a black waveform for G nucleotides (GG 
homozygote, top of image) a blue for C (CC homozygote, bottom image) and both a 
black and a blue waveform for the CG heterozygote (middle of fig 29). As can be seen 
in all three chromatograms, there is evidence of poor-quality data at the start of the 
sequence – as shown by the red bars (>1% chance of error) up to the ~10th base in 
sequence. The addition of the 18 bases from the universal primer at the 5’ sequence 
upstream of the F1R1 primer would have neatly removed this error-prone region. 
However, it was not technically feasible as the efficiency of the PCR reactions 




Figure 29. Chromatograms of forward sequences around the Survivin -31C/G position. 
Chromatograms at the top (GG homozygote, position 32), middle (CG heterozygote, 
position 33) and bottom (CC homozygote, position 35) are seen in figure 29. The green 
bars over the sequence number indicates the ‘phred’ base-calling accuracy in 
measurement, with an assumed error rate of <1%. When a red bar is seen (as in the case 





3.1.3.2 Telomerase Promoter 
Telomerase sequencing reactions were processed after all the data regarding the 
Survivin -31G>C was known. This delay meant access to the MacVector software was 
re-purchased as the annual subscription had elapsed. 
3.1.3.2.1 Quality Assurance 
Regrettably an update to the software meant the BLAST sequence analysis tool did not 
function as previously described for the Survivin sequences. These original Survivin 
sequences were re-run and gave the same non-interpreted reading, as given for the new 
Telomerase sequences, as the software stalled. An example of this error can be seen in 
fig 30. 
 
Figure 30. Analysis of the forward sequence from the Telomerase PCR products sample 144b using the ‘.ab1’ 
format. 
However, the Telomerase promoter sequences generated were generally a lot cleaner 
than those for Survivin, with significantly better base-calling ability when viewing the 
“.ab1” files. The ‘phred’ base call numerical values (denoted by the green box above the 
base) consistently gave quality scores >30 (i.e., 0.1% chance of error, 99.9% accurate) 
and regularly gave readings of 50 (0.001% error or 99.999% accurate) or more. An 
example of the quality assessment taken from a chromatogram report from the forward 
sequence of 144b is shown in table 25.  
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Chromatogram Raw Data report for 144b 
 Index 
Position  Base 
Phred 
Quality 
26   C 52 
27   C 45 
28   C 40 
29   G 40 
30   G 52 
31   G 52 
32   T 52 
33   C 32 
34   C 32 
35   C 32 
36   C 45 
37   G 45 
38   G 45 
39   C 52 
40   C 40 
41   C 45 
42   A 40 
43   G 45 
44   C 52 
45   C 55 
46   C 55 
47   C 52 
48   C 52 
49   T 45 
Table 25 Sequences from the Telomerase promoter were of significantly higher quality, as measured by the ‘phred 
quality’ given by the MacVector software. 
Shorter sequences of the PCR products were used as input queries on the BLAST search 
engine. The areas searched contained both of the positions of interest (-124 and -146) to 
ensure WT/mutational status was adequately checked (see below). An example of 












Ref Seq Result Duration of Search 
(minutes) 
96a 20 -55 (36) Forward 100% (36/36) 38 
96a 70 – 110 (41) Reverse 100% (41/41) 32 
137b 20 -55 (36) Forward 100% (36/36) 25 
137b 70 – 110 (41) Reverse 100% (41/41) 29 
112b 20 -55 (36) Forward 100% (36/36) 25 
112b 70 – 110 (41) Reverse 100% (41/41) 40 
144b 20 -55 (36) Forward 100% (36/36) 30 
144b 70 – 110 (41) Reverse 100% (41/41) 34 
146a 20 -55 (36) Forward 100% (36/36) 4 
146a 70 – 110 (41) Reverse 100% (41/41) 33 
Table 26.Telomerase PCR products from samples are shown alongside their regions of interest, sequence orientation 
and the Ref Seq result (accuracy) are shown alongside the duration of the search of the NCBI database. 
Assessing these shorter sequences still took some considerable time but confirmed 
primers had amplified the correct target DNA. Examples of these BLAST searches can 
be seen in figure 31. 
 
Figure 31. BLAST sequences for the Telomerase promoter are compared to NCBI reference  
Figure 31 shows sample 112b with forward (upper image) and reverse (lower image) 
sequences confirming 100% homology. 
3.1.3.2.2 Finding the ROI	
The region of interest for the Telomerase promoter was different from that of Survivin 




Target Forward Sequence Reverse Sequence 
-124 AGCCCC_TCCGGGCC CCCGGA_GGGG 
-146 ACCCCT_CCGGGT ACCCGG_AGGGG 
Table 27 Forward and reverse sequences for the mutational, or wild type, signatures in the Telomerase promoter 
region. 
The mutational hotspots in the forward sequences tended to be roughly in the region of 
position 30 (-146) and 50 (-124) and for the reverse orientation around 80 (-124) and 
100 (-146). The raw sequence data was searched using the targets outlined in table 27. 
The same approach of using the search function to find the regions of interest, whilst 
making a simultaneous quality assessment based on the Phred score, that has previously 
been adopted was used to ensure accuracy of base-calling of the neighbouring bases. 
3.1.3.2.3 Example Sequences 




Figure 32. Chromatograms of Telomerase promoter regions, as visualised on MacVector.  
A wild type promoter sequence is shown in the top sequence of figure 32, with blue C 
waveforms, with heterozygous CT alleles in the -124 (middle sequence, position 51) 
and the -146 position (bottom sequence, position 29).  
3.2 Interpreting Promoter Status  
Repeat experiments of either failed/un-interpretable runs were undertaken, maximising 
the data available for interpretation. Once as many sequences as possible were known, 
given the previously described limitations of using poor quality DNA, the un-blinding 
process was undertaken. On the rare occasions that repeated reactions yielded no 
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results, the unblinding process allowed these troublesome samples to be identified and a 
repeat cycle of randomisation, DNA retrieval, PCR reactions/analysis to be undertaken. 
The DNA was sometimes retrieved from the same block, or another tumour block to 
maximise the samples being studied. It was also relatively common that the background 
liver tissue block was either already, or was very nearly, exhausted due to the extensive 
IHC assessment of the liver tissues for the diagnostic work-up. When there was no 
background liver tissue available for research, only tumour samples were assessed. 
3.2.1 Survivin Promoter 
Excluding repeats, DNA from 261 samples underwent amplification with bi-directional 
confirmation of sequence in 254 samples (97.3%). This larger cohort includes the 
extrahepatic CCA. Of the 7 samples withdrawn from further analysis, one was 
withdrawn from the study as it is a spindle cell Cholangiocarcinoma and 6 others failed 
repeated attempts at PCR amplification. 
When dCCA were excluded from analysis, sequences from 234 individual samples were 
attempted with 5 withdrawn from consideration (the spindle cell CCA and 4 that could 
not be amplified successfully) giving a similar sequencing success rate of 97.8% 
(229/234) across samples. The 4 failed samples were all from tumour tissues.  
The Survivin promoter SNPs were fully concordant between background and tumour 
samples across all sequenced samples. This germline characteristic can be seen in 
figures 33-36. This is a surprising finding as it was expected that the -31 promoter SNP 
would mutate from WT in the background tissue. The pSurv CG heterozygotes (purple 
background), GG homozygotes (green background) and CC homozygotes (blue 
background) are highlighted in tumour (T) and background (BG) liver samples in 




























pSurv SNP CG CG CG CG CG CG CG CG CG CG CG CG 
Background/ 
Tumour T BG T BG T T BG T BG T T BG 

























































pSurv SNP CG CG CG CG CG CG GG GG GG GG GG GG GG GG GG GG GG GG GG GG 
Background/ 
Tumour T BG T BG BG T T BG BG T BG T BG T BG T T BG BG T 




Figure 35. Survivin -31G/C alleles in Hepatocellular carcinoma and background liver. 

















































The minor allele frequency for the -31G>C (rs9904341) Survivin promoter for C has 
been reported as between 0.31 – 0.47 (Allele Frequency rs9904341 - SNP - NCBI, 
2020). From all samples sequenced in this cohort the minor allele frequency for C is 
0.33, which is within these previously described limits. 
3.2.2 Telomerase Promoter 
For the Telomerase promoter, excluding repeats, DNA from a total of 271 individual 
tissues was retrieved. Five samples were withdrawn from this pool, comprising the 
spindle cell CCA and 4 samples with inconclusive results. Results were deemed 
inconclusive when there was a lack of agreement between bi-directional sequences. 
Therefor a total of 266 sequences (98.5%) of the original cohort of all liver neoplasms 
(i.e., including the extrahepatic CCA) were recorded. When the dCCA were excluded 
(leaving n=243), bi-directional sequences were taken from 98.8% (240/243) of samples 
processed. When more than one tumour sample was processed, a positive result was 
recorded if either tumour contained the -124/-146 mutation – with interesting inter and 
intra-tumoural heterogeneity that will be discussed below. 
The telomerase promoter mutations were absent in all background tissues and only 
present in tumour samples of hepatocellular lineage. Intriguingly, there were no 
pTERTMuts in any Cholangiocarcinoma or Adenomas studied. All mutations were 
heterozygous, in agreement with the published literature (Cevik, Yildiz and Ozturk, 
2015; Bell et al., 2016). The pTERTMuts status of all neoplasms has been outlined in 
table 28. 
Tumour WT (%) Mutant (%) 
Hepatocellular Carcinoma 40 (69%) 18 (31%) 
Cholangiocellular Carcinoma 36 (100%) 0 (0%) 
Mixed HCC-CCA 6 (86%) 1 (14%) 
Adenoma 10 (100%) 0 (0%) 
Table 28. Telomerase promoter mutation rates across the primary hepatic neoplasms studied. 
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With 31.0% (18/58) of HCCs containing a pTERT mutant, this is similar to other 
reported mutation rates of 30-60% (H. W. Lee et al., 2017; Nault et al., 2019). For the 
purposes of simplification, HCC has included fibrolamellar HCC in the reported 
numbers in table 28 as one FL-HCC that contained a -124 promoter mutation (C228T). 
Should comparisons exclude FL-HCC, then similar rates (32.1%, 17/53) of pTERT are 
mutated in traditional HCCs.  Of the 19 pTERTMuts found, 17 (89.5%) were in the -124 
position with 2 (10.5%) in the -146 position (C250T), in similar proportions to 
previously described (Nault et al., 2013). Both mutations in this hotspot region were 
mutually exclusive, also in agreement with previous results (Vinagre et al., 2013; Jiao et 
al., 2018).  
The pTERTMuts in various neoplasms can be viewed in figures 37 - 40 with -124/ -146 
mutants highlighted by a red/green box respectively in tumour (T) and background 
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Figure 39. Telomerase promoter mutations in Hepatocellular carcinomas. 

















































It was relatively common for there to be more than one tumour in the HCC-liver 
resections. When more than one tumour was present within the resected tissues, or when 
there were two whole tumour blocks from a single patient, every effort was made to 
retrieve DNA and sequence the Telomerase promoter regions in these cases. 
Regrettably this was somewhat limited by some blocks being absent from the archive, 
but in 13 of the 52 HCCs it was possible to undertake this dual-sequencing. The results 
from available samples can be seen in figure 41.  
 
Figure 41. Intra-tumoural and inter-tumoural heterogeneity in tumour samples from 13 patients. 
After initial difficulty sequencing tumour DNA from samples 24 & 116, tissue curls 
from a second tumour block were taken simultaneously when re-cutting the original 
tumour block. Somewhat surprisingly, intra-tumoural heterogeneity was found in these 
double-sequenced samples with both containing a WT and -124 pTERT mutation. An 
implication of this sampling bias being that the reported mutation rate may be higher 
than the 31% reported here, assuming satisfactory accuracy in the amplification and 
sequencing technique used. 
Intriguingly, inter-tumoural heterogeneity was found in samples 7, 14, 19, 42 and 143 
whilst samples 8, 13, 30, 39, 140 and 145 only contained pTERTWT.  
3.3 Statistical Analysis of Results 
Statistical analysis was performed using IBM SPSS Statistics 24. Correlation between 
promoter status and clinical parameters were examined using Pearson’s Chi squared test 
when there were >2 categorical dependent/independent variables. When both variables 
were nominal, Fishers exact test was used. The level of significance was set as 0.05 and 
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exact significance (two sided) been used throughout, with the Bonferroni method used 
to adjust p-values when comparing column proportions. 
Overall survival was defined as the time from the operation and death, or last follow up 
set to 6th January 2020. Survival curves were plotted using Kaplan-Meier method and 
analysed with the Log-rank test.  
Comparison between two groups was performed with the Mann-Whitney U-test as the 
outcome data was quantitative and non-normally distributed. Comparisons between 
three or more groups used the Kruskal-Wallis one-way analysis of variance (ANOVA) 
test for similar reasons. A P-value of <0.05 (two sided) was considered statistically 
significant.  
3.3.1 Survivin Promoter 
Pooled analysis of the results from the Survivin promoter sequencing across all 
neoplasia can be seen in table 29.  
 140 
pSurv: All Neoplasms N CC CG GG P-value 
Gender Female 44 3 22 19 0.954 
Male 65 5 34 26 
Outcome Alive 51 4 25 22 0.914 
Dead 58 4 31 23 
Fibrosis Absent 65 5 30 30 0.489 
Present 43 3 25 15 
Cirrhosis Absent 86 6 39 41 0.042 
Present 22 2 16 4 
Viral Status No Infection 94 6 47 41 0.342 
Viral Hepatitis 15 2 9 4 
Metabolic Risk 
Factors 
- 56 5 29 22 0.835 
+ 53 3 27 23 
Genetic Liver 
Disease 
- 99 8 52 40 0.609 
+ 10 0 5 5 
Tumour Type HCC 50 4 23 23 0.109 
FL-HCC 6 1 2 3 
CCA 36 3 21 12 
Mixed HCC-CCA 7 0 7 0 
Adenoma 10 0 3 7 
Table 29. Across all neoplasms studied, clinical measures are compared with alleles for the Survivin -31G/C.  
When considering all neoplasms studied, the only statistically significant finding was 
that that fewer cirrhotic patients were GG homozygotes. Survivin alleles with GG 
homozygotes: 18.2% (4/22) have background liver cirrhosis, compared to 47.7% 
(41/86) of non-cirrhotically-derived liver tumours. In the CG heterozygotes, 72.7% 
(16/22) of the cirrhotics were CG heterozygotes compared with 45.3% (39/86) of the 
non-cirrhotics, ꭓ² (2) = 6.341, p= 0.042. None of the other clinical measure differed 
significantly between Survivin promoter alleles. 
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3.3.1.1 All Malignancies 
When excluding the benign adenomas, comparisons between clinical and pathological 
characteristics and the pSurv alleles can been seen in table 30. There were no significant 
results. Viral hepatitis, metabolic risk factors and genetic liver disease also failed to 
demonstrate any significant differences and have not been shown in table 30.  
pSurv: Malignancies N CC CG GG P-value 
Gender Female 35 3 20 12 0.900 
Male 64 5 33 26 
Outcome Alive 41 4 22 15 0.863 
Dead 58 4 31 23 
Margin R0 57 5 29 23 0.741 
R1 41 3 24 14 
Fibrosis Absent 58 5 28 25 0.519 
Present 40 3 24 13 
Cirrhosis Absent 76 6 36 34 0.078 
Present 22 2 16 4 
Tumour 
Stage 
I & II 65 4 38 23 0.258 
III & IV 25 4 11 10 
Grade Well Diff 11 0 7 4 0.396 
Mild/Mod Diff 65 8 33 24 
Poorly Diff 17 0 11 6 
Vascular 
Invasion 
No VI 42 3 24 15 0.861 
VI 51 5 27 19 
+ 10 0 5 5 
Tumour Type HCC 50 4 23 23 0.168 
FL-HCC 6 1 2 3 
CCA 36 3 21 12 
Mixed HCC-CCA 7 0 7 0 
Table 30. Across all malignancies studied, clinical measures are compared with alleles for the Survivin -31G/C.  
A non-significant difference in the distribution of GG homozygotes in the non-
cirrhotic/cirrhotic groups is demonstrated in table 30. Nearly 20% of tumours (4/22, 
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18.2%) that develop in the context of cirrhosis are GG homozygotes, compared to 
44.7% (34/76) of malignancies from non-cirrhotic livers, ꭓ² (2) = 5.200, p= 0.078. 
When comparing Survivin promoter variants across tumour type, 46.0% (23/50) of 
HCCs, 33.3% (12/26) of CCAs and 0.0% (0/7) of Mixed tumours contain GG 
homozygotes, ꭓ²(6) = 8.974, p= 0.168.  
3.3.2 Survivin Promoter & Tumour Subtype 
3.3.2.1 HCC+FL-HCC 
There were no associations found between clinical measures and -31G/C Survivin 
promoter genotypes in either the grouped HCC + FL-HCC, as outlined in table 31, or 
HCC subgroups (data not shown). The analysis of pSurv and corresponding 
subgrouping of alleles does not yield any significant correlations with clinical disease in 
all HCCs.  
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pSurv: HCC & FL-HCC N CC CG GG P-value 
Gender Female 13 2 6 5 0.651 
Male 43 3 19 21 
Outcome Alive 28 3 13 12 0.859 
Dead 28 2 12 14 
Margin R0 39 4 16 19 0.619 
R1 16 1 9 6 
Fibrosis Absent 31 3 13 15 0.923 
Present 25 2 12 11 
Cirrhosis Absent 41 3 16 22 0.212 
Present 15 2 9 4 
Tumour 
Stage 
I & II 31 1 15 15 0.093 
III & IV 18 4 8 6 
Grade Well Diff 10 0 6 4 0.645 
Mild/Mod Diff 36 5 16 15 
Poorly Diff 6 0 3 3 
Vascular 
Invasion 
No VI 31 2 15 14 0.772 
VI 21 3 10 8 
Table 31. Across all HCC subtypes studied, clinical measures are compared with alleles for the Survivin -31G/C.  
Most HCCs were stage I/II and CC homozygotes comprised 3.2% of these tumours, 
however of the 18 stage III/IV HCCs the CC allele accounted for 22.2% of these, ꭓ² (2) 
= 4.667, p= 0.093. Otherwise, no significant difference in the distribution of alleles was 
found when comparing clinical parameters.  
3.3.2.2 Cholangiocarcinoma & pSurv 
As there were no pTERTMut in Cholangiocarcinoma, the analysis of promoter sequences 
was limited to pSurv. I found no significant correlations when comparing pSurv and 
clinically recorded data, as outlined in tables 32. Subgroup analysis, including the effect 
of dominant alleles (data not shown) also failed to find any significant difference 
between clinical parameters.  
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Unique to CCA tumours is the presence (or otherwise) of perineural invasion as well as 
the location (iCCA vs. pCCA) that has been routinely reported upon in the clinical 
records. However, there was no significant distribution in the alleles of the Survivin 
promoter SNP when considering any clinical parameter. When the iCCAs were 
assessed, there was also no difference in the distribution of the pSurv alleles, data not 
shown. 
pSurv: CCAs N CC CG GG P-value 
Gender Female 20 1 12 7 0.774 
Male 16 2 9 5 
Outcome Alive 12 1 8 3 0.862 
Dead 24 2 13 9 
Margin R0 12 1 7 4 1.000 
R1 24 2 14 8 
Fibrosis Absent 26 2 14 10 0.885 
Present 9 1 6 2 
Cirrhosis Absent 34 3 19 12 1.000 
Present 1 0 1 0 
Tumour 
Stage 
I & II 27 3 16 8 0.359 
III & IV 7 0 3 4 
Grade Well Diff 1 0 1 0 0.685 
Mild/Mod Diff 24 3 12 9 
Poorly Diff 9 0 6 3 
Vascular 
Invasion 
No VI 8 1 6 1 0.308 
VI 26 2 13 11 
Perineural 
Invasion 
- 18 2 12 4 0.446 
+ 18 1 9 8 
Table 32. Across all CCAs studied, clinical measures are compared with alleles for the Survivin -31G/C.  
3.3.2.3 Mixed 
As all seven of the mixed tumours were found to be CG heterozygotes, statistical 
analysis of differences in clinical/pathological findings was unable to be undertaken. 
 145 
3.3.2.4 Adenoma 
The benign adenomas clearly did not possess malignant behaviours (vascular invasion, 
stage, grade, etc) and so these inappropriate measures have been removed from the 
comparisons outlined in tables 33. There were also no CC homozygotes in the studied 
tumours, meaning the results are essentially the same and that comparing CC to 
CG+GG is not possible.   
 
Table 33. Clinical measures are compared in the Adenomas, depending on the Survivin -31G/C alleles. 
3.3.3 Discussion 
With the surprising result of 100% concordance between tumour and background liver 
tissues for Survivin’s rs9904341 across all samples there was a distinct lack of clinically 
meaningful correlations subsequent to this. The status of the Survivin -31 SNP should 
be considered a germline characteristic, rather than a somatically altered mutation that 
facilitates tumourigenesis.  
When the pooled results were interpreted the single statistically significant result is the 
Survivin GG homozygote occurring more often in non-cirrhotic livers that facilitated 
the growth of both benign and malignant neoplasms (p=0.042). When considering all 
malignant tumours, and their pSurv status, the distribution of GG tumours did not differ 
between cirrhotic and non-cirrhotic liver tissues, ꭓ² (2) = 5.200, p= 0.078.  
The significance these results is of limited value in this small cohort of patients. The 
GG allele did not correlate with any tumour type across all neoplasms (p= 0.109) or in 
the malignant cohort, p= 0.168. Given that GG homozygous patients have previously 
been shown to be associated with an increased risk of solid organ malignancy (in 
N CC CG GG P value
Female 9 0 2 7
Male 1 0 1 0
Absent 7 0 2 5
Present 3 0 1 2
+ 8 0 2 6








NSCLC at least) my findings should not be overstated, rather interpreted with caution 
(Aynaci et al., 2013). 
Otherwise, the Survivin promoter SNPs did not correlate with any other clinical or 
pathological characteristic that was measured.  Analysing Survivin promoter status in 

















3.3.4 Telomerase Promoter 
Given the more straightforward results from the pTERT sequences (heterozygous 
mutation or WT only) statistical analyses were more limited when compared to pSurv as 
can be seen from table 34. For the purposes of data analysis both the -146 and -124 
mutations were reported together as a ‘mutant’, in line with previous publications (Horn 
et al., 2013; Huang et al., 2013). 
pTERT: All Neoplasms N Mutant WT P value 
Gender Female 45 1 44 0.001 
Male 66 18 48 
Outcome Alive 51 6 45 0.210 
Dead 60 13 47 
Fibrosis - 66 6 60 0.009 
+ 44 13 31 
Cirrhosis - 87 10 77 0.004 
+ 23 9 14 
Viral Hepatitis - 96 14 82 0.131 
+ 15 5 10 
Metabolic Risk 
Factors 
- 57 8 49 0.453 
+ 54 11 43 
Genetic Liver 
Disease 
- 101 17 84 0.680 
+ 10 2 8 
Tumour Type HCC 35 17 52 0.002 
FL-HCC 6 1 5 
CCA 36 0 36 
Mixed HCC-
CCA 
7 1 6 
Adenoma 10 0 10 
Table 34. Clinical measures are compared between mutants and wild type Telomerase promoter across all 
neoplasms.  
From table 34 there are a few interesting correlations to report when considering 
Telomerase promoter mutations across the whole study cohort. Of the 19 pTERTMuts 
present, 18 occurred in men. Mutations occurred more often in 27.3% of men’s cancers 
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compared to 2.2% of female patients, p= 0.001. There were more pTERTMuts that grew 
on a background of fibrosis (29.5%) compared to non-fibrosis-derived liver tumours 
(9.1%, p= 0.009). Perhaps indicating a correlation with early tumour development. 
Telomerase promoter mutations also occurred more frequently in the context of 
background liver cirrhosis (39.1%) compared to non-cirrhotically derived liver tumours 
(11.5%, p= 0.004). Finally, pTERTMuts appear to be an HCC-lineage specific mutation, 
with 17/19 occurring in HCCs (ꭓ² (4) = 18.432, p= 0.002), one case occurring in FL-
HCC and the final pTERTMuts being in a mixed HCC-CCA tumour. There were no 
pTERTMuts in either the CCAs or the Adenomas in this cohort. There was no difference 
in the distribution of the clinical parameters: viral hepatitis (p= 0.131), metabolic 
disease (p= 0.453) and genetic liver disease (p= 0.680) so these parameters will not be 
discussed further.  
When excluding benign adenomas from consideration, pTERTMuts occur more often in 
men (27.7%) compared to women (2.8%, p= 0.001). Across all malignancies pTERTMuts 
occurs in 31.7% of patients with liver fibrosis compared with 10.2% in non-fibrotic 
hepatic tissue, p= 0.01. Non-cirrhotic livers yield tumours with pTERTMuts in 13.0% of 
cases compared to 39.1% of cirrhotic livers (p= 0.012).  
Across all malignancies, pTERTMuts occur more frequently in HCCs compared with 
CCA and Mixed tumours (ꭓ² (3) = 15.013, p= 0.003). However, in the malignant cohort 
there was no significant correlation with all-cause mortality, positive surgical margin, 
tumour stage/grade or vascular invasion. Risk factors such as viral hepatitis, metabolic 
risk factors or genetic liver disease also failed to demonstrate any correlation with 
pTERTMuts. When excluding the benign neoplasms, table 35 highlights the results from 
the pooled analyses.  
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pTERT: All Malignancies N Mutant WT P value 
Gender Female 36 1 35 0.001 
Male 65 18 47 
Outcome Alive 41 6 35 0.444 
Dead 60 13 47 
Margin R0 58 14 44 0.196 
R1 41 5 36 
Fibrosis - 59 6 53 0.01 
+ 41 13 28 
Cirrhosis - 77 10 67 0.012 
+ 23 9 14 
Tumour Stage I & II 65 9 56 0.221 
III & IV 26 7 19 
Grade Well Diff 11 2 9 0.401 
Mild/Mod Diff 66 14 52 
Poorly Diff 17 1 16 
Vascular 
Invasion 
- 42 7 35 0.794 
+ 52 10 42 
Tumour Type HCC 35 17 52 0.003 
FL-HCC 6 1 5 
CCA 36 0 36 
Mixed HCC-CCA 7 1 6 







3.3.5 Tumour Specific Analyses 
With pTERT found almost exclusively in HCCs, subgroup analysis of all HCCs (i.e., 
including FL-HCC, table 36) and traditional HCCs (excluding FL-HCCs, table 37) was 
undertaken.  
pTERT: HCC & FL-HCC N Mutant WT P value 
Gender Female 14 0 14 0.003 
Male 44 18 26 
Outcome Alive 28 5 23 0.049 
Dead 30 13 17 
Margin R0 40 13 27 1.000 
R1 16 5 11 
Fibrosis - 32 6 26 0.044 
+ 26 12 14 
Cirrhosis - 42 10 23 0.066 
+ 16 8 8 
Tumour 
Stage 
I & II 31 8 23 0.528 
III & IV 19 7 12 
Grade Well Diff 10 2 8 0.519 
Mild/Mod Diff 37 13 24 
Poorly Diff 6 1 5 
Vascular 
Invasion 
- 31 6 25 0.068 
+ 22 10 12 
Table 36. Clinical measures are compared between mutants and wild type Telomerase promoter sequences across all 
HCCs.  
Table 36 reports pTERTMuts in HCC & FL-HCC showing a strong male predominance 
with 40.9% of men harbouring a mutation compared with 0.0% of women, p= 0.003. 
There is also a weaker, although still significant, association with fibrosis (46.2% of 
tumours that arise in the context of fibrosis yield pTERTMuts compared with 18.8% of 
 151 
non-fibrotically derived tumours, p= 0.044. It’s interesting that the highest rate of 
finding pTERTMuts in HCCs is in those with fibrotic liver disease as it maybe the 
aetiology of HCC is different in those with a chronic liver disease with a longer duration 
giving more time for the mutation to emerge and predispose to HCC. The inter-
relationship between cirrhosis and pTERTMuts is less certain as 50.0% of cirrhotics have 
a mutation, compared with 23.8% of non-cirrhotic patients, p= 0.066.  
There is also a new association with all-cause mortality as 43.3% of those who die have 
a pTERTMuts compared with 17.9% of those who live, p= 0.049. However, this finding 
is of marginal significance given the smaller study numbers and the relatively large p-
value.  
All other clinical and histopathological characteristics did not demonstrate a significant 
difference between the pTERTMut/WT groups. Vascular invasion occurs more often 
(although non-significantly so) in 45.5% of tumours with pTERTMuts, compared with 
19.4% of non-mutated tumours, p= 0.068.  
When FL-HCC are excluded and traditional HCC’s pTERTMuts status is assessed, the 
results are shown in table 37. Mutations occur in 42.7% of male patients, compared with 
0.0% of females, p= 0.005. Of those who have died, 44.8% harbour a pTERTMuts 
containing tumour, compared with 17.4% of patients still alive, p= 0.043. Tumours that 
invade the vasculature have a higher pTERTMuts rate (52.6%) compared with non-
invasive tumours (20.17%, p= 0.031).  
In classical HCCs pTERTMuts occur in the context of fibrosis in 46.2% of patients, 
compared with 19.2% of those with non-fibrotic liver tissue, p= 0.075. And cirrhotics 
have a pTERTMuts rate of 50.0%, compared with 25.0% in non-cirrhotics, p= 0.111. 
Both of these previous measures were significantly associated with pTERTMuts, but in 
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the smaller sample size these are no longer significantly correlated, albeit with a 
convincing trend for pTERTMuts occurring in the context of fibrosis. 
pTERT: HCC only N Mutant WT P value 
Gender Female 12 0 12 0.005 
Male 40 17 23 
Outcome Alive 23 4 19 0.043 
Dead 29 13 16 
Margin R0 36 12 24 1.000 
R1 14 5 9 
Fibrosis - 26 5 21 0.075 
+ 26 12 14 
Cirrhosis - 36 9 27 0.111 
+ 16 8 8 
Tumour 
Stage 
I & II 29 8 21 0.516 
III & IV 17 7 10 
Grade Well Diff 8 2 6 0.689 
Mild/Mod Diff 35 13 22 
Poorly Diff 5 1 4 
Vascular 
Invasion 
- 29 6 23 0.031 
+ 19 10 9 
Table 37. Across traditional HCCs, clinical measures are compared between mutants and wild type Telomerase 
promoter sequences. 
3.3.5.1 Mixed 
In the small cohort of seven mixed tumours there were no significant relationships 
between clinical or pathological data and the pTERTMut. This is perhaps due, at least in 
part, to the small number of mixed tumours studied.   
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3.3.6 Discussion 
My results demonstrate that pTERTMuts are an HCC-lineage specific somatic mutation 
(p= 0.001), are associated with male gender (p=0.001), and adverse clinical measures 
when compared across the entire study cohort. When comparing malignant liver 
tumours pTERTMuts remain a male phenomenon (p= 0.001), occur more frequently in 
HCCs (p= 0.002), occur more frequently in the context of fibrotic (p= 0.01) and 
cirrhotic (p= 0.012) background liver tissues. Previously published data has also 
reported an absence of pTERTMuts in CCA, in agreement with our findings (Quaas et al., 
2014).  
The role of chronic inflammation selecting for pTERTMuts in malignancies is only 
significant when considering the whole tumour cohort and not in tumour sub-type 
analyses. This is possibly a reflection of the selection bias in patients offered surgery 
(fewer than expected patients with cirrhosis) or the small cohort of patients being 
studied. This aetiology of PLCs must also be considered with the established links 
between fibrosis, cirrhosis and HCC development compared to the much more sporadic 
neoplastic nature of CCAs. These differences could potentially explain how some 
correlations are apparent when considering larger groups (all hepatic 
neoplasms/malignancies and all HCC subtypes) but are absent when only considering 
classical HCCs. As fibrolamellar HCCs are histologically and genetically very different 
to traditional HCCs comparisons have been made assessing if there are differences 
when FL-HCCs are included/excluded. However, when comparing all HCC subtypes 
(including FL-HCC) there is a significant relationship between pTERTMut and fibrosis 
(p=0.044), but no significant relationship with tumourigenesis in the context of cirrhotic 
liver tissues, p= 0.066. Furthermore, when assessing all HCCs the male association 
endured (p= 0.003) as did the correlation with all-cause mortality, p= 0.049.  
 154 
When FL-HCC tumours are excluded, an HCC tumour specific analyses confirms the 
strong male association with pTERTMuts (p=0.005) and demonstrates weak, albeit 
statistically significant, correlations with vascular invasion (p= 0.031) and all-cause 
mortality (p= 0.043).  
Male preponderance of pTERTMuts has been previously reported in HCCs but no 
significant correlation for vascular invasion was reported in their cohort (Nault et al., 
2013). Work from a Korean cohort larger than ours (but still using FFPE tissues as a 
DNA source) have found pTERTMuts preferentially occurring in men (p= 0.027) and in 
28.8% of HCCs (H. W. Lee et al., 2017).  
When considering non-hepatic tumours, pTERTMuts have been associated with adverse 
clinical measures including vascular invasion in a recent meta-analysis of 11,382 cases 
of thyroid carcinoma (Yang et al., 2020). My work has increased the number of HCCs 
under study and also shown a similar association, indicating altered tumour biology 
based on a promoter mutation. 
3.3.7 Comparisons between Groups 
The continuous variables of age (years) and tumour size (mm) were recorded with 
comparisons made between promoter status overall, and at the level of tumour subtype. 
3.3.7.1 All Neoplasms 
No significant relationships were found between pSurv/ pTERT status and age or 
tumour size across all neoplasms, as outlined in table 38.  
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pSurv CC 8 51.0 59.5 +/- 19.2 67.5 54.4 66.6 +/- 37.6 55.0 
CG 56 56.0 62.6 +/- 12.9 64.0 56.6 78.3 +/- 53.1 70.0 
GG 45 54.4 59.8 +/- 15.8 63.0 53.1 72.5 +/- 46.1 60.0 
ꭓ²(2)  0.205  0.296  
p-value 0.903 0.862 
 
pTERT WT 92 58.4 77.8 +/- 48.0 63.0  53.4 60.0 +/- 14.8 63.0 
Mut 19 44.4 64.0 +/- 59.3 45.0 68.4 66.8 +/- 11.7 69.0 
U  653.0  1100.0  
p-value 0.083 0.065 
Table 38. For all neoplasms, clinicopathological characteristics are analysed based on the promoter mutational 
status of pSurv and pTERT.  
When comparing all neoplasms, a Kruskal-Wallis test showed that there was no 
significant difference in tumour size based on the Survivin promoter variants, ꭓ²(2) = 
0.205, p= 0.903, with mean rank scores of 51.0 for the CC homozygote, 56.0 for the CG 
heterozygote and 54.4 for the GG homozygote. Similarly, there was no significant 
difference in patient age based on the Survivin promoter variants, ꭓ² (2) = 0.296, p= 
0.862, with a mean rank of 54.4 (CC), 56.6 (CG) and 53.1 (GG).  
A Mann-Whitney U test demonstrated that pTERTMuts tended to occur in smaller 
tumours (median size 45mm, mean rank 44.37) compared to wild type (median size 
63mm, mean rank 58.4) but this was not a significant difference, U= 653.0, p= 0.083. 
With a median age of 69 years (mean rank 68.4) pTERTMuts tended to develop in 
develop in older patients, compared to pTERTWT, whose median age was 63 (mean rank 
53.4) however this was not a statistically significant difference, U= 1100.0, p= 0.065. 
This data will have been skewed by the presence of the benign adenomas, which are 
assessed below. 
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3.3.7.2 All Malignancies 
Grouped into malignant neoplasms, results are shown in table 39.  










pSurv CC 8 47.3 66.6 +/- 37.6 55.0 46.2 59.5 +/- 19.2 67.5 
CG 53 51.9 79.5 +/- 53.9 70.0 49.4 64.0 +/- 11.5 65.0 
GG 38 48.0 69.8 +/- 46.5 60.0 51.6 63.9 +/- 13.0 67.5 
ꭓ²(2)  0.482  0.281  
p-value 0.786 0.869 
 
pTERT WT 92 53.4 77.8 +/- 48.9 65.0  49.2 62.8 +/- 12.8 66.0 
Mut 19 40.7 64.0 +/- 59.3 45.0 58.7 66.8 +/- 11.7 69.0 
U  583.5  925.0  
p-value 0.089 0.204 
Table 39. For all malignant neoplasms, clinicopathological characteristics are studied based on the promoter 
mutational status of pSurv and pTERT. 
When comparing all malignant neoplasms, a Kruskal-Wallis test showed that there was 
no significant difference in tumour size based on the Survivin promoter variants, ꭓ²(2) = 
0.482, p= 0.786, with mean rank scores of 47.3 for the CC homozygote, 51.9 for the CG 
heterozygote and 48.0 for the GG homozygote. Similarly, there was no significant 
difference in patient age based on the Survivin promoter variants with a mean rank 
scores of 46.2 (CC), 49.4 (CG) and 51.6 (GG), ꭓ² (2) = 0.281, p= 0.869.  
Interestingly, pTERTMuts occurred in smaller malignant liver tumours (median size 
45mm, mean rank 40.7) when compared with pTERTWT tumours (median 65mm, mean 
rank 53.4) but this difference was not statistically significant, U= 583.5, p= 0.089. This 
finding is perhaps more representative of the role Telomerase plays in smaller 
malignant tumours, when considering the entire malignant cohort, but any further 
associations in tumour sub-group analysis may lack the study numbers required to fully 
describe this.  
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The median age for patients who develop a Telomerase mutation was 69 (mean rank 
58.7) which is older than patients with WT tumours (median 66, mean rank 49.2) but 
this difference was not significant, U= 925.0, p= 0.204.  
3.3.7.2.1 HCC& FL 
When comparing all HCCs, a Kruskal-Wallis test showed that there was no significant 
difference in tumour size based on the Survivin promoter variants, ꭓ²(2) = 0.796, p= 
0.672, with mean rank scores of 29.7 for the CC homozygote, 30.4 for the CG 
heterozygote and 26.4 for the GG homozygote. Similarly, there was no significant 
difference in patient age based on the Survivin promoter variants, ꭓ²(2) = 1.907, p= 
0.385, with a mean rank scores of 18.9 (CC), 29.6 (CG) and 29.3 (GG).  
A Mann-Whitney U test showed that pTERT status had no significant effect on tumour 
size with WT tumours tending to be larger (median size 82.5mm, mean rank 31.7) 
compared to the mutants (median size 45.5, mean rank 24.6), but this was not a 
statistically significant difference, U= 271.5, p= 0.137. Wild type tumours occurred in 
younger patients (median age 66, mean rank 28.0) when compared to mutant tumours 
(median age 70, mean rank 32.8), but this difference also failed to reach significance, 
U= 419.0, p= 0.321.  
3.3.7.2.2 HCC Only 
When comparing classical HCCs, a Kruskal-Wallis test showed that there was no 
significant difference in tumour size based on the Survivin promoter variants, ꭓ²(2) = 
1.117, p= 0.572, with mean rank scores of 30.3 for the CC homozygote, 26.8 for the CG 
heterozygote and 23.6 for the GG homozygote. Similarly, there was no significant 
difference in patient age based on the Survivin promoter variants, ꭓ² (2) = 1.306, p= 
0.520, with mean ranks of 17.6 (CC), 25.8 (CG) and 26.6 (GG).  
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A Mann-Whitney U test demonstrated that pTERTMuts status had no significant effect 
on tumour size. Wild type HCCs were larger (median 80mm, mean rank 28.5) 
compared to mutants (median 45mm, mean rank 22.4) but not significantly so, U= 
228.0, p= 0.175. Telomerase mutations occurred in HCCs from older patients (median 
age 72, mean rank 28.5) when compared with their WT counterparts (median age 67, 
mean rank 25.5) but lacked statistical significance, U= 331.0, p= 0.513. 
3.3.7.2.3 CCA 
When comparing all CCAs, a Kruskal-Wallis test showed that there was no significant 
difference in tumour size based on the Survivin promoter variants, ꭓ²(2) = 1.109, p= 
0.574, with mean rank scores of 12.7 for the CC homozygote, 19.5 for the CG 
heterozygote and 18.3 for the GG homozygote. Similarly, there was no significant 
difference in patient age based on the Survivin promoter variants, ꭓ² (2) = 1.600, p= 
0.449, with mean ranks of 25.8 (CC), 17.7 (CG) and 18.1 (GG).  
3.3.7.2.4 Adenoma 
A Mann-Whitney U test showed that the two pSurv variants present in the 10 benign 
tumours had no significant correlation with Adenoma size (U= 13.0, p= 0.667), and was 
not correlated with patient age (U= 9.0, p= 0.833). 
3.3.8 Discussion 
There is no significant difference between either Survivin promoter variants, or 
Telomerase promoter mutants, when comparing tumour size or patient age. However, 
when considering the whole cohort, median pTERTMuts were smaller compared to WT 
(p= 0.083) and occurred in older patients, p= 0.065.  
My findings from the HCC tumour sub-group analyses (both including and excluding 
FL-HCCs) found that pTERTMuts occurred (non-significantly) in older patients, and in 
smaller tumours, similar to others findings. Previously published work regarding 
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pTERTMutant tumours found them to be smaller (<5cm, p=0.01) and in older patients 
(>60 years old, p=0.08) (Nault et al., 2013). However, Nault’s work only assessed 
HCCs (as opposed to all hepatic neoplasms, including FL-HCC) and the significance of 
these differences was not reflected in the tumour subtype analysis.  
3.3.9 Survival Analysis 
Survival analysis was undertaken by plotting Kaplan-Meier curves using the Log Rank 
(Mantel-Cox) method for overall survival. When quoted the average survival data is 
recorded in the following manner: mean survival +/- standard error (95% confidence 
interval). There was extremely limited data in the clinical records of patient specific 
data, such as disease-free survival (dfs) or progression free survival (pfs) so only overall 
survival has been recorded.  
3.3.9.1 All Neoplasms 
Kaplan-Meier survival analyses for all neoplasm and their respective pTERT & pSurv 
status can been seen in figure 42. There were no significant associations across the 
whole cohort.  
There was no difference in survival between pTERTMut/WT, as shown in the Kaplan-
Meier plot (top left) in figure 42, ꭓ² (1) = 0.819, p= 0.366. Average survival data for 
WT tumours include a mean survival time of 81.5 +/- 7.4 months (95% CI 67.1 – 96.0) 
and median survival time of 76.0 +/- 27.0 months (95% CI 23.0 – 129.0). Patient with 
pTERTMuts had a mean survival time of 65.7 +/- 14.2 months (95% CI 37.9 – 93.5) and 
a corresponding median survival of 42.0 +/- 12.9 months (95% CI 16.7 – 67.3). Cox 
regression analysis also failed to demonstrate any correlation between Survival and 




Figure 42. Cumulative survival based on Telomerase/ Survivin promoter status across all  
There was also no difference in cumulative survival based on the Survivin promoter 
allele status, ꭓ² (2) = 0.251, p= 0.882. Average survival data for CC homozygotes 
includes a mean survival duration of 62.4 +/- 15.1 months (95% CI 32.7 – 92.0) with no 
median survival data fewer than 50% of these patients died. CG heterozygotes had a 
mean survival of 76.6 +/- 9.2 months (95% CI 58.5 – 94.6) and median survival of 55.0 
+/- 21.7 months (95% CI 12.5 – 97.4). GG homozygotes had a mean survival of 84.0 
+/- 10.7 months (95% CI 63.1 – 104.9) and median survival of 74.0 +/- 30.9 months 
(95% CI 13.4 – 134.6.  
When grouping C-containing alleles together (so-called C-dominance) there was no 
difference in Survival, ꭓ² (1) = 0.163, p= 0.687. The GG homozygotes had a mean 
survival of 84.0 +/- 10.7 months (95% CI 63.1 – 104.9) and median survival of 74.0 +/- 
30.1 (95% CI 13.4 – 134.6) compared with the grouped (CC+CG) mean survival of 
77.7+/- 8.7 months (95% CI 60.7 – 94.7) and median survival of 55.0 +/- 20.9 months 
(95% CI 14.1 – 95.9).  
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Comparing the CC homozygotes with G-dominant alleles found no significant 
difference on survival, ꭓ² (1) = 0.036, p= 0.849. Mean survival for CC homozygotes 
was 62.4 +/- 15.1 months (95% CI 32.7 – 92.0). The G-dominant alleles had a mean 
survival of 80.7 +/- 7.1 months (95% CI 66.8 – 94.6) and median survival of 62.0 +/- 
16.6 months (95% CI 29.6 – 94.4). Subsequent analyses in tumour subtypes also failed 
to find any correlation between allele-dominance and overall survival and have not been 
show in the following figures.  
3.3.9.2 All Malignancies 
When excluding the benign adenomas, the malignant neoplasms were considered 
together, as shown in figure 43, with no significant difference in cumulative survival. 
 
Figure 43. Cumulative survival based on Telomerase/ Survivin promoter status across all malignancies.  
There was no difference in survival between pTERTMut/WT, as shown in the Kaplan-
Meier plot in figure 43, ꭓ² (1) = 0.104, p= 0.747. Average survival data for WT tumours 
include a mean survival time of 71.8 +/- 7.7 months (95% CI 56.6 – 86.9) and median 
survival time of 36.0 +/- 22.7 (95% CI 0.0 – 80.5). Patient with pTERTMuts had a mean 
survival time of 65.7 +/- 14.2 months (95% CI 37.9 – 93.5) and a corresponding median 
survival of 42.0 +/- 12.9 months (95% CI 16.7 – 67.3).  
There was no difference in cumulative survival based on the Survivin promoter allele 
status, ꭓ² (2) = 0.278, p= 0.870. Average survival data for CC homozygotes includes a 
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mean survival duration of 62.4 +/- 15.1 months (95% CI 32.7 – 92.0) with no median 
survival data fewer than 50% of these patients died. CG heterozygotes had a mean 
survival of 71.9 +/- 9.4 months (95% CI 53.5 – 90.2) and median survival of 39.0 +/- 
16.2 months (95% CI 7.3 – 70.7). GG homozygotes had a mean survival of 69.5 +/- 
11.1 months (95% CI 47.7 – 91.3) and median survival of 42.0 +/- 24.4 months (95% 
CI 0.0 – 89.9).  
3.3.9.3 HCC+FL 
Subgroup analyses of all HCC tumours (including FL-HCC) also found no associations 
between promoter status and cumulative survival, as can be seen in figure 44.  
 
Figure 44. Cumulative survival based on Telomerase/ Survivin promoter status across all HCC subtypes.  
There was no difference in survival between pTERTMut/WT, as shown in the Kaplan-
Meier plot in figure 44, ꭓ² (1) = 3.043, p= 0.081. Average survival data for WT tumours 
include a mean survival time of 93.8 +/- 11.1 months (95% CI 72.0 – 115.5) and no 
median survival data as >50% of patients survived. Patient with pTERTMuts had a mean 
survival time of 61.5 +/- 13.9 months (95% CI 34.2 – 88.8) and a corresponding median 
survival of 39.0 +/- 8.0 months (95% CI 23.3 – 54.7). Cox regression analysis also 
failed to demonstrate any correlation between Survival and pTERTMut/WT status.  
There was no difference in cumulative survival based on the Survivin promoter allele 
status, ꭓ² (2) = 0.053, p= 0.974. Average survival data for CC homozygotes includes a 
mean survival duration of 48.2 +/- 12.7 months (95% CI 23.3 – 73.1) with no median 
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survival data fewer than 50% of these patients died. CG heterozygotes had a mean 
survival of 89.2 +/- 13.7 months (95% CI 62.3 – 116.0) and no median survival data 
fewer than 50% of these patients died. GG homozygotes had a mean survival of 84.0 +/- 
13.1 months (95% CI 68.4 – 105.2) and median survival of 74.0 +/- 26.7 months (95% 
CI 21.7 – 126.3.  
3.3.9.4 HCC Only 
Assessing associations between promoter status and survival in HCC (excluding FL-
HCC) also yielded no significant associations, as seen in figure 45.  
 
Figure 45. Cumulative survival based on Telomerase/ Survivin promoter status across traditional HCCs.  
There was no difference in survival between pTERTMut/WT, as shown in the Kaplan-
Meier plot in figure 45, ꭓ² (1) = 3.006, p= 0.083. Average survival data for WT tumours 
include a mean survival time of 73.5 +/- 8.8 months (95% CI 56.2 – 90.8) and no 
median survival data as >50% of patients survived. Patient with pTERTMuts had a mean 
survival time of 49.9 +/- 10.7 months (95% CI 29.0 – 70.9) and a corresponding median 
survival of 39.0 +/- 8.7 months (95% CI 21.9 – 56.7). Cox regression analysis also 
failed to demonstrate any correlation between Survival and pTERTMut/WT status.  
There was no difference in cumulative survival based on the Survivin promoter allele 
status, ꭓ² (2) = 0.029, p= 0.986. Average survival data for CC homozygotes includes a 
mean survival duration of 42.8 +/- 14.7 months (95% CI 14.0 – 71.5) with no median 
survival data fewer than 50% of these patients died. CG heterozygotes had a mean 
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survival of 66.8 +/- 10.5 months (95% CI 46.3 – 87.3) and a median survival of 62.0 +/- 
24.9 months (95% CI 13.1 – 110.9). GG homozygotes had a mean survival of 70.7 +/- 
10.8 months (95% CI 49.4 – 91.9) and median survival of 74.0 +/- 25.5 months (95% 
CI 23.9 – 124.0).  
3.3.9.5 Cholangiocarcinoma 
There were no pTERTMuts in CCA, but the survival curves for pSurv can be seen in 
figures 46 & 47. Figure 46 shows all CCAs analysed collectively and figure 47 is a 
subgroup analysis of all intrahepatic CCA.  
 
Figure 46. Cumulative survival based on Survivin promoter status across all CCAs.  
There was no difference in cumulative survival based on the Survivin promoter allele 
status, ꭓ² (2) = 2.403, p= 0.301. Average survival data for CC homozygotes includes a 
mean survival duration of 52.0 +/- 21.7 months (95% CI 9.4 – 94.6) with a median 
survival of 36.0 +/- 16.3 months (95% CI 4.0 – 68.0). CG heterozygotes had a mean 
survival of 56.3 +/- 11.8 months (95% CI 33.2 – 79.4) and a median survival of 30.0 +/- 
13.2 months (95% CI 4.2 – 55.8). GG homozygotes had a mean survival of 23.0 +/- 7.2 




Figure 47. Cumulative survival based on Survivin promoter status across intrahepatic CCAs.  
There was no difference in cumulative survival based on the Survivin promoter allele 
status, ꭓ² (2) = 1.867, p= 0.393. Average survival data for CC homozygotes includes a 
mean survival duration of 60.0 +/- 31.3 months (95% CI 0.0 – 121.0) with no median 
survival as >50% of patients survived. CG heterozygotes had a mean survival of 58.6 
+/- 12.5 months (95% CI 34.1 – 83.1) and a median survival of 39.0 +/- 17.0 months 
(95% CI 5.7 – 72.3). GG homozygotes had a mean survival of 25.6 +/- 8.5 months 
(95% CI 9.0 – 42.2) and median survival of 12.0 +/- 7.0 months (95% CI 0.0 – 25.7).  
3.3.9.6 Mixed Tumour pTERT survival analysis 
All seven of the mixed tumours were CG heterozygotes therefore assessing cumulative 
survival based on pSurv status was not possible. There was a single pTERTMuts in the 
mixed tumour cohort, the only survivor, however the small size of the cohort meant that 
this was did not result in a significant result when considering cumulative survival, ꭓ² 
(1) = 1.437, p= 0.231, figure 48.  
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Figure 48. Cumulative survival based on the Telomerase promoter status in mixed HCC-CCA. 
3.3.10 Discussion 
There are no significant relationships between promoter status and cumulative survival 
for either pSurv SNPs or the pTERTMuts. Even when tumour subgroups were analysed 
correlation between promoter status and cumulative survival was consistently absent in 
this small study cohort. Telomerase promoter mutations have been shown to be an 
HCC-lineage specific genetic alteration, and it appears that cumulative survival may be 
shorter in these patients both within the whole HCC cohort (p= 0.081) and when the FL-
HCCs are excluded (p= 0.083). In a larger cohort of HCCs this relationship could be 
further clarified, which highlights the possibility of using genetic analysis to stratify 
patients into high, and low-risk groups for clinical follow up.  
3.4 Promoter Sequences - Discussion 
Amplifying DNA extracted from FFPE tissues presented significant technical 
challenges but with persistence and much refinement of the methods used ultimately 
yielded some very interesting results. Given that every hospital pathology department in 
the country, if not the world, uses FFPE tissue blocks for diagnostic purposes the 
methods used here are readily transferable to an enormous potential research resource. 
This could open up the entire research archive for assessment (not only of UTAA 
promoter sequences) giving a truly representative picture of promoter sequences, which 
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might only be limited by archival and storage capacity and storage logistics. However, 
there are some limitations when using poor quality DNA but in the absence of a frozen 
tissue biobank, these results demonstrate similar detection rates to those found in the 
published literature – such as the minor allele frequency of pSurv and the rate of 
pTERTMuts in HCCs.  
3.4.1 Major Findings 
The Telomerase promoter mutation results are the most interesting, and statistically 
significant findings in the sequencing results. There was consistent evidence of 
pTERTMuts being associated with male gender when all neoplasms (p= 0.001) and the 
malignancies (p= 0.001) were compared.  
There was also considerable evidence of associations with pTERTMuts and HCC, and 
HCC-lineage, tumours in the whole cohort (p= 0.002) and in the malignant cohort (p= 
0.003). Therefore, the putative associations with fibrosis (p= 0.009), cirrhosis (p= 
0.004) in the whole cohort must be interpreted with some caution, as both fibrosis and 
cirrhosis are pre-cancerous conditions that cause HCCs to develop in the context of 
chronic cirrhosis.  
Within the HCC-only cohort of tumours the male preponderance was also present (p= 
0.005) as was a weak association with all-cause mortality (p= 0.043) and slightly more 
convincing association with vascular invasion (p= 0.031) and pTERTMuts. However, 
when considering cumulative survival there was reduced median survival in pTERTMuts 
compared to pTERTWT, but this lacked significance in both the classical HCCs (p= 
0.083) and when combined with FL-HCCs (p= 0.081).  
The Survivin promoter SNP was confirmed as a germline in nature given the 100% 
concordance between background liver, and tumour tissues. This was the limit of the 
major findings in the Survivin promoter sequence in this cohort.  
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3.4.2 Minor Findings 
Significantly fewer cirrhosis-associated neoplasms were associated with the Survivin 
promoter GG homozygous allele across the whole study cohort, p= 0.042. However, 
this result was not significantly replicated in sub-analyses, including the malignant 
cohort, p= 0.078. An apparently lower rate of cirrhosis in GG homozygotes (p= 0.042) 
is of some interest when assessing the whole cohort. This could be because of the two 
main tumour groups (HCC & CCA) there was an equal number of CG/GG (n=23) 
alleles in the HCCs, whilst there were more heterozygotes (21) compared to GG 
homozygotes (12) in the CCAs.  
When tumour size and patient age are considered, the pTERTMuts status may be 
important in larger malignancies. Across the whole cohort pTERTMuts correlate with 
larger tumours (p= 0.083) and advanced patient age (p= 0.065). However, then the 
benign Adenomas are excluded (of which 90% occur in young women in this study) 
pTERTMuts lose their correlation with patient age (p= 0.204) but still appear to occur in 
(non-significantly) smaller malignant tumours, p= 0.089.  
When considering pTERTMuts in the malignant cohort, the associations between fibrosis 
(p= 0.01) and cirrhosis (p= 0.012) are weaker, which is not terribly surprising given that 
Adenomas occur in young women, rather than in the context of chronic inflammation. 
The weak association between pTERTMuts and fibrosis in all HCCs (p= 0.044) becomes 
non-significant when the FL-HCCs – which are not associated with traditional risk 
factors for HCC development - are excluded (p= 0.075). This casts some doubt on the 
implication of these findings in this small study cohort. However, there is also a 
significant selection bias in these surgically managed tumours, which will certainly 
impact any potential impact of this data.  
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3.4.3 Commentary and Future work 
There is evidence of a potential sampling bias with both inter-tumour and intra-
tumoural heterogeneity in the expression of Telomerase promoter mutations. For 
patients 24 and 116, DNA extracted from different tumour tissue blocks gave different 
pTERTMuts results. This could either be due to true tumour heterogeneity, or a result an 
unsatisfactory lower limit of detection for assigning mutation/WT status in amplified 
DNA sequences. It is thought-provoking to consider whether pTERTMuts would also be 
present in metastatic tumours, which would require a refinement of the methodologies 
to allow sequencing from biopsy samples.  
However, the pTERT mutation rate (31-32%) is within the range that has been 
previously reported at an international level (30-60%) but is lower than expected for the 
predominantly European, compared to Asian, population that has been studied here. 
Whether this is a true representation, or falsely low is difficult to state with any 
certainty. To further answer this question, the same techniques could be used on DNA 
taken from multiple tissue blocks, to fully characterise the cohort. Introducing a more 
sensitive amplification methods could also achieve this. This has been shown in 
Melanoma, where Telomerase promoter mutations are an independent prognostic risk 
factor, so perhaps increasing the study size will lead to greater clarity on the role 
pTERTMuts have in HCCs, (Griewank et al., 2014). 
Future work could include using alternative techniques, such as droplet digital PCR 
(which has recently become more accurate) for detecting point mutations.  Detection 
rates for ddPCR have been quoted as being roughly double that of Sanger sequencing 
when detecting the Y373C FGFR3 mutation in bladder cancer (Borkowska et al., 2019). 
Some work has been published in the pTERT field quoting a lower limit of detection of 
0.17% when using ddPCR to assess malignant melanoma, albeit whilst using Sanger 
sequencing as the gold standard (McEvoy et al., 2017). 
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What must be remembered in this cohort is the sampling bias of patients that are fit 
enough to undergo major abdominal surgery. Only 23 of the patients are cirrhotic, 
which is known to be a major driver in carcinogenesis, so caution should be exercised 
when interpreting the findings. Further work could include sequencing needle biopsy 
specimens, to ascertain whether this is technically feasible and yields meaningful 
results. This would allow a more comprehensive cohort of tumour samples to be 
sequenced, helping to clarify any possible relationships I have found.  
The Survivin promoter work has, broadly, been less interesting than that of pTERTMuts. 
Apart from the concordance between tumour and background liver samples, there are 
few correlations with clinical disease outcomes as in the pTERT analyses. Expanding 
the Telomerase-activation studies to include other activating events (DNA integration, 
ALT, etc) could highlight the role of Telomerase in PLCs. Techniques required for this 
would need fresh/frozen materials, but these findings in FFPE tissues is a solid 
foundation to build upon.  
Critiquing the technical methods used would allow me to potentially improve the 
confidence of the sequencing results. It would potentially have been more scientifically 
rigorous to run a positive control for every PCR reaction, but given the use of no-
template negative controls ensuring no contaminated samples, it was felt that this was 
adequate. However, previous work in the field (i.e., not using a known positive control) 
has found this approach satisfactory, and been adopted in completely different fields 
where genotyping by PCR is done (Radojevic-Skodric et al., 2012; Jacquot et al., 
2019). As the number of samples processed simultaneously on a single gel (n=22) 
extracted using the same technique, samples acted as their own internal control, rather 
than relying on an exogenous/endogenous control run in the same reaction tube that 
may reduce the efficiency of the PCR (QIAGEN, 2020). As stated by QIAGEN on their 
website, negative controls are adequate to rule out any contaminations interfering with 
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the assessment of nucleic acids, whilst endogenous homologous internal controls will 
compete for reagents and reduce the efficiency of the reactions. 
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4 Survivin Immunohistochemistry 
4.1.1 Introduction 
This chapter describes my immunohistochemistry findings to define Survivin 
expression in a range of tumour types. Ensuring the proteomic detection, and 
quantification, of tumour-associated antigens required rigorous optimisation to ensure 
an accurate (and meaningful) interpretation of the data was possible. Assessing the 
expression of UTAA in PLCs was reliant on commercially available antibodies that 
have been extensively used in peer-reviewed publications. The Survivin antibody 
ultimately chosen for this research project has been used many times in the published 
literature (219 at the time of selection, 228 at the time of writing, including in FFPE 
studies) giving weight to the reliability of the results (Cell Signalling Technology, 
2020).  
4.1.2 Survivin IHC Optimisation 
Almost without exception Survivin 71G4B7 Rabbit monoclonal antibody (Cell 
Signalling) has consistently used nuclear staining in tonsillar tissue for a positive 
control. Published literature and online resources such as the Human Protein Atlas 
(HPA) confirm significant expression of nuclear Survivin in tonsil tissues, which made 
the initial optimisation steps straightforward (Thul et al., 2017; Cell Signalling 




Figure 49. Optimisation steps for the Survivin primary antibody. Images shown at 200X magnification. 
With citrate buffer for antigen retrieval and a 1:400 dilution of antibody with overnight 
incubation at 4 Celsius selected as giving the best balance of strong positive staining 
with minimal background ‘noise.’ Figure 49 highlights the quality of this antibody as 
there is no expression in background liver tissues. Experiments were repeated in 
triplicate, on different days, to ensure reproducibility and reliability of the protocol. 
Source material (Tonsil) was used in every batch of IHC as a positive control, and if the 
control tissue block was being diminished, a separate tissue block of tonsil was run in 
parallel to ensure consistency in nuclear staining between positive controls.  
4.1.3 QuPath Assessment of Tissues: Survivin 
The perfect artificial intelligence software would simultaneously analyse tissues, 
undertake quantification and use machine learning to constantly improve accuracy. This 
would involve QuPath assessing the morphological features observed in a specific 
tumour type and would require both exploratory and validation cohorts. However, this 
would have required some degree of un-blinding during this - hypothetical - 
optimisation process which, although desirable, was not feasible whilst working within 
the ethical constraints of this project.  
As outlined above: I, the researcher, am to be blinded to the tissues being studied. This 
meant the creation of classifiers (a method of training the software to recognise cell 
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types - more on this later) somewhat difficult. Training software to recognise HCCs and 
CCAs simultaneously as ‘tumour’ resulted in poor quality results when compared to an 
expert commentator’s assessment. As both HCCs and CCAs demonstrate significantly 
different cellular morphology it is unsurprising that an object classifier designed to 
differentiate between cells (i.e., tumour versus benign versus inflammatory cell) based 
on cellular morphology struggled in this combined cohort. Furthermore, when more 
than 10 images (each image-file being around 3-4 gigabytes in size) were open 
simultaneously with the same classifier the software regularly froze, or crashed, which 
made for a slow and frustrating process. 
As a result of both the ethical and logistical issues during optimisation, the decision to 
create individual classifiers for each slide was made. The classifier is able to detect both 
the nuclear haematoxylin (blue) and the chromogen (in this case a brown colour) using 
a process called colour deconvolution which the human eye is unable to do. QuPath’s 
default is to use DAB/Haematoxylin for classifiers, meaning this process is 
standardised, and therefore reproducible. This meant the quality of the data was reliable 
and also compared very favourably with an expert commentator's assessment of 
staining. It also meant the computing power available was not regularly overloaded 
when assessing protein levels, which sped up the quantification steps considerably. This 
case-by-case analysis relies on accurate assessment of the tissue samples being studied, 
with an inherent bias that should be acknowledged when interpreting the results. 
Whole tissue slides were assessed for the proportion and intensity of staining positivity 
in both tumour and background liver samples. Selective tissues can be seen in the 
images below, comparing the raw image files (bottom row) and the colour coded (top 
row) data post-processing in figure 50.  
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Figure 50. HCC tumours with varying degrees of nuclear positivity for Survivin. Scale bar: 100 microns. 
The colour scheme is as follows: negative (blue), + (yellow), ++ (orange) and +++ (red) 
as the intensity of the nuclei staining progresses (lower images) with warmer colours 
(upper images) predominating from left to right in figures 50 & 51. Both negatively 
staining tumour nuclei and stromal cells are shown by subtly different shades of blue. 
 
Figure 51 CCA tumours with varying degrees of nuclear positivity for Survivin. Scale bar: 100 microns. 
For CCA, the differences in staining intensity can be seen in figure 51. In both figures 
50 and 51 there is evidence of clear nuclear staining with minimal stromal, or 
cytoplasmic, staining.  
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4.1.4 IHC Results: Survivin 
Survivin immunohistochemistry staining, allowing levels to be assessed, was achieved 
in 98.2% (109/111) of tumours and in 85.6% (95/111) of the background tissues. The 
two tumour samples that were not able to be assessed were both extensively necrotic 
and therefore did not counterstain with nuclear haematoxylin, thus rendering them un-
assessable. Of the 16 cases where background liver tissue was unable to be assessed 13 
(11.7%) were because there was no background tissue available for the study, and the 
remaining three (2.7%) were extensively necrotic and also lacked haematoxylin 
counterstaining. Internal positive controls (lymphocytes) were present and all tissues 
and demonstrated, stained positively, and were accounted for when the project classifier 
was being trained.  
Average expression of Survivin, quantified using both the Allred (0, 2 – 8) and H-scores 
(0 – 300), can be seen in table 40. Comparisons between paired tumour and background 
staining, and the statistical significance of these differences, can also be seen in this 
table. 
All Neoplasms H-Score Allred Score 
Tumour Background Tumour Background 
Mean +/- S.D. 82.9 +/- 62.6 15.1 +/- 1.4 5.2 +/- 1.4 3.3 +/- 1.0 
Min - Max (Range) 0.5 - 239.8 (239.3) 0.0 - 148.7 (148.7) 2 – 8 (6) 2 – 7 (5) 
Median 63.9 3.6 5.0 3.0 
Test Statistic Z= -8.1, p= 4.8 E-16 t(92) = 13.1, p= 9.2E-23. 
Table 40. Average tumour and background liver Survivin levels using the H-score and Allred score.   
Table 40 shows significantly more Survivin in tumour compared with paired 
background tissue-staining scores across all samples by both quantification methods. 
The median values (for the non-normally distributed difference in H-Score) and paired 
mean values (using the normally distributed difference in Allred score) both confirmed 
significantly more Survivin expression in tumour, compared to paired background liver 
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tissues (p= 4.77E-16 and p= 9.19E-23 respectively). It is noteworthy at this stage to 
emphasise that the differences in Allred scores are normally distributed, and that the 
tumour protein levels have greater statistical significance. In analyses comparing protein 
expression in tumour compared to background liver tissues the overall differences in 
expression were visualised, thus determining the statistical test subsequently selected. 
The Wilcoxon signed-rank test does not assume normality, as opposed to the Paired-
Samples T-test, the most appropriate statistical test was used depending on the original 
data. The test statistic used can be simply ascertained when consulting the tables below: 
the Z-score (i.e., Z=) denotes the Wilcoxon signed-rank test whilst the Paired-Samples 
T-test is shown by (t(degrees of freedom)= ).  
Given the germline nature of the Survivin promoter rs9904341 I investigated for 
potential differences between the intensity of staining in tumour/background tissues 
with CC, CG and GG Survivin alleles. No significant differences were found figure 52 
demonstrates the non-significant differences across the three alleles. 
 
Figure 52. No allele preferentially expressed more Survivin when assessing all neoplasms, using both the Allred and 
H-Scores.  
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Also, there was a significant difference in Survivin staining between tumour types when 
considering both the neoplastic tissues (figure 53, top row) and background livers 
(bottom row).  
Figure 53 outlines differences in Survivin expression by tumour sub-type. 
 
Figure 53. Differential expression of Survivin by tumour type. 
The H-scores (ꭓ² (4) = 10.923, p= 0.027) and the Allred scores (ꭓ² (4) = 9.701, p= 
0.046) varied between tumour types with average values shown in tables 41 and 42.  
H-Score HCC FL-HCC CCA Mixed 
HCC-CAA 
Adenoma 
Mean +/- S.D. 68.6 +/- 57.4 138.0 +/- 73.8 100.7 +/- 62.5 83.5 +/- 65.8 60.3 +/- 54.8 
Median 53.1 143.2 98.1 79.3 54.8 
Mean Rank 47.9 79.7 64.6 55.0 43.0 
Table 41 Average H-score values (scale 0 – 300) for Survivin expression across tumour types.  
Table A shows the highest level of detected Survivin was found in FL-HCCs with the 
lowest in Adenomas. Uncorrected pairwise comparisons of the H-scores are 
significantly different between FL-HCC and Adenoma (p= 0.025), HCC and CCA (p= 
0.016) and HCC and FL-HCCs (p= 0.020). However no pairwise differences differed 




Allred Score HCC FL-HCC CCA Mixed HCC-CAA Adenoma 
Mean +/- S.D. 5.0 +/- 1.3 6.5 +/- 1.2 5.6 +/- 1.4 5.3 +/- 1.1 4.9 +/- 1.4 
Median 5.0 7.0 6.0 5.0 5.0 
Mean Rank 48.4 81.7 62.5 54.9 46.7 
Table 42. Average Allred scores (0, 2 - 8) for Survivin expression across tumour types.  
When the Allred score was used the highest levels were also detected in FL-HCCs (as 
shown in table 42) and the lowest in Adenomas. Similar to the H-score analysis, 
uncorrected pairwise comparisons for Allred scores are also significantly different 
between FL-HCC and Adenoma (p= 0.028), HCC and CCA (p= 0.036) and HCC and 
FL-HCC (p= 0.012). Similar to the H-score findings, once the significance was adjusted 
for multiple analyses, none of these differences were statistically significant. 
In summary I have found that there is a significant difference in tumour/ background 
liver Survivin expression (table 40) with differential expression of Survivin depending 
on the tumour type (figure 53). However, within this small study cohort the significance 
of pairwise comparisons is not certain when corrected for multiple analyses, meaning 
further work would help clarify whether this is a true relationship, or not.  
4.1.4.1 Clinical Correlates with Tumour Survivin Expression 
Survivin levels across the whole cohort were correlated with clinical measures. Table 43 
outlines protein expression differences between groups with P-values representing the 
level of significance of differences between the nominal outcome variable (Gender: 
M/F. Outcome: Dead/Alive, etc) and whether the tumour/ background Survivin 
quantification scores have a statistically significant difference between these groups. 
There is no data in table 43 about whether these differences are positive or negatively 
correlated, as this will be addressed subsequently. 
No statistically significant association between variation in Survivin expression in 
background liver tissue and clinical correlates was found. However, tumour Survivin 
expression was found to correlate with several clinical characteristics.    
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All Neoplasms Tumour Survivin Background Survivin 
H-Score Allred Score H-Score Allred Score 
Gender 0.591 0.568 0.964 0.694 
Outcome 0.007 0.011 0.433 0.360 
Fibrosis 0.231 0.272 0.824 0.812 
Cirrhosis 0.053 0.061 0.923 0.742 
Viral Hepatitis 0.213 0.267 1.000 0.906 
Metabolic Risk Factors 0.575 0.933 0.748 0.974 
Genetic Liver Disease 0.834 0.996 0.228 0.594 
Table 43. The distribution of Survivin staining across all neoplasms, based on clinical measures. 
Survivin expression appears to be differentially expressed between patients who have 
gone on to die, compared to those still alive. There is no significant difference in tumour 
Survivin expression (quantified using both the Allred and H-score) between: genders, 
fibrosis/cirrhosis derived tumours, and did not differ based on any further underlying 
inflammatory condition (viral hepatitis, metabolic or genetic diseases). Importantly: 
there were no significant relationships found between Survivin expression in 
background liver tissues and any clinical parameter measured. However, some caution 
must be exercised when comparing malignant characteristics (vascular invasion, margin 
positivity, etc) when the benign Adenomas are included – despite these being coded as 
missing data in SPSS – therefore these results will be further clarified below, figure 54.  
 
Figure 54. Higher Survivin levels are associated with all-cause mortality. 
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As can be seen from figure 54, using both the Allred and H-Scores, the mean ranks of 
Survivin were higher in tumour of those who died (62.04 and 62.66 respectively) 
compared to those alive (46.99 and 46.29, respectively). The level of statistical 
significance varies depending on the method of quantification used (p= 0.007 for the H-
Score and p= 0.011 for the Allred score).  
Scale variables such as tumour size in mm, and patient age at the time of operation were 
compared with the intensity of staining measures, as outlined in table 44.  
 
Table 44. There is no correlation between tumour/background Survivin levels and the patient age (years) or the 
tumour size (mm).  
There are no significant correlations between age or tumour size and Survivin in 
tumours or background liver tissues, but there is a suggestion of a positive correlation 
between tumour size and the intensity of staining (correlation coefficients ~ 0.17) and 
with significance P~0.076 reflected in similar values from both methods of recording 
tumour intensity staining. Patient age and tumour size are compared to staining intensity 
using Spearman’s rank test with 2-sided P-values with the level of significance set at 
0.05. 
Continued use of both quantification methods makes for a somewhat clunky and 
repetitive analysis. Given that the Allred scores are easier to visualise, interpret, uses a 
smaller scale, appears to be more representative of the study cohort and have been used 
in other published works for differentiating between high/low protein expressors this 
method will be used for the remainder of the analysis. Stratifying tumours by high/low 
protein expression based on their Allred score has been reported in breast cancers. It 
appears to be a suitable way of conveying protein expression by combining both the 
H Score Allred H Score Allred
Correlation Coefficient 0.160 0.113 -0.101 -0.16
P Value 0.097 0.243 0.330 0.122
Correlation Coefficient 0.171 0.170 0.054 -0.031





Tumour Survivin Background Survivin
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intensity of staining, as well as the percent of tumour that positively stain (Ellis et al., 
2010; Campbell et al., 2016). In both of these published papers an Allred score of 6-8 
was deemed ‘high expression’ when assessing the Oestrogen/Progesterone receptor 
expression when used to prognosticate, or otherwise stratify patients for offering an 
alternative chemotherapy regimen. However, two methods differentiating between 
groups was undertaken for completeness, as shown in figure 55. 
Assigning a threshold for a SurvivinHigh score of 5-8 (left image) or 6-8 (right image) 
helps to differentiate survival characteristics based on Survivin expression in tumours as 
shown in the Kaplan-Meier survival curves in figure 55.  
 
Figure 55. Tumours that express high levels of Survivin are associated with a reduced cumulative survival. 
With high levels of tumour Survivin (i.e., SurvHigh = Allred score 6 – 8) demonstrating a 
clearer, more statistically significant, reduction in cumulative survival, ꭓ² (1) = 13.013, 
p= 0.003. Using this method, patients with SurvivinLow-expressing tumours had a longer 
median survival (62.0 +/- 17.0 months, 95% CI 28.6 – 95.4) compared with 
SurvivinHigh-expressing neoplasms (24.0 +/- 3.2 months, 95% CI 17.7 – 30.3).  
Using the alternative (but not used elsewhere in the literature) threshold for tumour 
positivity (e.g., 0-4 low, and 5-8 high) gave a non-significant reduction in overall 
survival in tumours that express more Survivin, p= 0.056. Therefore, the higher cut off 
value for expression (Allred low scores 0-5 and high 6-8) was used for all further 
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tumour subgroup analyses. This approach was supported both by my data and the 
literature, table 45, (Ellis et al., 2010; Campbell et al., 2016). 





Gender Female 45 55.6 (25) 44.4 (20) 0.437 
Male 65 63.1 (41) 36.9 (24) 
Outcome Alive 51 74.5 (38) 25.5 (13) 0.006 
Dead 59 47.5 (28) 52.5 (31) 
Fibrosis - 66 59.1 (39) 40.9 (27) 0.841 
+ 43 62.8 (27) 37.2 (16) 
Cirrhosis - 87 56.3 (49) 43.7 (38) 0.090 
+ 22 77.3 (17) 22.7 (5) 
Viral Status - 95 58.9 (56) 41.1 (39) 0.778 
+ 15 60.0 (10) 40.0 (5) 
Genetic Liver 
Disease 
- 100 60.0 (60) 40.0 (40) 1.00 
+ 10 60.0 (6) 40.0 (4) 
Tumour HCC 52 73.1 (38) 26.9 (14) 0.032 
FL-HCC 6 33.3 (2) 66.7 (4) 
CCA 35 42.9 (15) 57.1 (20) 
Mixed 7 57.1 (4) 42.9 (3) 
Adenoma 10 70.0 (7) 30.0 (3) 
pSurv Allele CC 8 75.0 (6) 25.0 (2) 0.352 
CG 55 65.5 (36) 34.5 (19) 
GG 45 53.3 (24) 46.7 (21) 
Table 45. High tumour Survivin and clinical correlations. 
High tumour Survivin is correlated with all-cause mortality, being detected in 52.5% 
(31/59) of those who have died compared with 25.5% (13/51) of those still alive, p= 
0.006. SurvivinHigh was expressed to varying degrees depending on the tumour type, ꭓ² 
(4) = 10.209, p= 0.032. The majority of HCCs preferentially expressed SurvivinLow with 
73.1% (38/52) falling into this category, whilst the majority of CCAs (57.1%, 20/35) 
had SurvivinHigh.  However as comparing malignant traits when including benign 
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tumours (Adenomas) within a cohort this may lead to some erroneous data being 
produced, these characteristics will be more fully assessed below. 
More non-cirrhotic-derived tumours (43.7%, 38/87) expressed SurvivinHigh levels 
compared with tumours from cirrhotic patients (22.7%, 5/22), albeit to a non-significant 
extent, p= 0.090. Higher Survivin expression did not significantly correlate with gender, 
fibrosis, viral hepatitis, metabolic liver disease, genetic liver disease or any of the 
Survivin promoter variants, or subgroups of these variants. Teasing out the role of high 
tumour Survivin will be examined in the tumour subtype sections that follow. 
4.1.5 Tumour Subgroup Analysis 
As mentioned above, given the heterogeneous nature of the tumours being studied 
includes both benign and malignant neoplasms as well as clinical measures particular to 
certain tumours (e.g., perineural invasion in CCA, no malignant characteristics in 
Adenomas) subgroup analysis was undertaken to fully understand the study cohort. 
4.1.5.1 All Malignancies 
The clinical presentation, management and disease-course of primary liver malignancies 
is clearly very different from that of benign hepatic neoplasms. As such it is possible to 
compare malignant characteristics (tumour size, tumour stage, vascular invasion, etc) 
between tumour types, as well as overall survival data, further highlighting differences 
in Survivin expression and disease characteristics.  
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4.1.5.2 Clinicopathological Features 
Reassuringly there was a highly significant difference between tumour and background 
Survivin levels, as shown in table 46.  
All Malignancies Allred Score 
Tumour Background Liver 
Mean +/- S.D. 5.3 +/- 1.3 3.3 +/- 1.1 
Min – Max (range) 2 – 8 (6) 2 – 7 (5) 
Median 5.0 3.0 
Test Statistics t(82) = 12.9, p= 1.8E-21 
Table 46. Average Survivin expression in the malignant cohort. 
Differences in mean Allred scores between tumour (5.3) versus background liver (3.3) 
were normally distributed (t(82)= 12.9, p= 1.8E-21), highlighting the highly significant 
nature of this relationship. 
Survivin expression, based on tumour type, is shown in figure 56.  
Survivin was differentially expressed across malignant tumour types with FL-HCCs 
expressing the most (mean rank 73.7, median 7.0), followed by CCAs (56.2, median 
6.0), Mixed tumours (49.0, median 5.0) and finally HCCs (43.1, median 5.0), ꭓ² (3) = 
9.079, p= 0.028, figure 56.  
P=	0.028 
Figure 56 Differential Survivin expression by tumour type in malignancies.  
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Allred Score: All Malignancies Correlation Coefficient (rho) P-Value 
Patient Age 0.087 0.393 
Tumour Size 0.201 0.046 
Table 47. Across all malignancies, higher Survivin levels may be positively correlated with larger tumours. 
When assessing tumour size and differential staining, it appears there is a weakly 
significant positive correlation (rho = 0.201, p= 0.046) between tumour size and Allred 
score. With benign tumours excluded it appears that larger tumours grow by evading 
apoptosis, table 47. There was no correlation between patient age and Survivin 
expression, p= 0.393. Comparing clinical characteristics in the malignancies is shown in 
table 48.  
All Malignancies Tumour Allred Score Distribution 
Outcome (Dead vs Alive) P= 0.016 
Margin P= 0.056 
Cirrhosis P= 0.039 
Stage I & II vs. III & IV P= 0.047 
Vascular Invasion P= 0.008 
Table 48.  Survivin distribution across all malignancies, based on clinic-pathological characteristics. 
In the malignant cohort there is a highly significant relationship between tumour 
Survivin in tumours with vascular invasion (p= 0.008), as well as there being some role 
in overall outcome, p= 0.016. There is also a significant difference between those with 
liver cirrhosis (p= 0.039 and a marginally significant difference in Survivin expression 
when early (I & II) and late (III & IV) stage tumours, p= 0.047. Tumour Survivin 
expression did not differ significantly between R0 and R1 resection specimens, p= 
0.056. 
As shown in table 48 another property that is significantly different between groups is 
the vascular invasion of tumour. These differences are shown graphically, with more 
data, in figure 57.  
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Figure 57. Higher Survivin levels are associated with vascular invasion of tumour samples. 
Tumours with vascular invasion (VI+) had a greater Allred score (mean rank of 52.9) 
compared to VI- malignancies (mean rank of 38.5, U=1372, p= 0.008). Median Survivin 
values for VI+ tumours was also greater (6.0) than in VI- tumours (5.0). Both of these 
metrics highlight the invasive nature of Survivin expressing tumours and how greater 
Survivin expression can correlate with adverse histopathological features in this study 
cohort. 
Differences in Survivin staining in early versus late-stage disease is of borderline 
significance with mean ranks lower in early (41.7) compared to late stage (53.5) 
disease, U= 1012, p=0.047, as shown in figure 58.  
 
Figure 58. Higher Survivin levels may be associated with more advanced stage disease.  
Median Survivin values for early-stage disease (5.0) was also lower than those found in 
more advanced tumours (6.0), implying this is perhaps a true representation of these 
average values. 
As mentioned above, it was somewhat surprising to find higher levels of Survivin in 
tumours from non-cirrhotic, compared with cirrhosis-derived tumours when all 
malignant neoplasms are assessed, as shown in figure 59, p= 0.039. 
 188 
 
Figure 59. Across all malignancies, higher Survivin levels are significantly associated with tumours that arise in 
non-cirrhotic livers. 
Surgically resected cirrhosis-derived liver tumours express less Survivin, as quantified 
with the Allred score, (mean rank 38.77) compared with non-cirrhosis-derived tumours 
(mean rank 52.61), U= 600, p= 0.039. However, the median values for both being 5.0, 
highlighting the borderline significance of this finding.  
Furthermore, the study cohort is not representative of the majority of patients with liver 
cancer, meaning these findings need to be interpreted with caution owing to this 
selection bias. The asymmetric distribution of tumours arising on a background of 
cirrhosis (n=22, mostly classical HCCs) compared to those tumours arising from non-
cirrhotic livers (n=76, almost all CCAs) will confound this finding. As I have shown 
above, CCAs express significantly more Survivin than HCCs so the significance of 
cirrhosis/ low-expressing tumours correlating is of perhaps somewhat limited value.  
4.1.5.3 Overall Survival based on Survivin Expression 
There remains a weakly significant difference in Survivin in tumours when assessing 
all-cause mortality, as shown in figure 60, p= 0.016. 
 
Figure 60. Across all malignancies, higher Survivin levels are significantly associated with all-cause mortality.  
 The Allred scores in malignant tumours from patients who have gone on to die is 
higher (mean rank 55.67) than in tumours from patients who are still alive (mean rank 
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41.98, U= 1518), p= 0.016. This is also reflected in the median values of those who died 
(6.0) compared with the alive patients (5.0).   
Assessments of cumulative survival in SurvivinHigh malignancies is shown in the Kaplan 
Meier survival curve in figure 61, ꭓ² (1) = 11.321, p= 0.001.  
 
Figure 61. High Survivin expressing malignancies have a reduced cumulative survival.  
Median survival in SurvivinLow expressing malignancies was 80.0 +/- 25.8 months (95% 
CI 29.4 – 130.6) compared to the shorter survival observed in SurvivinHigh expressing 
tumours 39.0 +/- 12.6 months (95% CI 14.2 – 63.8), p= 0.001.  
4.1.5.4 Dichotomised Survivin Expression and clinical features.  
Table 49 outlines how high tumour Survivin is associated with the adverse clinical 
measures of all-cause mortality, tumour stage and vascular invasion. As shown below in 
table 49, high tumour Survivin was more common in tumours from patients who 
subsequently died (31/59, 52.5%) compared with those still alive (10/41, 24.4%) p= 
0.007. Over half of tumours (28/51, 54.9%) that invaded the vasculature had high 
tumour Survivin compared with 21.4% (9/42) in non-invasive tumours, indicating the 
association with this malignant characteristic, p= 0.001. SurvivinHigh is also present in 
more advanced tumours (stages III & IV), being detected in 60.0% (15/25) of late stage, 
compared with 32.3% (21/65) of early-stage disease, p= 0.029. 
 
 190 





Outcome Alive 41 75.5 (31) 24.4 (10) 0.007 
Dead 59 47.5 (28) 52.5 (31) 
Margin R0 58  67.2 (39) 32.8 (19) 0.062 
R1 40 47.5 (19) 52.5 (21) 
Fibrosis - 59 57.6 (34) 42.4 (25) 0.680 
+ 40 62.5 (25) 37.5 (15) 
Cirrhosis - 77  54.5 (42) 45.5 (35) 0.084 
+ 22 77.3 (17) 22.7 (5) 
Tumour 
Stage 
I & II 65 67.7 (44) 32.3 (21) 0.029 
III & IV 25 40 (10) 60 (15) 
Tumour 
Stage 
I 30 83.3 (25) 16.7 (5) 0.007 
II 35 54.3 (19) 45.7 (16) 
III 19 36.8 (7) 63.2 (12) 
IV 6 50 (3) 50 (3) 
Grade  Well 11 72.7 (8) 27.3 (3) 0.716 
Mild/ Mod 65 58.5 (38) 41.5 (27) 
Poor 17 58.8 (10) 41.2 (7) 
Vascular 
Invasion 
- 42 78.6 (33) 21.4 (9) 0.001 
+ 51 45.1 (23) 54.9 (28) 
Tumour HCC 52 73.1 (38) 26.9 (14) 0.018 
FL-HCC 6 33.3 ( 2) 66.7 (4) 
CCA 35 42.9 (15) 57.1 (20) 
Mixed 7 57.1 (4) 42.9 (3) 
pSurv 
Allele 
CC 8 75.0 (6) 25.0 (2) 0.228 
CG 52 65.2 (34) 34.6 (18) 
GG 38 50 .0 (19) 50.0 (19) 
Table 49. High tumour Survivin correlates with the clinic-pathological measures.  
When further characterising individual tumour stages, SurvivinHigh was found at 
increased levels in more advanced tumour stages with only 16.7% (5/30) of stage I, 
45.7% (16/35) of stage II, 63.2% (12/19) of stage III and 50.0% (3/6) of stage IV, 
expressing high levels of tumour Survivin, ꭓ² (3) = 11.777, p= 0.007. Also, SurvivinHigh 
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expression was significantly different between tumour types as only 34.6% (18/52) of 
HCCs compared with 57.1% (20/35) of CCAs highly expressed Survivin, ꭓ² (3) = 9.674, 
p= 0.018.  
There is a non-significant increase in tumour Survivin detected in tumours from non-
cirrhotic (35/77, 45.5%) compared with cirrhotic livers (5/22, 22.7%) p= 0.084. Fewer 
of the R0 resections (19/58, 32.8%) expressed high tumour Survivin levels, compared 
with R1 resections (21/40, 52.5%, p= 0.062). There is no correlation between high 
tumour Survivin and tumour grade (p= 0.716), fibrosis (p= 0.680) or cirrhosis (p= 
0.084) and no association with increased levels of Survivin and any particular 
rs9904341 allele, p= 0.228. 
SurvivinHigh may be a useful adjunct in determining higher-risk liver tumours as 
adversely associated clinical measures (vascular invasion, advanced tumour stage and 
highlighting patients that are at an increased risk of early death) are significantly 
associated with these characteristics in this relatively small malignant cohort. 
4.1.5.5 HCC 
In HCCs, as with all neoplasms I have studied, there is a significant increase in Survivin 
expression in tumours compared to background liver tissues, as shown in table 50.  
HCC Allred Score Tumour Background Liver 
Mean +/- S.D.  5.1 +/- 1.3 3.3 +/- 1.1 
Min – Max (range) 2 – 8 (6) 2 – 7 (5) 
Median 5.0 3.0 
Test Statistic t(42) = 8.8, p= 3.8E-11 
Table 50. Average Survivin expression in HCCs, and paired background livers.  
There remains a greater expression of Survivin in tumours compared to paired 
background liver samples, when quantified using the Allred score (mean tumour 5.1 
compared to background, 3.3, t(42)= 8.8, p= 3.8E-11). As has been shown above, the 
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Survivin quantification has, on average, been lower than that detected in other tumour 
types. An in-depth analysis to ascertain the role of Survivin in HCCs will show 
correlations with some malignant characteristics.  
To further clarify the role of Survivin in HCCs and any potential relationships between 
adverse clinical measures, table 51 highlights significant differences between groups.   
Clinical measures: HCC Significance of Allred Score Differences 
Between Groups 
Fibrosis P= 0.142 
Cirrhosis P= 0.238 
Stage I & II vs III & IV P= 0.106 
Vascular Invasion P= 0.013 
Tumour Grade* P= 0.007 
Table 51. Differential Survivin expression, based on clinic-pathological characteristics in HCC, when FL-HCCs are 
excluded. 
 Survivin expression differs significantly between tumours with vascular invasion (p= 
0.013) and between tumour grades, p= 0.007. Figures 62 and 63 assess these differences 
further. 
 
Figure 62. HCCs with vascular invasion express more Survivin.  
As figure 62 demonstrates, the Allred score mean ranks for VI+ tumours are 29.8 vs 
20.1 (VI-) U= 377, p= 0.013. Median Survivin is greater in VI+ tumours (6.0) compared 
with their VI- counterparts (5.0).  
As can be seen from figure 63, there is significantly more Survivin staining in 
mild/moderately differentiated HCCs (mean rank 26.6, median 5.0) compared to well 
differentiated tumours (9.4, median 4.0) ꭓ² (2) = 10.037, p= 0.005. Interestingly there is 
 193 
minimal increased Survivin expression in poorly differentiated tumours (mean rank 
26.3, median 5.0) compared with MMD (p= 1.00) and WD tumours, p= 0.087. These 
differences represent an increase in apoptosis inhibitor quantity in tumours of less 
favourable differentiation.  
 
Figure 63. Survivin expression in HCCs can discern well-differentiated tumours from mild/moderately differentiated 
HCCs. 
There was no correlation between Survivin expression and the patient’s age (p= 0.085), 
or tumour size, p= 0.448. High expression of tumour Survivin is not associated with 
cumulative survival, ꭓ² (1) = 2.225, p= 0.136. Median survival in SurvivinLow HCCs 
was 62.0 +/- 27.3 months (95% CI 8.4 – 115.6) did not differ significantly when 
compared with SurvivinHigh HCCs 24.0 +/- 15.0 (95% 0.0 – 53.4).  
Survivin expression in the background liver from which various tumour grades grew 
from can be seen in figure 64. Survivin expressed by the background liver varied 
significantly depending on the tumour grade that subsequently grew, ꭓ² (2) = 6.692, p= 
0.035. The Survivin mean rank of background liver from which well differentiated 
tumours grew (14.80) was significantly lower than livers which gave poorly 




Tumour Grade: Hepatic Survivin N Mean Rank Mean +/- S.D. Median 
Well Differentiated 5 14.8 2.8 +/- 0.8 3.0 
Mild/Moderately Differentiated 30 19.7 3.3 +/- 1.2 3.0 
Poorly Differentiated 5 30.8 4.0 +/- 0.7 4.0 
 
Figure 64. Levels of Survivin in background liver samples may be significantly different between livers that go on 
to develop well versus poorly differentiated tumours.  
 
Categorising HCCs into high/low Survivin expressers based on Allred score showed a 









Fibrosis - 26 69.2 (18) 30.8 (8) 0.755 
+ 26 76.9 (20) 23.1 (6) 
Cirrhosis - 36 69.4 (25) 30.6 (11) 0.506 
+ 16 81.3 (13) 18.7 (3) 
Tumour Stage I & II 29 86.2 (25) 13.7 (4) 0.007 
III & IV 17 47.1 (8) 52.9 (9) 
Tumour Stage* I 21 90.5 (19) 9.5 (2) 0.026 
II 8 75 (6) 25 (2) 
III 14 50.0 (7) 50.0 (7) 
IV 3 33.3 (1) 66.7 (2) 
Grade  Well 8 100 (8) 0.0 (0) 0.130 
Mild/ Mod 35 65.7 (23) 34.3 (12) 
Poor 5 80 (4) 20 (1) 
Vascular 
Invasion 
- 29 89.7 (26) 10.3 (3) 0.002 
+ 19 47.4 (9) 52.6 (10) 
pSurv Allele CC 4 50.0 (2) 50.0 (2) 0.172 
CG 23 87.0 (20) 13.0 (3) 
GG 23 69.6 (16) 30.4 (7) 
Table 52. High tumour Survivin correlates with the clinico-pathological characteristics in HCCs.  
High Survivin was significantly associated with vascular invasion and more advanced 
disease.  Just over half the tumours that invade the vascular network (VI+) express high 
levels of Survivin (10/19, 52.6%) compared to around 1 in 10 of less invasive tumours 
(3/29, 10.3%, p= 0.002). High Survivin is expressed in 52.9% (9/17) of advanced stage, 
compared to 13.8% (4/29) of early-stage disease, p= 0.007. When comparing individual 
tumour stages, more express high Survivin at a more advanced stage with 9.5% (2/21, 
stage I), 25% (2/8, II), 50% (7/14, III) and 66.7% (2/3) of stage IV tumours having high 
tumour Survivin levels, ꭓ²(3) = 9.124, p= 0.026. This stepwise increase in Survivin 
expression across adversely associated tumour grades suggests a possible role for this 
apoptosis inhibitor in HCC progression.   
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4.1.5.6 A Note on FL-HCCs 
There was preferential expression of Survivin by FL-HCCs (median Allred score: 7.0), 
differentiating them from HCCs. Given the clear difference in Survivin expression 
between HCCs and FL-HCCs, as well as the different clinical presentation (younger 
patients, not associated with cirrhosis and only a single death within the follow up 
period) these tumours have therefore have been excluded from the HCC analysis. When 
considering a small cohort of six tumours, there are no significant correlations between 
Survivin expression and any clinical parameter, including cumulative survival.   
4.1.5.7 CCA 
The Cholangiocarcinomas also express significantly more Survivin in tumour, 
compared to paired background liver samples as shown in table 53.  
CCA Allred Score Tumour Background Liver 
Mean +/- S.D. 5.3 +/- 1.4 3.1 +/- 0.9 
Min – Max (range) 2 – 8 (5) 2 – 5 (3) 
Median 6.0 3.0 
Test Statistic t(26) = 7.3, p= 9.4E-8 
Table 53. Average Survivin expression in CCAs and paired background liver tissues. 
Unlike in HCC, in CCA differences in tumour Survivin protein levels were associated 
with the promoter variants of rs9904341, figure 65, p= 0.047. The mean ranks of CC 
(6.67), CG (17.2) and GG (22.17) are significantly different (p= 0.047) with particular 
difference between the homozygous alleles, as outlined in figure 65, when pairwise 




Figure 65. Survivin promoter variants differentially express Survivin protein In CCAs.   
Comparisons of Survivin expression between groups (based on clinical measures) is 
outlined in table 54.  
Clinical measures: CCA Significance of Allred Score 
Differences Between Groups 
Outcome P= 0.005 
Fibrosis P= 0.092 
Stage I & II vs III & IV P= 0.024 
Vascular Invasion P= 0.310 
Tumour Grade* P= 0.291 
Perineural Invasion P= 0.045 
Table 54. Survivin expression in all CCAs varies based on clinico-pathological characteristics. 
Tumour Survivin levels appear to differ significantly in all-cause mortality (outcome), 
early vs late-stage disease and perineural invasion. Allred scores for Survivin 
expression in early and late-stage disease is shown in figure 66. 
 
Figure 66. Higher Survivin expression in more advanced stage disease in CCA.  
Tumour Survivin is lower in early-stage disease (mean rank 15.2, median 5.0) compared 
with more advanced disease (mean rank 25.0, median 6.0), in this study cohort, U= 129, 
p= 0.024.  
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CCA has a propensity to spread through the neural network (perineural invasion) of the 
liver and this feature was associated with higher levels of Survivin expression, figure 
67. 
 
Figure 67. Higher Survivin levels may be associated with perineural invasion in CCA.  
The presence or absence of perineural invasion (PI+/-) was recorded in 35 of the CCAs 
included in this study. Of the 35 CCAs included, the Allred score mean rank for those 
with perineural invasion (21.4) was significantly higher than those tumours without 
perineural invasion (14.4, U= 214, p= 0.045). Whilst this is a small cohort and includes 
both intrahepatic and perihilar CCA, it’s interesting to see this adverse clinical measure 
associate with higher Survivin levels and that this is also reflected in Survivin median 
values (PI+ 6.0, PI- 5.0).  
There is a non-significant trend towards fibrosis-related CCAs expressing more tumour 
Survivin when compared with their non-fibrotic counterparts using Allred-score, U= 
146, p= 0.092. However, for all CCAs there was no correlation between the scale 
variables age (rho = 0.291, p= 0.089) and tumour size (rho = 0.181, p= 0.299). 
4.1.5.8 Survival data and Survivin Expression 
Quantified levels of Survivin protein and how these differ across all-cause mortality are 
outlined in figure 68.  
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Figure 68. Higher tumour Survivin levels are associated with all-cause mortality. . 
Comparing the Allred score mean ranks (alive 11.4, dead 21.5, U= 217.5, p= 0.005) 
demonstrates that higher Survivin level, as it was for HCC, is associated with all-cause 
mortality. This is supported by median CCA Survivin being lower in those patients still 
alive (5.0) compared to those who have subsequently died (6.0). Cumulative survival 
analysis with CCA categorised into high and low Survivin groups is shown in figure 69.  
 
Figure 69. Cumulative survival differences based on Survivin expression in CCA.  
There is a significant reduction in overall survival in CCA that express high levels of 
Survivin, ꭓ² (1) = 9.823, p= 0.002. Median survival in SurvivinHigh CCA is 15.0 +/- 7.8 
months (95% CI 0.0 – 30.3) compared to an overall median survival of 24 +/- 6.7 
months (95% 10.9 – 37.1). As 60% of those with SurvivinLow CCAs are still alive, a 
median value (i.e., 50% survival) has not yet been reached, and cannot therefore be 
commented upon. However, differences in mean survival in SurvivinLow (mean 86.6 +/- 
15.0 months, 95% CI 57.3 – 115.9) and SurvivinHigh (mean 25.0 +/- 6.2 months, 95% CI 
12.8 – 37.1) tumours make it a potential biomarker for assisting in prognosticating 
survival in CCA.  
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4.1.5.9 SurvivinHigh and Clinicopathological Correlates in CCA 
Clinical correlations and low/high expressing CCAs are shown in table 55. 





Outcome Alive 12 83.3 (10) 16.7 (2) 0.001 
Dead 23 21.7 (5) 78.3 (18) 
Fibrosis - 26 53.8 (14) 46.2 (12) 0.053 
+ 8  12.5  (1) 87.5 (7) 
Tumour 
Stage 
I & II 27 55.6 (15) 44.6 (12) 0.021 
III & IV 6 0.0 (0) 100 (6) 
Tumour 
Stage* 
I 5 80.0 (4) 20.0 (1) 0.048 
II 22 50.0 (11) 50.0 (11) 
III 5 0.0 (0) 100.0 (5) 
IV 1 0.0 (0) 100.0 (1) 
Grade  Well 1 0.0 (0) 100.0 (1) 1.000 
Mild/ Mod 23  47.8 (11) 52.2 (12) 
Poor 9 44.4 (4) 55.6 (5) 
Vascular 
Invasion 
- 8 62.5 (5) 37.5 (3) 0.418 
+ 25 40.0 (10) 60.0 (15) 
Perineural 
Invasion 
- 17 52.9 (9) 47.1 (8) 0.315 
+ 18 33.3 (6) 66.7 (12) 
pSurv 
Allele 
CC 3 100.0 (3) 0.0 (0) 0.021 
CG 20 50.0 (10) 50.0 (10) 
GG 12 16.7 (2) 83.3 (10) 
Table 55. High Survivin expression in CCAs, and clinic-pathological characteristics. 
All-cause mortality is linked with high tumour Survivin, with 78.3% of those patients 
that went on to die expressing high levels, compared with just 16.7% of patients still 
alive, p= 0.001. One hundred percent of the advanced stage tumours expressed high 
levels of Survivin compared with 44.4% of early-stage tumours, p= 0.021. When 
assessing each individual CCA stage, and comparing high Survivin expression, a stage-
dependent pattern emerged. Twenty percent (1/5) of stage I tumours expressed high 
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Survivin levels which increased with more advanced tumours, as shown by increased 
Survivin expression by stage II (11/22, 50%), III (5/5, 100%) and IV (1/1, 100%) 
tumours, ꭓ²(3) = 7.590, p= 0.048. 
Unlike in HCC an allele-dependent expression of Survivin was demonstrated in CCA. 
The CC allele tumours only expressed low levels of Survivin (i.e., 0% high Survivin 
expression) with 50% (10/20) of CG heterozygotes and 83.3% (10/12) of the GG 
homozygotes expressing high Survivin levels, ꭓ² (2) = 7.778, p= 0.021.  
4.1.5.10 Differentiating CCAs: Perihilar vs. Intrahepatic 
There was no difference in Survivin expression between iCCA and pCCA tumour 
samples, p= 0.654. However, when comparing the background liver levels of Survivin, 
a significant difference becomes apparent.  
Of the 36 CCAs studied 28 had background liver tissues available for assessment. Four 
of these were from pCCAs, which demonstrated significantly higher Survivin 
expression compared to the background livers from iCCAs. Quantification found a 
mean rank iCCA (13.21) lower than pCCA (22.25) to a significant extent, U= 79, p= 
0.042. The significance of this difference is uncertain, but could possibly be related to 
chronic inflammation from, for example, biliary stasis that is known to occur more 
frequently in perihilar, and distal CCAs. Further work is required to clarify these 
findings.  
4.1.5.11 iCCA 
Analysing the iCCAs as a separate group found similar correlations as the CCA cohort 
overall. Mean Allred scores for tumour (5.3) compared with background liver (2.9, 
t(22)= 7.4, p= 2.3E-7) confirm that Survivin is expressed more in iCCA tumours 
compared to background liver samples, with no difference in Survivin expression based 
on the three rs9904341 alleles, p= 0.143.  
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As in the CCA cohort, Survivin expression in iCCA was associated with tumour stage 
(figure 70, p= 0.026), perineural invasion (Mean ranks PI+18.7, PI- 12.4, U= 146.5, p= 
0.048) and increased mortality (mean rank dead 18.1, alive 9.9, U= 155.5, p= 0.009).  
 
Figure 70. Survivin expression differentiates between stage I and stage III disease in iCCA.   
SurvivinHigh expressing iCCA was also shown to be associated with reduced cumulative 
survival, ꭓ² (1) = 6.934, p= 0.008, figure 71.  
 
Figure 71. High Survivin expressing iCCA have a reduced cumulative survival. 
Median survival in SurvivinHigh iCCA is 19.0 +/- 8.0 months (95% CI 3.3 – 34.7) 
compared to an overall survival of 27.0 +/- 8.0 months (95% CI 11.3 – 42.7). Average 
survival for SurvivinLow (>50% still alive therefore median statistics from KM are not 
calculated. However, mean Survival for SurvivinLow is 88.0 +/- 16.6 months (95% CI 
55.6 – 120.5) which is greater than that of SurvivinHigh iCCAs (28.8 +/- 7.4 months, 
95% CI 14.3 – 43.2).  
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4.1.5.12 Mixed 
There were only seven mixed CCA-HCCs for comparison which are of particular 
clinical interest owing to their mixed cell-lineage. As there are so few of these mixed 
tumours this does limit the strength of any conclusions.  
As for all other PLCs Survivin expression was higher in tumour than background liver 
table 56.  
Mixed Allred Score Tumour Background Liver 
Mean +/- S.D. 5.3 +/- 1.1 3.7 +/- 1.2 
Min – Max (range) 4– 7 (3) 3– 6 (3) 
Median 5.0 3.0 
Test Statistic Z = -2.2, p= 0.026 
Table 56. Average Survivin expression in mixed tumour and paired background liver.  
The Allred score mean differences were also significantly higher in tumour samples 
(5.3) compared to background liver (3.7, Z= -2.232, p= 0.026). All of the mixed 
tumours were rs9904341 CG heterozygotes so comparisons between allele’s Survivin 
levels was not possible. 
Of the 7 mixed tumours, 3 were high expressors of Survivin (Allred 6-8). In this small 
study subset of samples, there were no significant differences in the distribution of 
Survivin expression between any groups (based on clinical characteristics). Mixed 
tumours that expressed high levels of Survivin were not associated with a change in 
cumulative survival, ꭓ² (1) = 0.856, p= 0.355. 
All of the tumours (3/3, 100%) from patients with metabolic risk factors expressed high 
levels of Survivin, with the converse being true of those without metabolic risk factors 
(i.e., 0/4, 0%) p= 0.029.  
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4.1.5.13 Adenomata 
The benign Adenomas also expressed more Survivin in tumours tissue than paired 
background liver using the Wilcoxon signed rank method, as shown in table 57. 
Adenoma Allred Score Tumour Background Liver 
Mean +/- S.D. 4.9 +/- 1.5 3.5 +/- 0.7 
Min – Max (range) 3 – 7 (4) 3 – 5 (2) 
Median 5.0 3.0 
Test Statistic Z = -2.3, p= 0.024 
Table 57. Average Survivin expression in Adenomas and paired background liver tissues. 
Allred score median values for tumour Survivin (5.0) is greater than in background liver 
(3.0, Z= -2.263, p= 0.024). No correlation was seen between Survivin levels and clinical 
characteristics, patient age (rho= 0.204, p= 0.571), tumour size (rho= -0.168, p= 0.642) 
or the promoter rs9904341. As expected with benign tumours, all patients were alive at 
end of follow up, so there were no survival differences.  
4.1.6 Discussion	
Using a digital pathology platform to quantify expression of a single protein (Survivin) 
has been achieved in both tumour and paired background liver samples using whole 
slide images. With neoplastic expression of Survivin is consistently higher in both 
benign and malignant neoplasms, it appears to be a method deployed during the 
neoplastic growth of liver tumours, whether they are benign or malignant growths. This 
is analogous to previous reports of gastric carcinoma expresses more Survivin compared 
to normal gastric mucosa (Gu et al., 2014), as well as Survivin being reported as 
expressed by both benign and malignant ovarian neoplasms, (He et al., 2018). 
4.1.6.1 Major Findings 
Digital approaches for quantification and stratification of Survivin expression have 
discovered correlations between clinical characteristics and protein expression at the 
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level of the entire cohort and in tumour subgroup analyses. When considering the whole 
study cohort (including the benign Adenomas), Survivin is present at higher levels in 
tumours of those patients with a poorer prognosis – those that die sooner, demonstrating 
its role in overall survival, p= 0.011.  
Further to this, elevated tumour Survivin has been consistently demonstrated to 
correlate with clinical characteristics including vascular invasion (p= 0.008) and all-
cause mortality (p= 0.016) and positively correlated with tumour size (p= 0.046) in the 
malignant tumours under study. However, when subsequent size (and age) correlations 
between Survivin expression are explored in tumour subtypes, there is no further 
evidence in support of these initial findings. This may be because the sample size is 
simply too small, or indeed it could be an example of a false discovery due to serial 
analyses.  
Within the two main tumour sub groups (HCC and CCA) there is a divergence of 
clinical behaviours when it comes to Survivin-expressing tumours. CCAs express more 
Survivin than classical HCCs (p= 0.028), which explains the somewhat anomalous 
correlation of cirrhosis and lower tumour Survivin, p= 0.039. More HCCs (compared to 
CCAs) develop in the context of cirrhosis so it seems sensible that the data reflects this. 
It is also possible that cirrhotic liver is less able to inhibit apoptosis given then increased 
cellular turnover as a result of the chronic inflammatory process. Therefore, tumours 
from non-cirrhotic tissues are perhaps more able to react to (and overcome) 
physiological control mechanisms, such as apoptosis, given their inflammation-naïve 
state. However, this cohort is not representative of all PLCs, owing to the selection bias 
inherent in this surgically managed group of patients, potentially limiting the 
transferability of these results. It is important to remember that FL-HCCs expressed the 
most Survivin of all the tumours under study. As these tumours are both clinically (i.e., 
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present in younger, non-cirrhotic patients) and morphologically distinct from classical 
HCCs, this perhaps explains the inverse relationship to Survivin expression.   
When assessing HCCs, there is a strong correlation between Survivin expression and 
tumour grade (p= 0.007) as well as vascular invasion (p= 0.013) but no adverse survival 
associated with Survivin-expression, p= 0.246. Vascular invasion has recently been 
reported as being associated with Survivin expressing HCCs, similar to my findings 
(Kapiris et al., 2019). More historical data has correlated Survivin expression with VI, 
local recurrence and disease-free survival, but not tumour grade, (Fields et al., 2004). It 
is clear that Survivin expression is related to some HCC tumour characteristics, but 
further work is required to fully ascertain these relationships. 
The three grades of HCC (well, mild-moderately and poorly differentiated) express 
significantly different amounts of Survivin ꭓ² (2) = 10.032, p= 0.007. This highlights a 
novel, potentially useful method of stratifying well differentiated tumours from 
mild/moderately differentiated has been highlighted in this study based on their ability 
to express Survivin.  Significantly lower levels of tumour Survivin were found in well 
differentiated HCCs (compared to mild/moderately differentiated HCCs) using the 
Allred score, p= 0.005. Further to this, the level of Survivin expressed by the 
background liver varied significantly depending on the tumour grade that it 
subsequently generates, p= 0.035. The Survivin in background livers from which well 
differentiated tumours grew was significantly lower than livers which gave poorly 
differentiated HCCs, p= 0.042. Thus, quantifying the Survivin in background liver 
tissue could help identify poorly differentiated HCCs – which could be a useful aid 
when fully assessing the histopathological characteristics. 
When considering Survivin expression in CCAs – elevated expression is associated 
with a poor outcome (p= 0.005), advanced tumour stage (p= 0.024), perineural invasion 
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(p= 0.045). As CCAs are less common than HCCs, and generally confer a poorer 
prognosis Survivin expression could be clinically useful to identify higher risk tumours 
to help monitor future surgically managed patients. There is limited published data on 
the role of Survivin in CCA, with a study from 2004 in a cohort of 24 patients being one 
of the largest other groups having been studied which also found poorer outcomes in 
patients with high levels of expression, (Javle et al., 2004). As such, the work I have 
presented here contributes significantly to the body of knowledge and further outlines 
the clinical parameters correlate with high tumour Survivin expression.  
4.1.6.2 Other Findings 
Further evidence of malignant characteristics has potentially been demonstrated when 
considering tumour stage. Using the Allred method for quantification there appears to 
be more Survivin present in advanced stage (III and IV) malignancies compared with 
the earlier stage tumours, U= 1012, p= 0.047. An important caveat to consider here is 
the fact that tumour stage is being compared across tumour types, which is not typically 
done clinically. However, it is interesting to compare this finding with the tumour sub-
group analyses. Elevated levels of Survivin have previously been associated with 
advanced grades of cervical cancer, renal cell cancer and HCCs (Baytekin et al., 2011; 
Liu et al., 2015; Kapiris et al., 2019). 
Oddly, the FL-HCCs expressed the most Survivin compared to HCCs (p= 0.028) yet 
carry a better prognosis. As the histological and clinical characteristics of FL-HCC are 
also very different from traditional HCCs these two entities were separated for the 
purposes of analysis. It is unclear why there is significantly more Survivin in this small 
cohort of tumours, so future work could involve increasing the numbers of FL-HCCs 
assessed to better understand the role of Survivin in these rare tumours. 
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When assessing cholangiocarcinomas, the first evidence of allele-dependant Survivin 
expression becomes apparent in our study cohort, with GG homozygotes expressing 
more Survivin, p= 0.047. These GG homozygotes have been demonstrated to have a 
higher risk of developing oral cancer in Taiwanese patients (Weng et al., 2012) 
and occur more commonly in malignant glial cell brain tumours, compared with benign 
intracranial neoplasms in a Turkish cohort (Kafadar et al., 2018). These results back up 
the cell culture data, where GG homozygotes express more Survivin than other alleles, 
therefore it does make sense that (at least in this Western cohort of patients) the GG 
alleles correlate with increased Survivin expression. However, a complicating factor for 
this being patient ethnicity, as there is an established difference in allele frequencies 
depending on ethnicity based on a recent metanalysis, with more cancers in Survivin 
promoter CC homozygotes in Asians (but not Caucasians) adding further complexity to 
the data interpretation (Xu et al., 2014).  
When all CCAs are included (iCCA and pCCA) significantly more Survivin has been 
detected in GG, compared to CC homozygotes, when using the Bonferroni correction 
for adjusted significance, p= 0.048. Similar results, albeit lacking statistical 
significance, are found when the iCCA are compared, p= 0.143. Once again; a larger 
cohort of patients would allow me to clarify whether this relationship further.  
Advanced stage tumours expressed more Survivin when comparing stage III/IV disease 
with stage I/II CCAs, p= 0.024. Mechanistically it makes sense that the more advanced 
a tumour has spread, the more able it is to evade normal physiological control, such as 
programmed cell death. A relatively CCA-specific characteristic (perineural invasion) 
was found to when higher Survivin expression was detected with PI+ tumours 
expressing more than PI-, U= 214, p= 0.045. This is yet further evidence of Survivin 
expression potentially being a useful adjunct in assessing PLCs in routine clinical care. 
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However, this is a small cohort and further work would be required to fully describe the 
potential use of Survivin expression in CCAs.  
Of the 36 CCAs studied 28 had background liver tissues available for assessment. Four 
of these were from pCCAs, which demonstrated significantly higher Survivin 
expression compared to iCCAs. Quantification found a mean rank for iCCA which was 
lower than that of pCCA, p= 0.042. It is interesting that Survivin is differentially 
expressed in the liver tissues, based on the anatomical location of the primary tumour. 
This may be secondary to inflammatory reaction than can occur in cholestasis, which is 
known to occur more frequently in CCAs that develop further down the biliary tree. 
4.1.6.3 SurvivinHigh Expression 
In SurvivinHigh expressing malignancies median survival was found to be significantly 
shorter compared to SurvivinLow expressing malignancies, further characterising adverse 
survival in tumours that strongly express Survivin protein, ꭓ² (1) = 11.32, p=0.001. 
Similar results have also been previously reported in oesophageal cancer (Grabowski et 
al., 2003). Therefore, elevated Survivin expression could be used to highlight patients 
who would benefit from closer follow up after surgery. 
When the malignancies are stratified into SurvivinHigh/Low groups based on their Allred 
score, more Survivin expression correlates with advanced tumour stage (III & IV, p= 
0.029), as well as demonstrating a stepwise increase in protein as tumour stage 
increases, ꭓ² (3) = 11.777, p= 0.007.  
High Survivin expressing malignancies were grouped together and correlated with a 
reduced cumulative survival, p= 0.001. Other common associations across the entire 
malignant cohort between SurvivinHigh included increased expression in tumours with 
vascular invasion (p= 0.001) and in CCAs, p= 0.018.  
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In tumours that have invaded the vasculature, significantly more of these had 
SurvivinHigh levels of expression, further indicating the relevance of this relationship, p= 
0.001. Vascular invasion has only recently been reported as being associated with 
Survivin expressing HCCs, similar to my PLC findings (Kapiris et al., 2019).  
The SurvivinHigh expressing HCCs did have a lower cumulative survival, as well as 
being more prevalent in late-stage disease (p=0.007) and in tumours that invaded the 
vasculature (P= 0.003), partly replicating the findings of Kapiris et al in their recent 
HCC research (Kapiris et al., 2019). There is an incremental increase in SurvivinHigh 
expression through stages I-IV of HCCs, further clarifying the role of Survivin as an 
adverse clinical feature, ꭓ²(3) = 9.124, p= 0.026. Using a different technique, but finding 
similar results to us, Montorsi and colleagues used real time PCR to demonstrate 
significantly more Survivin in HCC than background liver (P= 0.01) and that increased 
Survivin levels correlated with high tumour grade (P= 0.05) and vascular invasion (P= 
0.005) (Montorsi et al., 2007). 
Whilst SurvivinHigh CCAs are associated with all-cause mortality (p= 0.001) and a 
reduced cumulative survival (p= 0.002) and a more advanced stage of disease, p= 0.021. 
In CCAs tumour Survivin was linked to all-cause mortality, p= 0.005. Splitting CCAs 
into SurvivinHighl/Low expression has confirmed this, with SurvivinHigh having a 
significantly shorter overall survival, ꭓ² (1) = 9.823, p= 0.002. 
4.1.7 Conclusion 
Quantifying Survivin expression in liver cancers has been shown to correlate with 
adverse clinical measures, including overall survival, in this study cohort. This early 
evidence suggests there may be a role in quantifying Survivin expression during the 
routine clinical diagnostic work up to highlight high risk patients.  When considering 
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the main liver cancer sub-types, different characteristics correlated with elevated 
Survivin levels in both the tumour, and occasionally the background liver samples.  
4.1.8 Further Work 
It has been possible to commence liver cancer research in the Southwest region, whilst 
including relatively small numbers for research, whilst using novel histological 
quantification methods. Further work could include expanding the study cohort to 
include patients that are surgically resected at another hospital, or even using local 
tumour biopsy samples. Both of these avenues have potential logistical limitations 
(geographical and potentially exhausting the tissue archive respectively) but would help 
by further clarifying my initial findings.  
Given the promising results from the Survivin expression in tumours, it would seem 
sensible to fully explore whether this protein is detectable in the circulation. Whether 
circulating tumour DNA or, as outlined below, other haematological assays could be 
used to quantify this. Correlations between Survivin expression in peripheral samples as 
well as in tumour will only be possible in a prospectively recruited cohort. Greater 
understanding of the biological processes involved in apoptosis inhibition would also be 
of merit, warranting further work in this field. Specific investigations into the role of 
epigenetic alterations such as promoter methylation status, and whether microRNAs 






5 Telomerase Immunohistochemistry 
5.1.1 Introduction 
This chapter outlines my Telomerase IHC findings. As extra optimisation steps were 
required in the processing and interpretation of Telomerase IHC, and the previously 
reported concerns surrounding Telomerase IHC data interpretation there are 
understandably some concerns regarding the true accuracy of these results (il Yu et al., 
2017). However, during the work here, there has been internal consistency within this 
research project, as well as some extensive optimisation steps that have been outlined 
below.  
5.1.2 QuPath Assessment of Tissues: Telomerase 
By way of example of the 4 categories of tissue staining, figure 72 demonstrates 
representative HCCs with figure 73 the CCAs. Negative (-) tissue stains do have some 
small background staining and blue nuclei. As the colour scheme becomes warmer from 
yellow (+) to orange (++) and red (+++) the intensity of staining increases accordingly.  
 
Figure 72. HCC tumours with varying degrees of nuclear positivity for Telomerase. Scale bar: 100 microns. 
In figures 72 & 73 there is evidence of non-specific background staining for Telomerase 
that was reduced through extensive optimisation. The current QuPath software package 
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was only able to quantify nuclear staining intensity even though cytoplasmic expression 
may be present in the tissue. This is an obvious area for improvement in future work for 
this project.  
 
Figure 73. CCA tumours with varying degrees of nuclear positivity for Telomerase. Scale bar: 100 microns.   
5.1.3 IHC Results: Telomerase 
When comparing tumour versus background liver staining intensity, both the H-Score 
and Allred score were used initially, as shown in table 58.  
All Neoplasms H-Score Allred Score 
Tumour Background Tumour Background 
Mean +/- S.D. 31.6 +/- 32.5 19.4 +/- 25.7 4.1 +/- 1.1 3.6 +/- 0.1 
Min - Max (Range) 0.1 – 157.2 (157.1) 0.1 – 180.2 (180.1) 2 – 7 (5) 2 – 7 (5) 
Median 21.9 11.4 4.0 3.0 
Test Statistic t(94) = 3.750, p= 0.000306 t(94) = 4.272, p= 0.000046 
Table 58. Average Allred and H-Score for quantifying Telomerase expression across all neoplasms.  
Data from 95 paired samples (95/111, 85.6%) assessed demonstrated a significant 
difference in quantified Telomerase between tumour and background liver tissues using 
both the H-score (t(94) = 3.750, p=0.000306) and Allred score (normally distributed, t 
(94) = 4.272, p=0.000046).  
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Assessing the role pTERTMut, and how these mutations affect the levels of Telomerase 
detected across all neoplasms (despite being an HCC-lineage-specific mutation) can be 
seen in figure 74. Comparisons between the mutational status of the tumour tissues as 
well as background liver tissues, some of which went on to develop a mutation were 
made.  
 
Figure 74. The effect of Telomerase promoter mutation on expressed Telomerase protein, across all neoplasms.  
Across all hepatic neoplasms there is no significant relationship between Telomerase 
promoter mutants and detectable levels of tissue Telomerase. Furthermore, there is no 
difference in Telomerase levels in the background tissues near Telomerase promoter 
mutation containing tumours.  
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Differences in Telomerase levels across tumour subtypes is shown in figure 75.
 
Figure 75. Tumour Survivin may be preferentially expressed in CCAs.  
There were no significant differences in Telomerase expression, based on tumour 
subtype using either the Allred score [ꭓ²(4) = 6.048, p= 0.196)] or the H-Score [ꭓ²(4) = 
9.281, p= 0.054].  
Individual tumour scores are shown in tables 59 & 60, based on the Allred score and H-
score respectively.  
Allred Score HCC FL-HCC CCA Mixed 
HCC-CAA 
Adenoma 
Mean +/- S.D. 4.0 +/- 1.0 4.3 +/- 1.5 4.4 +/- 1.1  4.1 +/- 0.9   4.1 +/- 1.0 
Median 4.0   4.0 5.0  4.0   4.0 
Mean Rank  48.4 55.1 64.6 56.0 53.0 
Table 59. Average Allred scores (0, 2 - 8) for Telomerase expression in tumour sub-types. 
With CCA only expressing slightly more Telomerase than any of the other tumour 
subtypes, albeit to a non-significant extent, p= 0.196. These findings are replicated 







H-Score HCC FL-HCC CCA Mixed 
HCC-CAA 
Adenoma 
Mean +/- S.D.  26.4 +/- 32.1  42.6 +/- 44.0 44.7 +/- 32.7  37.3 +/- 31.0  33.4 +/- 34.1  
Median 17.4   25.9  41.8 27.7   22.3 
Mean Rank  45.7 61.3 66.2 60.3 53.6 
Table 60. Average H-score values (scale 0 – 300) for Telomerase expression in tumour sub-types. 
The H-score has a wider range in average values but still fails to differ between tumour 
subtypes, p= 0.054. The standard deviation of the Telomerase levels is consistently 
greater than 30.0, and sometimes greater than the mean value – indicating the results 
need to be interpreted with caution.  
If the FL-HCC and HCCs are included in one group then the Allred score demonstrates 
greater Telomerase expression found higher expression is CCAs (mean rank 64.6), 
Mixed tumours (56.0), Adenomas (53.0) compared with HCCs (49.1), albeit to a non-
significant extent, ꭓ²(3) = 5.784, p= 0.123. However, using the H-score finds a 
statistically significant expression of Telomerase in tumour types, ꭓ²(3) = 7.974, p= 
0.047, with a mean rank Telomerase score of 66.2 for CCAs, 60.3 for Mixed tumours, 
53.6 for Adenomas and 47.4 for HCCs. This is further assessed in figure 76.  
 
Figure 76. Tumour-specific Telomerase expression.  
With mean ranks of 66.2 (CCA) and 47.4 (all HCCs) there is significantly more 
Telomerase in the cholangiocellular tumours, when assessing pairwise comparisons 
p=0.032. There is no significant difference between other tumour types, but it is 
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interesting to note that the mean ranks of mixed tumours (60.3) lies between that of 
CCAs and HCCs, albeit to a non-significant extent in this small study cohort. 
The distributions of clinical measures and whether these vary with levels of Telomerase, 
and their respective significance was explored across all clinical parameters. The only 
example of any difference in the distribution of Telomerase Allred scores in these 
groups was when Metabolic risk factors were concerned and was replicated in both the 
Allred (p= 0.007) and H-score (p= 0.004).   
There is a significant difference in the distribution of tumour telomerase levels in 
patients with, and without, metabolic risk factors. This is further assessed in figure 77. 
 
Figure 77. Telomerase expression in tumours is not associated with metabolic risk factors. 
It appears that, across all neoplasms, there is more Telomerase detected in tumours that 
arise in the absence of metabolic risk factors or associated conditions when compared to 
patients who have metabolic risk factors (overweight, obese, non-alcoholic fatty liver 
disease or diabetes mellitus). Those tumours that develop in the absence of metabolic 
risk factors (mean ranks H-score 66.37, Allred 62.51) have significantly more 
Telomerase than tumours from metabolic patients (mean rank H-score 45.83, Allred 
46.77) to a relatively high level of significance (H-score p= 0.004, Allred p= 0.007).  
Relationship between age (years) and tumour size (mm) and the Allred or H scores is 
shown in table 61.  
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Table 61. There is no correlation between tumour/background Telomerase levels across all neoplasms and the 
patient age (years) or the tumour size (mm). 
No significant correlations between tumour/background liver staining intensity and 
patient age/ tumour size were found. All correlation coefficients were negative, as 
shown in table 61, but lacked statistical significance.  
When stratifying high and low levels of tumour Telomerase, and whether this affects 
cumulative survival, Kaplan-Meier curves were created to assess these subgroups, 
figure 78.  
 
Figure 78. Telomerase expression is not associated with cumulative survival. 
Both thresholds used for assessing high/low tumour Telomerase did not find a 
significant difference in cumulative survival. With the higher threshold for designating 
‘high expression’ of Telomerase, there is a non-significant difference in survival, ꭓ² (1) 
= 0.931, p= 0.335. TelomeraseLow expression gave a median survival of 74.0 +/- 21.8 
months (31.2 – 116.8) compared to a median of 39.0 +/- 13.5 months (95% CI 12.5 – 
65.5) in TelomeraseHigh expressing tumours.  
H Score Allred H Score Allred
Correlation Coefficient -0.059 -0.017 -0.078 -0.070
P Value 0.544 0.863 0.449 0.495
Correlation Coefficient -0.031 -0.028 -0.028 -0.012





Tumour Telomerase Background Telomerase
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When considering the more stringent high telomerase category (Allred scores 6-8), 
which has been used in the literature and in the Survivin analyses above, disease 
characteristics compared across these groups can be seen in table 62. 





Gender Female 44 56.8 (25) 43.2 (19) 0.224 
Male 65 69.2 (45) 30.8 (20) 
Outcome Alive 50 70.0 (35) 30.0 (15) 0.317 
Dead 59 59.3 (35) 40.7 (24) 
Fibrosis - 65 58.5 (38) 41.5 (27) 0.160 
+ 43 72.1 (31) 27.9 (12) 
Cirrhosis - 85 60.0 (51) 40.0 (34) 0.143 
+ 23 78.3 (18) 21.7 (5) 
Viral Hepatitis - 94 62.8 (59) 37.2 (35) 0.566 
+ 15 73.3 (11) 26.7 (4) 
Metabolic Risk 
Factors 
- 57 50.9 (29) 49.1 (28) 0.003 
+ 52 78.8 (41) 21.2 (11) 
Genetic Liver 
Disease 
- 99 63.6 (63) 36.4 (36) 1.000 
+ 10 70.0 (7) 30.0 (3) 
pTERT Mutant WT 90 61.1 (55) 38.9 (35) 0.190 
Mut 19 78.9 (15) 21.1 (4) 
Tumour HCC 50 78.0 (39) 22.0 (11) 0.027 
FL-HCC 6 66.7 (4) 33.3 (2) 
CCA 36 44.4 (16) 55.6 (20) 
Mixed 7 57.1 (4) 42.9 (3) 
Adenoma 10 70.0 (7) 30.0 (3) 
Table 62. Clinico-pathological correlates based on high Telomerase expression. 
TelomeraseHigh levels are seen in 49.1% (28/57) of tumours from patients without 
metabolic disease such as diabetes, obesity and fatty liver disease compared with 21.2% 
(11/52) of those with metabolic conditions, p= 0.003. Also, TelomeraseHigh levels are 
also noted to occur in 55.6% (20/36) of CCA tumours compared with 42.9% (3/7) of 
 220 
mixed tumours, 30.0% (3/10) of Adenomas, 22.0% (11/50) of HCCs, and in 33.3% 
(2/6) of FL-HCCs, ꭓ² (4) = 10.573, p= 0.027.  
Otherwise, there was no increased Telomerase expression in either gender, in those that 
have subsequently died (outcome variable), fibrosis, cirrhosis, genetic or viral hepatitis 
driven tumours. Malignant characteristics will be assessed below. 
5.1.4 Tumour Subgroup analysis 
Owing to the heterogeneous nature of the tumours studied, with clear differences 
between staining preference between tumour types, tumour groups, and subgroups were 
further analysed.  For the sake of simplicity, consistency, and to avoid repetition, the 
Allred score has been used preferentially in subsequent analyses. 
5.1.4.1 All Malignancies. 
As a hallmark of cancer, and to reduce any potentially confusing bias in the analysis 
Telomerase levels in malignant tumours have been compared to background tissues, as 
shown in table 63.  
All Malignancies Allred Score 
Tumour Background 
Mean +/- S.D. 4.1 +/- 1.1 3.5 +/- 1.0 
Min - Max (Range) 2 – 7 (5)  2 – 7 (5) 
Median  4.0 3.0 
Test Statistic t(84) = 4.272, p= 0.000052 
Table 63. Average Telomerase expression on malignant tumours and paired background livers. 
There are increased levels of Telomerase expressed in tumour tissues than 
corresponding background liver sample. The Allred score mean values for tumour 
Telomerase (4.1 +/- 1.1) was significantly higher that background liver (3.5 +/- 1.0), 
t(84) = 4.264, p= 0.000052. 
Between the malignancies, average Telomerase expression can be seen in figure 79.  
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Figure 79. Telomerase expression is not tumour specific.  
Of the malignant tumours, CCAs expressed the most Telomerase (mean rank 58.5, 
median 5.0) compared to HCCs (mean rank 43.8, median 4.0), FL-HCCs (mean rank 
49.9, median 4.0) and Mixed tumours (mean rank 50.7, median 4.0) but this was not 
statistically significant, ꭓ² (3) = 5.978, p= 0.113. 
Telomerase expression and potential correlations with age and tumour size are shown in 
table 64. There are no statistically significant correlations between tumour size, or 
patient age, and the quantification of Telomerase tumour tissues. 
Allred Score: All Malignancies Correlation Coefficient (rho) P-Value 
Patient Age -0.051 0.619 
Tumour Size 0.019 0.855 
Table 64. There is no correlation between tumour/background Telomerase levels and patient age, or tumour size in 
malignant tumours.   
When exploring whether clinical characteristics are associated with differential 
Telomerase expression, the results can be seen in table 65.  
All Malignancies Tumour Allred Score Distribution 
Gender P= 0.073 
Outcome P= 0.809 
Metabolic Risk Factors P= 0.002 
Table 65. Differential expression of Telomerase based on clinico-pathological findings. 
Differences in the tumour Telomerase distribution are seen when comparing patients 
with, and without, metabolic disease risk factors or associated conditions (p= 0.002) and 
P= 0.113
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a non-significant difference of Telomerase expression based on gender is also apparent, 
p= 0.073. These differences are further assessed below in figures 80 & 81. 
 
Figure 80. Higher tumour Telomerase levels are found in tumours from patients that do not have metabolic risk 
factors. 
The Allred score demonstrates a statistically significant difference in Telomerase 
detected, depending on whether the patient has a metabolic condition, such as diabetes 
or fatty liver disease. The Allred score also finds more Telomerase in non-
metabolically-derived tumours (mean rank 57.6) compared with metabolically-derived 
tumours (mean rank 40.6), U= 794, p= 0.002. Implying that tumours arising in patients 
with metabolic risk factors/associated conditions do not preferentially deploy 
Telomerase as a method of tumour cell immortalisation.  
Comparing the effect gender has on tumour Telomerase is set out in figure 81. 
 
Figure 81. Higher tumour Telomerase levels may be found in malignant tumours from female patients. 
When comparing mean ranks of Telomerase across all malignant tumours, there is 
preponderance for female patients to preferentially express Telomerase. This data, albeit 
non-significant, indicates that gender may play a role in Telomerase expression across 
liver cancers, (mean ranks: F 56.7, M 45.3, U= 885, p= 0.073). 
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5.1.4.2 Survival and Telomerase expression 
Table 62 has already demonstrated that Telomerase quantification is not a useful tool in 
highlighting patients who go on to die, p= 0.809. When assessing any relationship 
between high tumour Telomerase and cumulative survival, Kaplan Meier survival 
curves can be seen in figure 82. There was no significant difference in cumulative 
survival observed when comparing high and low Telomerase malignancies. 
 
Figure 82. Telomerase levels in malignancies does not correlate with cumulative survival. 
Using the more stringent cut off for designating TelomeraseHigh expression (Allred 6-8), 
there is a non-significant effect on cumulative survival, ꭓ² (1) = 0.695, p= 0.404. 
Median survival 32.0 +/- 9.9 months (95% CI 12.5 – 51.5) in TelomeraseHigh tumours 
compared to a median survival of 42.0 +/- 21.6 (95% CI 0.0 – 84.4) in TelomeraseLow 
expressing tumours.  
Correlating high tumour Telomerase and clinical characteristics highlighted two 
significant relationships as shown in table 66. There was a non-significant difference in 
high Telomerase expressing tumours based on patient gender with 48.6% (17/35) of 










Gender Female 35 51.4 (18) 48.6 (17) 0.081 
Male 64 69.2 (45) 30.8 (20) 
Outcome Alive 40 70.0 (28) 30.0 (12) 0.297 
Dead 59 59.3 (35) 40.7 (24) 
Metabolic Risk 
Factors 
- 55 49.1 (27) 50.9 (28) 0.001 
+ 44 81.8 (36 18.2 (8) 
pTERT Mutant WT 80 60.0 (48) 40.0 (32) 0.184 
Mut 19 78.9 (15) 21.1 (4) 
Tumour HCC 50 78.0 (39) 22.0 (11) 0.011 
FL-HCC 6 66.7 (4) 33.3 (2) 
CCA 36 44.4 (16) 55.6 (20) 
Mixed 7 57.1 (4) 42.9 (3) 
Table 66. High tumour Telomerase and clinic-pathological correlates. 
TelomeraseHigh levels are found in 50.9% (28/55) of the non-metabolically driven 
malignancies compared to those 18.2% (8/44) from metabolic patients, p= 0.001. When 
comparing malignant tumour sub-types, TelomeraseHigh was found in 55.6% (20/36) of 
CCA compared with 42.9% (3/7) of Mixed tumours and 23.2% (11/50) of HCCs and 
33.3% (2/6) FL-HCCs, ꭓ² (2) = 10.411, p= 0.011.  
5.1.4.3 HCCs  
Fibrolamellar tumours were excluded from analysis of HCCs. Comparisons of the 44 
paired tumour-background tissues are shown in table 67.  
HCC Allred Score Tumour Background Liver 
Mean +/- S.D.   3.9 +/- 1.0 3.6 +/- 1.1 
Min – Max (range) 2 – 7 (5) 2 – 7 (5) 
Median 4.0 4.0 
Test Statistic t(43) = 1.699, p= 0.096 
Table 67. Average Telomerase levels in HCCs and paired background liver tissues. 
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In the HCC only cohort there remains no significant difference between tumour and 
background telomerase levels. The Allred score for HCC tumour (3.9 +/- 1.0) was 
marginally greater than that found in background liver (3.6 +/- 1.1) meaning there is a 
non-significant difference between Telomerase protein in liver and tumour samples 
tested, t(43) = 1.699, p= 0.096. This is the first evidence of a universal tumour antigen 
not being differentially expressed by tumour and background liver, perhaps indicating it 
is not a useful tool for assessing HCCs. If the FL-HCCs and classical HCCs are 
included together in a single cohort there remains a non-significant difference between 
tumour and background liver Telomerase-expression, further emphasising this finding, 
t(50) = 1.997, p= 0.051. 
The pTERTMuts status and Telomerase protein levels in tumour and background tissues 
were non-significantly different, as shown in figure 83. 
 
Figure 83. Telomerase promoter mutations do not result in increased Telomerase protein expression in HCCs. 
HCCs containing Telomerase promoter mutants expressed less Telomerase protein 
(mean rank 24.35) compared to WT HCCs (mean rank 26.09) when comparing Allred 
scores, but this difference was not statistically significant, U= 261, p= 0.670.  
There was no significant distribution in the Telomerase expression between any clinical 
parameter. Furthermore, there was no significant correlations between Telomerase 
protein and patient age (rho= 0.082, p= 0.572) or tumour size (rho= 0.062, p= 0.669).  
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No difference in cumulative survival for high and low Telomerase expressing HCC 
tumours was found, as shown in figure 84. 
 
Figure 84. HCCs expression of Telomerase does not correlate with cumulative survival. 
Stratifying TelomeraseHigh/Low expression did not demonstrate a difference in cumulative 
survival, ꭓ² (1) = 0.180, p= 0.671. Median of 42.0 +/- 21.7 (95% CI 0.0 – 84.5) in 
tumours with high nuclear Telomerase compared to a median 62.0 +/- 19.6 (95% CI 
22.9 – 101.1) in low-expressing tumours did not reach statistical significance. In 
addition to this, there were no clinical correlations differentially expressed between 
TelomeraseHigh/Low expressing tumour.  
5.1.4.4 All CCA 
There is more Telomerase in CCA tumours when comparing to paired background liver 
samples, as shown in table 68. 
CCA Allred Score Tumour Background Liver 
Mean +/- S.D.  4.2 +/- 1.1 3.3 +/- 0.8 
Min – Max (range) 2 – 6 (4) 2 – 5 (3) 
Median 5.0 3.0 
Test Statistic t(27) = 4.076, p= 0.000362 
Table 68. Average Telomerase in CCA and paired background liver tissues. 
Average Telomerase protein expression was greater in CCA tumours (4.18 +/- 1.06) 
compared to paired background liver tissues (3.32 +/- 0.77), t(27) = 4.076, p< 0.0004. 
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When assessing the distribution of telomerase staining across clinically distinct groups, 
there are a few significant differences that have been highlighted in table 69. 
Clinical measures: CCA Significance of Allred Score 
Differences Between Groups 
Metabolic Risk Factors P= 0.001 
Perineural Invasion P= 0.481 
iCCA vs pCCA P= 0.016 
Table 69. Telomerase expression is differentially expressed based on clinico-pathological properties. 
Telomerase appears to be differentially expressed when patients have metabolic 
diseases, and is also significantly different between pCCA and iCCA.  
The metabolically related tumours and the levels of Telomerase are shown in figure 85. 
 
Figure 85. Higher tumour Telomerase levels are found in CCAs in patients that do not have metabolic risk factors. 
Higher telomerase is found in the non-metabolically derived tumours when quantified 
with the Allred score (mean ranks 23.21 vs 11.90, U= 58.5, p= 0.001) registering these 
highly significant results. 
The difference in Telomerase between perihilar (pCCA) and intrahepatic CCA (iCCA) 
is shown in figure 86. 
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Figure 86. Higher tumour Telomerase levels are associated perihilar CCA compared to intrahepatic CCA. 
Allred score (mean ranks iCCA 16.63, pCCA 27.83) demonstrates higher levels of 
tumour Telomerase expressed by pCCAs, based on this small study cohort, U= 146, p= 
0.016.  
When correlating Telomerase expression with age and tumour size, a couple of 
interesting results are highlighted. The levels of Telomerase in the background liver are 
negatively correlated with patient age. The negative correlation coefficients (Allred 
score rho= -0.417, p= 0.027) indicate that younger patients with CCA express more 
Telomerase compared to their older counterparts. No correlations between tumour 
Telomerase and the clinical characteristics (including tumour size) were found.  
There is no significant difference between TelomeraseHigh/Low expression and 
cumulative survival, as outlined in figure 87. 
 
Figure 87. CCA Telomerase expression is not correlated with cumulative survival. 
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There is no difference in survival between high and low Telomerase expressing 
tumours, ꭓ² (1) = 0.030, p= 0.862. Average survival for TelomeraseHigh expressing CCA 
tumours with a median survival of 24.0 +/- 3.5 months (95% CI 17.1 – 30.9) compared 
with low expressing tumours that have median survival of 27.0 +/- 11.3 (95% CI 4.8 – 
49.2).  
Tumours that express high levels of Telomerase are shown in table 70, with significant 
differences in clinical measures highlighted.  





Gender Female 20 45.0 (9) 55.0 (11) 1.000 
Male 16 43.8 (7) 56.3 (9) 
Outcome Alive 12 50.0 (6 ) 50.0 (6) 0.729 
Dead 24 41.7 (10  58.3 (14) 
Metabolic Risk 
Factors 
- 21 19.0 (4) 81.0 (17) 0.001 
+ 15 80.0 (12) 20.0 (3) 
Perineural 
Invasion 
- 18 50.0 (9) 50.0 (9) 0.738 
+ 18 38.9 (16) 61.1 (20) 
CCA Location iCCA 30 53.3 (16) 46.7 (14) 0.024 
pCCA 6 0.0 (0) 100.0 (6) 
Table 70. High CCA Telomerase and clinico-pathological properties.  
More of the non-metabolically related tumours (81.0%) have TelomeraseHigh compared 
to just 20% of metabolically related tumours, p= 0.001. Interestingly tumour location 
and TelomeraseHigh are related with 100% of the pCCA expressing increased levels of 
telomerase compared to 46.7% of iCCA, p= 0.024.  
5.1.4.5 iCCA 
Differentiating between CCAs based on anatomical location will help to highlight 
potential differences in their telomerase expression profiles. Table 71 shows that iCCA 
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continue to express significantly more telomerase in tumour, compared to paired liver 
samples. 
iCCA Allred Score Tumour Background Liver 
Mean +/- S.D.  4.0 +/- 1.0 3.3 +/- 0.8 
Min – Max (range) 2 – 6 (4) 2 – 5 (3) 
Median 4.0 3.0 
Test Statistic t(23) = 3.093, p= 0.005 
Table 71. Average Telomerase expression in iCCA and paired background liver tissues. 
Intrahepatic CCAs express more Telomerase in tumour (4.0 +/- 1.0) than background 
liver (3.3 +/- 0.8) of paired samples are compared, t (23) = 3.3093, p= 0.005. The role 
metabolic risk factors play in telomerase expression is further explored in figure 88. 
 
Figure 88. Higher iCCA Telomerase levels are associated with patients that do not have metabolic risk factors. 
Allred scores (mean rank – 20.31, + 10.00, U = 35, p= 0.001) indicate that non-
metabolically derived iCCAs express more Telomerase compared to their metabolically 
driven counterparts. No significant correlation coefficients were found when compared 
Telomerase protein levels with patient age (rho= -0.302, p= 0.104) or tumour size (rho= 
0.116, p= 0.543).  
Stratifying iCCA into TelomeraseHigh/Low expression demonstrated no difference on 
cumulative survival, as shown in figure 89, ꭓ² (1) = 0.050, p= 0.823. 
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Figure 89. High Telomerase expression does not correlate with cumulative survival in iCCA. 
Median survival for TelomeraseHigh is 24.0 +/- 16.7 months (95% CI 0.0 – 56.8) 
compared to a non-significantly increased survival in TelomeraseLow tumours: median 
survival 27.0 +/- 11.3 months (95% CI 4.8 – 49.2).  
As shown in table 70 above, non-metabolically driven iCCAs expressed more 
Telomerase compared to metabolically driven tumours. With 75.0 % (12/16) of the non-
metabolic iCCA expressing TelomeraseHigh levels compared to 14.3% (2/14) of the 
metabolically-associated iCCAs, p= 0.001. No other significant relationships between 
TelomeraseHigh/Low expression and clinical characteristics was found. 
5.1.4.6 Mixed 
The small number of mixed tumours included in the cohort were assessed for their 
Telomerase-related characteristics. There was no significant difference in Telomerase 
expression between tumour and background liver, as shown in table 72. 
Mixed Allred Score Tumour Background Liver 
Mean +/- S.D.  4.1 +/- 0.9 3.6 +/- 0.8 
Min – Max (range) 3 – 5 (2) 3 – 5 (2) 
Median 4.0 3.0 
Test Statistic Z= -1.633, p= 0.102 
Table 72 Average mixed tumour and paired background liver Telomerase expression. 
There is no significant difference in the distribution of telomerase protein across various 
clinical parameters, including pTERTMut status, p= 0.857.  When considering if 
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Telomerase correlates with age and tumour size, there may be a positive correlation 
between older patients with mixed tumours, as shown in table 73. 
Allred Score: Mixed Tumours Correlation Coefficient (rho) P-Value 
Patient Age 0.794 0.033 
Tumour Size -0.019 0.968 
Table 73. Patient age and Telomerase expression positively correlate in Mixed tumours. 
The Allred score correlates positively with patient age (coefficient 0.794, p= 0.033). It 
is hard to interpret this data in such a small cohort size, so further work is warranted, but 
it appears to show that there may be a significant correlation between patient age and 
Telomerase expression in mixed HCC-CCA tumours.  
High expression of Telomerase may be protective in the mixed tumour cohort, as shown 
in the cumulative survival Kaplan Meier survival plots in figure 90. 
 
Figure 90. High levels of Telomerase in mixed tumours does not correlate with cumulative survival. 
Average survival for these low expressing tumours includes a median survival of 8.0 +/- 
4.0 months (95% CI 0.2 – 15.8) compared to a median survival 32.0 +/- 10.6 (95% CI 
11.2 – 52.8) for the TelomeraseHigh tumours, ꭓ² (1) = 0.781, p= 0.377. 
5.1.4.7 Adenomas 
The benign neoplasms are assessed for completeness, with irrelevant malignant 
characteristics excluded from analysis. There is no difference between tumour and 




Tumour Background Liver 
Mean +/- S.D.  4.1 +/- 1.0 3.8 +/- 1.0 
Min – Max (range) 3 – 6 (3) 2 – 6 (4) 
Median 4.0 4.0 
Test Statistic Z= -0.749, p= 0.454 
Table 74. Average Adenoma and paired background liver Telomerase expression. 
On average tumours expressed a non-significantly higher quantity of Telomerase 
protein compared to their paired liver samples. The Allred score gave a higher value for 
tumour (4.1 +/- 1.0) compared to liver tissue (3.8 +/- 1.0) but this also failed to reach 
statistical significance, Z= -0.749, p= 0.454. Correlations between Telomerase protein 
and age/tumour size are shown in table 75.  
Allred Score: Adenomas Correlation Coefficient (rho) P-Value 
Patient Age 0.750 0.012 
Tumour Size -0.489 0.151 
Table 75. Patient age and Telomerase expression positively correlate in Adenomas. 
A positive correlation exists between the age of the patient and Telomerase expression, 
correlation coefficient = 0.750, p= 0.012. There was no significant difference in the 
distribution of high Telomerase-expressing tumours between relevant clinical or 
pathological characteristics. 
5.1.5 Discussion 
The findings from my Telomerase protein detection, and correlations with clinical 
parameters, has not reflected previously published data. This is potentially due to 
technical issues surrounding the IHC protocol, or data interpretation processing on 
QuPath. However, it is also plausible that these findings are an accurate representation 
of Telomerase expression in liver tumours, but proving this would require further 
conformational work.  
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5.1.5.1 Major Findings 
When assessing all neoplasms, Telomerase protein is more prevalent in tumour, 
compared to background liver, when using both the H-score (p= 0.000046) and Allred 
score (p= 0.000306) similar to previously published results (Zhou, Lu and Zhu, 2016). 
Quantifying using mRNA levels has previously found a 15-fold increase in expression 
between HCC and background liver (Choi et al., 2020). Patient age, gender and tumour 
size not been associated with Telomerase expression in this cohort, as previously 
reported in primary liver cancer (Zhou, Lu and Zhu, 2016).  
Across the entire cohort, higher levels of tumour Telomerase has been consistently 
detected in patients without metabolic risk factors, (Allred, p= 0.007; H-score p= 
0.004). This implies obesogenic states result in a metabolic disturbance do not utilise 
Telomerase in tumour tissues to the same extent as non-metabolically driven tumours.   
When comparing all malignancies, tumours expressed more Telomerase than their 
paired background liver tissues, p<0.00006. There is evidence of CCAs preferentially 
expressing more Telomerase compared to HCCs (pairwise comparison p= 0.016). The 
correlation between Telomerase and non-metabolically associated tumours continues 
(p= 0.002) as well as a potential female gender related increase in protein expression 
(Allred score, p = 0.073). This gender bias was not reflected in tumour specific 
analyses, and has not been reported in the published literature. There was no difference 
in Telomerase expression when malignancies were grouped based on their promoter 
mutational/WT status, p= 0.306, consistent with previously published data from PLCs 
(Huang et al., 2015).  
Malignancies with TelomeraseHigh protein levels tended to be non-metabolic-related 
tumours (50.9%, 28/55) compared to just 18.2% (8/44) of patients with a metabolic risk 
factor, p= 0.001. Cholangiocarcinomas expressed higher levels of Telomerase (55.6%, 
 235 
20/36) compared with mixed tumours (42.9%, 3/7) and HCCs (23.2%, 13/56), p= 0.005. 
There was a non-significant association between gender and high-expression of 
Telomerase which occurred in 48.6% (17/35) of women and only 29.7% (19/64) of 
men, p= 0.081. 
The tumour-specific expression of Telomerase is also seen when CCAs are directly 
compared to HCCs (pairwise comparison, p= 0.032). However, only the CCA tumour 
subgroup expressed more Telomerase than their paired background liver using both the 
H-score, p< 0.0005, and Allred score, p< 0.0004. As supported by previous evidence of 
Telomerase activity in CCAs, with mRNA present in exfoliated needle biopsies (Itoi et 
al., 2000).  
High Telomerase-expressing CCAs were more often non-metabolically derived than 
metabolically driven, p= 0.001. Perhaps this is a cholangiocyte-specific example similar 
to previously published data, which used RNA sequencing to demonstrate that 
metabolic genes are downregulated in TelomeraseHigh expressing hepatocytes (Lin et al., 
2018).   
There was anatomical variation in Telomerase expression, with more Telomerase in 
perihilar CCAs compared to their intrahepatic counterparts, p = 0.016. The mechanisms 
behind this site-specific increase in protein expression are unclear, but perhaps result 
from earlier biliary stasis and obstruction, which occurs earlier in the disease process for 
more proximal tumours. This would support data from Ozaki et al who studied 
Telomerase expression in 19 iCCA, five of these tumours which were due to 
hepatolithiases, and their control samples being benign hepatolithiasis-associated biliary 
tissues which occasionally expressed Telomerase (Ozaki et al., 1999). Adding further 
weight to this is the fact that I have also found CCAs with TelomeraseHigh expression 
tend to be pCCA (100%, 6/6 in my study) compared to iCCA (only 14/30, 46.7%), p= 
0.024.  
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Intrahepatic CCAs expressed more Telomerase than their paired background liver, p= 
0.005. Intrahepatic CCA that developed in the absence of metabolic disease expressed 
more Telomerase than metabolically-associated iCCAs, regardless of the quantification 
method used in assessing staining (p= 0.001). This was confirmed when iCCAs were 
stratified into TelomeraseHigh/Low expressers. TelomeraseHigh expressing tumours 
occurred in 75% (12/16) of the non-metabolic tumours, compared with just 14.3% 
(2/14) of the metabolic-associated iCCAs, p= 0.001. 
When assessing my data in the whole cohort and tumour subgroups, I also did not detect 
any increase in Telomerase protein in pTERTMuts. This implies my findings reflect what 
has already been reported in hepatocellular tumours, (Huang et al., 2015).   
5.1.5.2 Minor Findings 
Two thirds of R1 CCA tumours expressed high levels of Telomerase, compared with 
one third of R0 tumours, p= 0.081. In this small study sample, this is perhaps early 
evidence of more malignant behaviour in Telomerase-expressing CCAs. 
Further interesting data from the background liver tissues of CCA tumours has found a 
negative correlation between protein expression and patient age. Correlation 
coefficients between Allred score and patient age (coefficient = -0.417, p= 0.027) 
suggests younger patients who develop hepatic CCAs express more significantly more 
Telomerase in their native, non-malignant livers.  
Surprisingly, when considering all HCCs, there was not preferential express tumour 
expression of Telomerase compared to background liver tissues (p= 0.051) which 
remained when FL-HCCs were excluded, p= 0.096. There was no difference in 
Telomerase expression in the promoter mutants, compared with WT, p= 0.820. There 
was no Survival benefit in TelomeraseLow expressing HCCs and no correlations with 
patient age, or tumour size.  
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Across all HCC subtypes, the well differentiated HCCs expressed higher Telomerase 
levels (4/9, 44.5%) compared with mild/moderately differentiated (8/37, 21.6%) and 
poorly differentiated tumours (0/6, 0.0%), but this was not a significant finding, p= 
0.093. Only one third (10/30) of non-metabolic-driven HCCs expressed high 
Telomerase levels, compared to 11.5% (3/26) of metabolic related tumours, but this was 
also a non-significant finding, p= 0.065. 
When fibrolamellar HCCs were excluded from analysis there was little change in the 
Telomerase expression findings. These HCCs failed to express significantly more 
Telomerase than their paired background liver tissues, H-score p= 0.438, Allred p= 
0.096. There was also no difference in Telomerase expression between WT and 
promoter mutants, Allred p= 0.670, H-score p= 0.992.  
High Telomerase expression in HCCs was not associated with adverse survival, patient 
age or tumour size. A potential difference finding higher Telomerase expression in one 
third (8/24) of non-metabolic, compared with 11.5% (3/26) of metabolic, tumours also 
failed to reach significance, p= 0.091. 
Mixed CCA-HCC tumours shared more characteristics with HCCs than CCAs when 
Telomerase protein expression was considered. There was no difference in protein 
levels between tumour and background liver tissues, similar to the HCC group. There 
was also a positive correlation between patient age and Telomerase expression, again 
similar to the HCC cohort.  
The positive correlation between patient age and Telomerase levels (Allred score: rho = 
0.794, p= 0.033) in both mixed tumours and benign Adenomas (correlation coefficient 
= 0.750, p= 0.012) indicates that both of these tumour types preferentially express more 
Telomerase protein in older patients.   
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5.2 Discussion of Results 
When attempting to put my findings within the current body of scientific knowledge, it 
is difficult to know how accurate my results are. Previously published works have found 
limited relationships between Telomerase expression and adverse clinical outcomes, or 
tumour characteristics (il Yu et al., 2017). Reassuringly, my work assessing Telomerase 
in liver tumours has not yielded many meaningful findings.  
In addition to this: cumulative survival was not affected by Telomerase levels, similar to 
results from hepatocellular carcinoma, renal cancer, oral squamous carcinoma and 
cervical carcinoma (Carkic et al., 2016; il Yu et al., 2017; Yang et al., 2017; Trifunovic 
et al., 2018). The Kaplan Meier survival curves for the main tumour subtypes failed to 
demonstrate a difference in cumulative survival when tumours were stratified based on 
TelomeraseHigh/Low expression. 
It has been previously reported that epithelial cells with a high rate of self-renewal, such 
as those found in the GI tract, tend to express Telomerase protein and enzyme activity, 
albeit to a lesser extent than compared to tumour samples (Tahara et al., 1999). The 
epithelial cells’ ability to express Telomerase protein might confound my findings in 
this relatively small study. Cholangiocarcinoma can also express Telomerase mRNA in 
85% of iCCA, as detected by in-situ hybridisation, indicating my findings replicate an 
alternative technique previously utilised on fresh tissue samples (Ozaki et al., 1999). 
Transcriptional evidence of Telomerase activation is present in serum blood samples 
with hTERT mRNA detected in 84.5% of CCAs indicating that Telomerase activity is 
expected to be detected in the majority of CCAs (Leelawat et al., 2006). 
Telomerase promoter mutants are hepatocellular, not cholangiocellular, lineage specific 
genetic alterations (Quaas et al., 2014). Elevated transcriptional activity due to 
pTERTMuts does not always correlate with promoter status. Previous multi-tumour 
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studies that found pTERTMuts result in elevated Telomerase levels in both adult gliomas 
and thyroid cancers, but not HCCs, despite these tumours harbouring similar rates of 
promoter mutation (Huang et al., 2015; il Yu et al., 2017). 
However, chronic inflammatory conditions within the liver, such as fibrosis and 
cirrhosis, have been reported to be associated with elevated Telomerase activity (Nault 
et al., 2013; Lin et al., 2018). My data failed to find similar increases (at least by protein 
expression) across the study cohort as a whole, or during the individual tumour 
analyses. Similarly, previously published work has found elevated Telomerase activity 
to correlate with advanced stage disease and poorer tumour differentiation in HCCs that 
was not reflected in my data (Zhou, Lu and Zhu, 2016).  
When assessing Telomerase levels in both HCC and background liver samples, Choi et 
al used RT-PCR from curative resection specimens and reported a fifteen-fold increase 
in Telomerase expression in tumour tissues (Choi et al., 2020). Early research found 
significant enzymatic activity, when quantified using the TRAP assay, in HCCs 
(Shimada et al., 2000). My results, albeit using an alternative method of quantification, 
have failed to find any significant difference in Telomerase levels between HCCs (+/- 
FL-HCCs) and background liver tissues. This is perhaps due to differences in genomic 
and transcriptomic alterations that are not translated to altered proteomic expression, or 
perhaps as a result of a flawed scientific approach.   
A key step in Telomerase-related carcinogenesis for HCCs is the nuclear translocation 
of the enzyme, which was the basis of using only nuclear positivity as a method for 
detection by the QuPath software package (Chen and Kong, 2010). I have been unable 
to reflect any of the previously published data by using IHC on archived FFPE samples 
as a proxy for either the TRAP assay or comparing with transcriptomic data quantified 
with PCR. However, evidence from the literature stating that the presence of 
Telomerase protein, as measured by Western blot, does not always correlate with 
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enzymatic activity detected by the TRAP assay (Tahara et al., 1999). Clearly simple 
comparisons between quantification methods is an overly simplified approach, requiring 
further work to clarify this.  
More recent work has also found varying rates of Telomerase protein and 
transcriptional material in HCCs. Using IHC to detect and quantify hTERT positive 
cells in 84.6% of HCCs with 78.2% of cases having detectable Telomerase mRNA, 
(Zhou, Lu and Zhu, 2016). These findings are of a similar magnitude, and as such, the 
differences between my findings and the published data are difficult to explain.  Given 
that the only resource material available for this project is FFPE, meaning further work 
in fresh/frozen tumour samples would be required in a validation cohort.  
Previous reports have demonstrated elevated levels of protein correlating with 
worsening differentiation in HCCs as well Telomerase being present in biliary epithelial 
cells (Kawakami et al., 2000). Perhaps the reasons for lower detection of tumour 
Telomerase is due to QuPath’s inability to characterise cytoplasmic staining. Notably, 
Zhou et al have stated that cytoplasmic Telomerase is more much more prominent in 
HCCs, whereas Huang et al feel it is detectable in both nuclear and cytoplasmic cellular 
compartments (Zhou, Lu and Zhu, 2016; Huang et al., 2017). Whilst the nuclear 
staining appears to be very robust, there are many non-specific light shades of brown 
that – upon review of their figures - both Zhou and Huang feel should be regarded as 
positive staining.  
More recently published works, albeit in renal cell cancer research, have acknowledged 
there is some cytoplasmic staining but have focussed on nuclear positivity when 
assessing hTERT expression in Renal cancers (Saeednejad Zanjani et al., 2019). Indeed, 
Zanjani published an example of their four staining intensities (negative -, weak +, 
moderate ++ and strong +++) for hTERT protein detected during IHC in renal cell 
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cancer, as shown in figure 91, (Saeednejad Zanjani et al., 2019). These are very similar 
to our staining intensities observed in the process of IHC optimisation. 
 
Figure 91. Assessing hTERT in renal cell cancer (RCC): negative staining (A), weak positive staining (+ B), 
moderate positivity (++, C) and strong positive staining (+++, D). 
Whilst it is known that malignant cholangiocytes and hepatocytes express Telomerase 
activity, protein levels have not previously been compared between the two tumour 
types (Itoi et al., 2000; Zhou, Lu and Zhu, 2016).  However, Telomerase protein has 
been reported in both normal cholangiocytes and hepatocellular tumours (using IHC) so 
further work clarifying this expression is required (Kawakami et al., 2000).  
Given the reservations associated with IHC quantification of Telomerase protein 
mentioned in the literature, it would be very reassuring to have secondary-confirmation 
of my IHC-quantification findings, (Kim et al., 2013).  
5.2.1 Further Work 
The most consistent finding from my work is increase in Telomerase expression in 
tumours that are not associated with metabolic conditions. Further exploration of 
exactly what happens to Telomerase expression in metabolic conditions (diabetes 
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mellitus, etc) may help to understand why these tumours express lower levels of 
Telomerase. Indeed, it may be a significant oversimplification to lump together all fat-
related conditions, especially as fatty change in the liver is a common alteration due to 
hepatotoxic insults.  
By greatly increasing the number of cases under study would be another way of 
confirming my putative correlations. The role of patient age has on Telomerase 
expression (as highlighted in the mixed and benign cohort) is one such example where 
greatly increasing these numbers could confirm this initial results. Another relatively 
simple, if not labour intensive, method would be to compare relative Telomerase 
expression in this dataset, with a secondary technique. This would give greater 
confidence in the validity of my findings. Repeating IHC using an alternative antibody, 
or using an alternative method (such as ISH) seems like a sensible place to start.  
As mentioned above, there are a number of methods of inducing alterations in 
Telomerase expression – including promoter hypermethylation status studies using 
DNA bisulfite conversion and pyrosequencing, (Fotouhi et al., 2019). Epigenetic 
changes (not promoter mutation) have been shown to result in increased Telomerase 
expression in small bowel neuroendocrine tumours. This approach used fresh/frozen 
samples but it could be attempted with FFPE-extracted DNA – as has been undertaken 
elsewhere, (Doyle, O’Riain and Appleton, 2011).  
In addition to the epigenetic alterations, assessing viral DNA insertion as well as TERT 
amplification/ translocation events could help increase the understanding of Telomerase 
in PLCs. More recent work has also assessed the role of telomere length in aggressive 
liver tumours, with the exciting possibility of targeting these with anti-TERT antisense 
oligonucleotides as a targeted therapy, which has worked in cell culture and mouse 
models of HCC (Ningarhari et al., 2020).  
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6 Ongoing and Future Work 
Owing to time constraints and a global pandemic this section will outline my ongoing 
and planned future work for the haematological detection of universal tumour antigens.  
6.1 ELISA Results 
There ELISA results stalled at the optimisation stage and therefore failed to offer 
meaningful results for the whole cohort. The data is separately analysed for Survivin 
and Telomerase, as outlined below. 
6.2 Survivin 
As outlined in section 2.7.13 the calibration curves for Survivin ELISA were 
satisfactory, with a high R2 giving confidence when estimating the results.  
Diluting standards and samples with the manufacturers provided diluent gave the results 
shown in table 76. This includes samples at 1X and 0.1X (i.e., diluted 1:10 in diluent) to 
explore the accuracy of the assay. These results were somewhat disappointing as 
measurements could not be reliably made, given that the majority of samples lay in off 
scale concentrations (between the low standard [31.3pg/ml] and the zero-standard 
diluent) meaning these results were not within the reference range. Furthermore, there is 
also a paradoxical increase in OD when the serum is diluted - see 4E& 4F - between 
sample 45 (neat) and its 1:100 dilution (5A & 5B), table 76.  
 
Table 76. Plate outline shown on the left panel with standards highlighted: yellow background, zero-standard shown 
with purple. Known High (red background), medium (orange) and low (green) concentrations of Survivin are also 
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present. Respective study numbers, and dilutions from 3G onwards. All reagents diluted with the provided diluent 
buffer. Right panel shows corrected results (OD 450-570nm) with red highlighting measurements that are between 
the low standard (31.3 pg/ml) and the zero standard, i.e., not on the scale for measurement.  
Taken in combination, these results imply the ELISA kit is not able to detect human 
Survivin from serum samples with any confidence. The Survivin immunoassay control 
was only used in the first experiment as the recombinant protein, present in diluted 
porcine serum, was of limited value once we had established the assay was working. 
To explore the serum-effect on this commercially available kit the experiment was 
repeated using 10% (v/v) healthy volunteer (HV) serum, using the provided diluent. 
These results can be seen in table 77.  
 
Table 77. Left panel shows standards highlighted on a yellow background with a zero standard on a purple 
background, and healthy volunteer (HV) compared with cancer patients’ (numerical values) serum. Right panel: 
results highlighted with red font are between the low standard (31.3pg/ml, OD: 0.055) and the zero standard 
(0pg/ml, OD: 0.016). 
Once the serum-effect was accounted for there were no detectable of Survivin in any of 
the samples tested. This is a somewhat disappointing result given that the ELISA kit 
used up precious biological samples and cost ~£500 for one plate. It is for these reasons, 
as well as time pressure, that an alternative direction was pursued.  
6.3 Telomerase 
The sandwich ELISA for Telomerase gave mixed results, as outlined below. The high 
standard (10ng/ml) Telomerase reading dipped compared to the 5ng/ml sample and was 
therefore excluded from the equation to estimate concentration from observed OD – 
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demonstrated by the lack of yellow-highlight in table 78. The provided diluent was used 
and giving the results from the ELISA are shown in table 78.  
 
Table 78. Standard are highlighted (yellow background, zero-standard with purple. Plate layout is shown on the left 
sided table.  The results (table on the right) appear to indicate an increase in the detected Telomerase with a 1:10 
dilution – compare results from 4A&B with 5A&B. 
There appears to be an increase in Telomerase detected in the 1:10 diluted samples, 
compared to physiological serum, similar to the Survivin ELISA results. This casts 
further doubt on the usefulness of this assay, and therefore severely limits the 
implications of these results.  
Further to this, when attempting to explore the role human serum has on this assay, as 
show in table 79, data from the calibration standards run in 10% HV diluting serum was 
of exceedingly poor quality.  
 
Table 79. Using the same layout, and samples, as shown in table 78 – the effect 10% HV Serum has on the ELISA is 
shown here. Standard are highlighted on a yellow background with a purple background demonstrating the results 
from the zero-standard. The highest detected level in this ELISA was in the zero standard, meaning that further 
analysis was futile. 
As shown in table 79, the highest values recorded were in the zero standard, making all 
of the corrected readings at 450nm negative values (standard OD (ng/ml) – diluent OD 
1 2 3 4 5
A 1.268 1.519 0.384 0.325 1.103
B 1.511 1.406 0.368 0.347 1.135
C 1.464 1.204 0.472 0.209 0.853
D 1.331 1.245 0.716 0.24 0.719
E 1.138 1.287 1.214 0.248 0.841
F 1.096 1.206 1.618 0.273 0.846
G 1.153 1.445 1.510 0.241 0.784
H 1.618 1.799 1.627 0.358 0.872
OD's for 10% HV Serum used as diluent: Telomerase
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(0ng/ml) = negative number). As a result of this, and the wide ranges seen in the 
calibration curve (figure 7) no further interpretation of these ELISA results were 
undertaken. 
6.4 Discussion 
For separate reasons both the Survivin and Telomerase ELISAs failed to yield any 
meaningful data. The Survivin assay failed to give any results above the low-standard’s 
OD, making the interpretation of the respective concentration speculative, inaccurate 
and below the level of detection. Previously published work has used the same assay to 
successfully detect Survivin in serum from pancreatic cancer patients, so perhaps all of 
these HCC serum samples were negative for Survivin (Moazeni-Roodi et al., 2019). 
However, Jia et al, used an alternative ELISA kit and feel that Survivin is not a 
promising serological marker for HCC, which would agree with the findings from the 
limited sample of HCC patients that have been studied here (Moazeni-Roodi et al., 
2019). 
There were a couple of issues from the Telomerase assay. The inexplicable lowering of 
the detected OD from the 5ng/ml to the 10ng/ml standards and the increase in OD when 
detecting 0.1X compared to 1X sera make the interpretation of this assay troublesome. 
As a result, this measurement was excluded from the standard curve that may make 
higher Telomerase levels difficult to interpret. As the Survivin ELISA data was so poor, 
optimisation with the Telomerase ELISA experiments were undertaken using non-PLC 
serum samples. Serum from patients undergoing liver resection for metastatic colorectal 
cancer was used as these cases are more common than PLC resections, making the 
biological samples a slightly less precious research resource.  
Colorectal cancer does indeed express Telomerase, so serum from these cases was 
deemed an appropriate substitute (Moazeni-Roodi et al., 2019). However, as serum 
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from PLC patients was not used, we are unable to comment on the role of circulating 
Telomerase levels as a potential biomarker, more that the Abexxa ELISA kit gave some 
unexpected results that should be repeated before any firm conclusions can be stated. 
Antibody and contaminant molecule interactions (the so called ‘matrix effect’) can be 
ameliorated by a dilution step, as shown elsewhere in the published literature (Moazeni-
Roodi et al., 2019). A 1:10 dilution of was undertaken in an attempt to reduce this error, 
as shown in table 78. To further investigate this would require more reagents and 
‘spiking’ samples with a known concentration of Telomerase to fully understand 
whether or not these interactions are real or not (Moazeni-Roodi et al., 2019). This 
would, of course, require more reagents and use up precious samples but remains an 
avenue for future research to pursue.  A repeat assay would also clarify the decrease in 
OD from 5ng/ml to 10ng/ml, but would require further reagents. As a result, this 
approach was not pursued further.  
Diluting the Telomerase standards and samples in 10% HV serum was attempting to 
clarify whether or not there was a serum-effect in the sandwich ELISA. Sadly, this used 
up the last few wells, and did not yield any useful information.  
To further research this, repeat experiments could be undertaken as a first step to ensure 
the results are reproducible. However, the ELISA results gathered to date have been of 
very limited use, and at quite a significant cost. It was therefore felt that the detection of 
circulating UTAAs would be better explored using an alternative method. 
6.5 Exosome Results 
An initial run failed to yield any results and was no immediately repeated because of the 
COVID-19 pandemic and subsequent societal lockdown. As can be seen from figure 92, 
the experiment appears to work with the calibrators (TERT and BIRC5) from cell line 
Huh7.5 being readily detected, and the exosomal housekeeping RNA (HPRT1) is also 
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detected. Regrettably, all of the samples processed failed to register a single positive 
result, all samples were run in duplicate.  
 
Figure 92. Quantitative PCR data from amplified Exosomal RNA. The calibrators (TERT and BIRC5) demonstrate 
the presence of this RNA from the Huh7.5 cell line and highlights that the reaction works. The internal control, 
HPRT1, is also detected.  
This data comes from CRC serum samples, and is optimised, so could be repeated in 
blood from PLC patients. 
6.6 Discussion 
The internal control, HPRT1, and the calibrator, Huh7.5, have both worked very well 
indeed. It is very exciting to have a completely optimised protocol, with proof of 
principal for an assay to work. The next steps would include undertaking RNA 
extraction from exosomes derived from liver cancer, stable cirrhotics, and healthy 
volunteers to explore and describe these cohorts.  
7 Discussion 
7.1 Introduction 
The aim of this project was to assess the role universal tumour antigens play in primary 
liver neoplasms, and how greater understanding of UTAAs and their role in tumour 





internationally assessing these immortalising proteins, as well as alterations in the 
promoter regions, in both fresh/frozen and FFPE tumour samples.  
Telomerase was hoped to be a druggable target for personalised therapies, yet initial 
results in this field have been disappointing. However, promoter mutants have been 
considered as a potential biomarker for a wide range of cancers, (Moazeni-Roodi et al., 
2019).  Similarly, Survivin’s role in tumour biology has made it an attractive target for a 
wide range of anticancer-therapies (small molecule inhibitors, targeted RNA-
degradation, inhibition of homodimerization and immunotherapies) regrettably with 
limited clinical effects, (in der Stroth et al., 2020). However, Survivin’s role as a 
candidate biomarker requires ongoing research in a broad tumour population.  
7.2 Challenges 
Logistical challenges of commencing human-tumour research in a new site have limited 
the scope of this research project. Ethical approval took nine months, and as there was 
only formalin fixed tissues available for research, a more comprehensive analysis was 
not possible, as fresh/frozen tissues would have been required. However, usable DNA 
from archived tissues was able to be extracted and amplified to give promoter 
sequences. This labour-intensive approach required significant optimisation for both the 
pSurv and pTERT sequences, and is comparable with other reported data.  
Protein expression of UTAA in FFPE tissues was also achieved, and quantified, for 
both the UTAA under study. The Survivin data appears robust, as crisp nuclear 
positivity was detected when a well-published primary antibody was used. Regrettably, 
the Telomerase antibody required additional significant optimisation, with extra 
blocking steps, and also required extra calibration for protein detection using the digital 
software package, QuPath. Interestingly, the Telomerase primary antibody has not been 
as extensively used in the literature as its Survivin counterpart.  
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When using digital pathology techniques to detect protein expression, true whole-
tumour assessment was possible, giving highly detailed data on the whole-slide image 
and therefore a more accurate representation of protein expression by the liver tumours.  
Significant challenges were met when the blood-work was undertaken to detect UTAA 
protein, and RNA levels. The commercially available ELISAs for both Survivin and 
Telomerase were not sensitive enough to detect any protein in the serum samples 
assessed. However, the exosomal work, whilst not yielding any results per se, includes 
both a calibrator and a positive control, and is an exciting prospect for future work as it 
appears to be fully optimised.  
The clinical archive, and clinically-relevant data included in this study has some 
potential for improvement, which could alter the interpretation of my data. Gradations 
of fibrotic indices have not been used, as they are absent in the older material, meaning 
the binary presence/ absence has been used in its place. The same is true the survival 
data. Clinical timelines have simply not been recorded in a centralised database, 
meaning measures such as time to recurrence, disease-specific survival, overall survival, 
progression-free survival have not been compared, instead the somewhat clinically 
clumsy measure of overall survival was used. This has obvious implications on the 
validity of my correlations with the outcome data, given that the assumption has been 
made that the patient died of primary liver cancer, and not a secondary disease process.  
The only way to avoid all of these biases would be to utilise a formal biobank where 
time has been taken to individually record this data. Regrettably this was beyond the 
scope of this research project, but is certainly achievable if more research resources 
were available locally.  
However, the lessons I have learned as a principal investigator have proved to be 
invaluable, and will doubtless be of use in future research projects.  
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7.3 Promoter Mutations 
Firstly, it is possible to use archived FFPE tissues for research purposes, and to 
sequence promoter regions (a known difficult target) which gives meaningful results 
that can be correlated with clinical parameters. The Survivin promoter SNP rs9904341 
has been proven to be a germline characteristic as there is concordance between 
background liver and tumour samples. Given that Survivin is re-expressed in 
malignancies, further qualifying the mechanisms behind this would be of scientific, and 
potentially clinical, benefit. 
Across all neoplasms the GG promoter homozygotes tended to occur in patients who do 
not have liver cirrhosis, p= 0.042. When data from the pSurv and IHC results is 
combined in the CCA group, GG homozygotes express more Survivin protein than CC 
homozygotes, p= 0.048. Whilst C-dominance of the rs9904341 SNP has been linked to 
increased cancer risk in studies based in Asia, there is no such link in Caucasian 
populations that have been studied (Moazeni-Roodi et al., 2019). In this British cohort 
of patients, I have early evidence that there may be a link between this GG genotype 
and adverse clinical outcomes, which warrants further research for clarification.  
In all liver tumours, Telomerase promoter mutants have been shown to be associated 
with male gender (p= 0.001), liver fibrosis (p= 0.009), liver cirrhosis (p= 0.004) and 
HCCs, with 32.7% possessing a pTERTMut (p= 0.002). In tumour sub-group analysis, 
there is a male preponderance (p= 0.005), an association with vascular invasion (p= 
0.031), and possible evidence of shortened overall survival as pTERTMut are associated 
with all-cause mortality (p= 0.043) as well as poorer cumulative survival, p= 0.083.  
Globally, pTERTMuts have been reported to occur in 43.9% (1831/4170) of HCCs, (in 
der Stroth et al., 2020). My data has achieved comparable rates, but not recreated these 
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findings, which have been quoted as being present in over 60% of HCCs in a European 
cohort, (Nault & Zucman-Rossi, 2016).  
There is also evidence of both intra-tumoural and inter-tumoural heterogeneity in the 
pTERTMuts in HCCs, which may benefit from further work using either FFPE or 
fresh/frozen materials. Whether these specific driver mutations result in clonal 
expansion within a particular tumour has not been proven in my results, assuming the 
methods I have used are completely accurate. Cross-validation with a second technique 
(ddPCR, or a KASP assay) could confirm these results (Hubáček et al., 2015; McEvoy 
et al., 2017).  
The HCC tumour-specificity of pTERTMuts has previously been reported, with only 
1.9% of all iCCAs sequenced possessing this genetic alteration, (Quaas et al., 2014; in 
der Stroth et al., 2020). Of the 362 iCCAs that have been sequenced (and published) 
only 7 have contained a pTERTMut (in der Stroth et al., 2020). My work in sequencing 
DNA from 30 iCCAs has contributed to this field, and also confirmed previous results 
that more distal tumours (pCCA, n= 6 in my study with n= 86 in Nakamura et al) also 
do not harbour pTERTMuts (Nakamura et al., 2015). 
7.4 Survivin Expression 
Using digital pathology methods to detect Survivin immunohistochemical expression in 
liver tumours has been successfully demonstrated. Each of the main tumour subtypes 
under study have given subtly different results which, should they be validated in a 
larger cohort, could be used as a clinically-relevant adjunct in routine patient care. 
Survivin has demonstrated greater expression in liver tumours (both benign and 
malignant) highlighting its role in tumourigenesis.  
Larger malignancies have been shown to express more Survivin (p= 0.046) and there is 
an association with death (p= 0.016), advanced tumour stage (p= 0.047) and vascular 
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invasion (p= 0.008). Tumours that highly express Survivin are associated with death (p= 
0.007), are of a more advanced stage (p= 0.007), and have invaded the vasculature (p= 
0.001) despite being more most expressed in FL-HCCs (p= 0.018). Cumulative survival 
is also reduced in malignancies that express high levels of Survivin protein, p= 0.001.  
Liver tumour subtypes behave differently, with advanced HCC tumour grades 
expressing more Survivin (p= 0.007) as well as correlating with vascular invasion (p= 
0.013). Even assessing the background liver in HCC patients could be of benefit, with 
differential Survivin expression depending on the tumour grade that subsequently grow, 
p= 0.042. The Survivin promoter SNPs studied showed those homozygous for GG 
express more Survivin in Cholangiocarcinoma, p= 0.048. There are also clinical 
correlations between CCA and death (p= 0.005), advanced stage disease (p= 0.024) and 
perineurally invasive tumours (p= 0.045). Cumulative survival in CCA reduced in 
tumours that express high levels of Survivin (p= 0.002), as is tumour stage (p= 0.021) 
and GG homozygosity (p= 0.021).  
These results could be translated to clinical medicine and used as an aide when 
assessing higher-risk liver tumours.  
7.5 Telomerase Expression 
Telomerase expression in liver tumours has brought mixed results, and raised more 
questions than providing answers. Background liver Telomerase expression is present in 
all liver tissues, meaning using this method to differentiate tumour from background 
liver is not appropriate. In the malignant tumours, pairwise comparisons between 
tumours types was able to demonstrate differences in Telomerase expression between 
HCCs and CCAs, p= 0.032. Tumours with Telomerase promoter mutations do not 
express more Telomerase in any cohort, or subgroup analysed.  
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Somewhat oddly, non-metabolically driven malignancies expressed more Telomerase, 
p= 0.004. The reasons behind this require further work as they may be an artefactual 
finding in an overly simplified model of liver tumour aetiology. Non-metabolically 
derived CCA express more Telomerase (p= 0.001) as do perihilar CCAs (p= 0.016). 
Cumulative survival did not differ between patients whose tumours expressed high or 
low Telomerase levels, meaning this would be a poor method of stratifying high-risk 
patients.   
Both the mixed tumours (p= 0.033), and the benign adenomas (p= 0.012) have an 
apparent correlation between patient age and Telomerase expression. Further work to 
ascertain why these particular tumours behave like this is required, especially as 
pTERTMuts status is clearly not involved. This could include assessment of the role of 
TERT amplification/ translocation or (less relevant in this study population) genetic 
insertion events in the context of HBV, (Nault et al., 2019). 
Overall assessing Telomerase protein expression has not yielded many meaningful 
results in this study, especially given the concerns previously raised as to the validity of 
Telomerase quantification by IHC, (Kim et al., 2013).  
7.6 Haematological Detection 
Haematological expression of UTA has not proven helpful in assessing patients with 
hepatic neoplasms. The ELISA experiments have failed to produce data of a quantity 
required to comment on the role of Survivin or Telomerase in liver neoplasms, as has 
previously been reported when using Telomerase quantification in lung cancer 
(Targowski et al., 2010). Of note previous research in HCCs failed to find a role for 
serological detection of Survivin, (Jia et al., 2015).  
The scientific approach has yielded some very promising early results in the 
optimisation of the exosomal quantification work, but not yet enough to correlate with 
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clinical or research parameters, including tissue expression or promoter variants that 
have been assessed in this project.  
7.7 Bias and Statistics 
During this research project every effort has been made to reduce any inherent bias that 
may alter the results. However, the specimens that have been studied are all from 
patients who were medically fit enough to undergo major abdominal surgery, meaning 
an inherent selection bias that is out with my control. The only way to ensure the results 
demonstrated above are accurate in all liver tumours would be to include biopsy 
specimens, thereby representing the patient cohort more accurately. The volume of 
tumour tissue from needle-biopsy specimens is sometimes so limited that this is deemed 
insufficient for a formal medical diagnosis, meaning inclusion into research projects 
would not be possible. A potential way around this issue would include second-pass 
biopsies (which further increase the risk of morbidity and mortality to the patient) for 
future research projects.  
Numerous analyses have been made on the same data presented above with some 
corrections for repeated statistical tests, i.e., Bonferroni correction. However, a formal 
assessment of possible false-discovery rates has not been undertaken when assessing the 
neoplastic/malignant/ tumour subgroup analyses. This means these results and possible 
inferences on clinical practice should be interpreted/ acted upon with caution.  
7.8 Conclusion 
In conclusion, I have used a variety of techniques to explore the role of UTAA in 
primary liver neoplasms. Noteworthy highlights include the successful Sanger 
sequencing of promoter regions from DNA extracted from FFPE tissues, and the use of 
a digital pathology platform to quantify protein expression of UTAA in PLCs – which 
correlated with clinical parameters. As my sequencing results provided evidence of 
 256 
pTERTMuts being an HCC-lineage specific genetic alteration, sadly the IHC for 
Telomerase was quite disappointing. Whilst the Survivin sequencing data failed to yield 
any meaningful results, the IHC results demonstrated significant correlations, some of 
which are novel.  
However, the lack of progress on my biobanked blood samples is a source of 
frustration, despite numerous attempts at protein quantification using an ELISA. The 
Exosomal work is very promising and may yield meaningful results if fully pursued.  
Being the first researcher in the South West of England to explore a new cohort of 
patients has been a real privilege. Progress through the original ethics application has 
provided me with an invaluable set of transferable skills for my future research 
activities. Being involved in the embryonic stages of biobank recruitment has also been 
of significant benefit, and has given me a new perspective on the effort involved in 
patient identification and recruitment.  
8 Future Work 
Immediate future work will include using an optimised protocol on serum samples 
taken from patients with primary liver diseases, including cirrhosis and cancer, using 
the real time quantitative PCR method. Assessing the RNA content in the exosomal 
fraction of blood from these patients will help clarify whether the role of UTAA in 
PLC.  
However, alternative methods could also be used such as the relative quantification of 
serum protein using mass spectrometry. Recent work has used liquid chromatography 
mass spectroscopy (LC/MS) in a cell culture model of HCC, using hTERT knockdown 
(siRNA) methods (Choi et al., 2020). Similar approaches have described the role of 
Survivin in CD4+ T cells play in patients with HIV (Kuo et al., 2018). One of the many 
benefits of using LC/MS over individual protein detection methods is the sheer volume 
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of data that could be generated from a few samples. Not only would I be able to 
ascertain whether Survivin and/or Telomerase are detected in blood samples, but I 
would be able to study numerous targets simultaneously, including other enzymes/ 
proteins involved in their respective signalling pathways.  
The Telomerase enzymatic action has only been determined by using the TRAP assay, 
which requires fresh/frozen tissue samples. Given unlimited resources, it would have 
been beneficial to attempt this assay in tumour samples from patients to better 
understand the role of Telomerase in primary liver cancers. Further work on 
understanding the role of Telomerase in PLCs could also assess the other methods 
(currently known) that can result in Telomerase activation: TERT amplification, TERT 
translocation and viral insertion into the TERT gene, (Nault et al., 2019). Epigenetic 
changes (such as promoter methylation) could also be explored in my research cohort, 
as has been demonstrated in neuroendocrine tumours of the small bowel, (Fotouhi et al., 
2019).  
My data has shown Survivin to be a potentially useful biomarker in PLCs. Stratifying 
tumours by Survivin protein expression may be a useful method of identifying higher-
risk cases, but this would need to be supported by a larger study cohort. Whether liver 
tumours shed peripherally detectable Survivin, to act as a haematological biomarker, 
also warrants further assessment.  
The methylation status of the Survivin promoter, and correlations with Survivin 
expression (both transcribed and proteomic) has given mixed results in a variety of 
cancers (Lyu et al., 2018). Assessing the methylation of the Survivin promoter in liver 
cancers, and correlating this with the results presented here would be a first for liver 
cancer. Alternative methods of assessing the epigenetic control of Survivin expression 
could also include the quantification of microRNAs, and how these compare with 
proteomic Survivin (Rahban et al., 2019).  
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In summary there are many possible avenues to pursue when considering how to expand 
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